FOLATE RECEPTOR ALPHA AS A DIAGNOSTIC AND PROGNOSTIC MARKER FOR FOLATE RECEPTOR ALPHA-EXPRESSING CANCERS

BACKGROUND OF THE INVENTION

In humans, the high affinity receptor for folate comes in three isoforms: alpha, beta, and gamma. The alpha and beta forms are typically bound to the membranes of cells by a glycosyl phosphatidylinositol (GPI) anchor. They recycle between extracellular and endocytic compartments and are capable of transporting folate into the cell. Soluble forms of FRα may be derived by the action of proteases or phospholipase on membrane anchored folate receptors.

Folate receptor alpha (also referred to as FRα, FR-alpha, FOLR-1 or FOLR1) is expressed in a variety of epithelial tissues, including those of the choroid plexus, lung, thyroid, kidney, uterus, breast, Fallopian tube, epididymis, and salivary glands. Weitman, S D et al. Cancer Res 52: 3396-3401 (1992); Weitman S D et al, Cancer Res 52: 6708-6711. Overexpression of FRα has been observed in various cancers, including lung cancer (e.g., bronchioalveolar carcinomas, carcinoid tumors, and non-small cell lung cancers, such as adenocarcinomas); mesothelioma; ovarian cancer; renal cancer; brain cancer (e.g., anaplastic ependymoma, cerebellar juvenile pilocytic astrocytoma, and brain metastases); cervical cancer; nasopharyngeal cancer; mesodermally derived tumor; squamous cell carcinoma of the head and neck; endometrial cancer; endometrioid adenocarcinomas of the ovary, serous cystadenocarcinomas, breast cancer; bladder cancer; pancreatic cancer; bone cancer (e.g., high-grade osteosarcoma); pituitary cancer (e.g., pituitary adenomas); colorectal cancer and medullary thyroid cancer. See e.g., U.S. Pat. No. 7,754,698; U.S. Patent Application No. 2005/0232919; WO 2009/132081; Bueno R et al. J of Thoracic and Cardiovascular Surgery, 121(2): 225-233 (2001); Elkanat H & Ratnam M. Frontiers in Bioscience, 11, 506-519 (2006); Fisher R. E. J Nucl Med, 49: 899-906 (2008); Franklin, W A et al. Int J Cancer, Suppl 8: 89-95 (1994); Hartman L. C. et al. Int J Cancer 121: 938-942 (2007); Iwakiri S et al. Annals of Surgical Oncology, 15(3): 889-899; Parker N. et al. Analytical Biochemistry, 338: 284-293 (2005); Weitman, S D et al. Cancer Res 52: 3396-3401 (1992); Saba N. F. et al. Head Neck, 31(4): 475-481 (2009); Yang R et al. Clin Cancer Res 13: 2557-2567 (2007). In some types of cancers (e.g., squamous cell carcinoma of the head and neck), a higher level of FRα expression is associated with a worse prognosis, whereas in other types of cancers (e.g., non-small-cell lung cancers), a higher level of FRα expression is associated with a better prognosis. See, e.g., Iwakiri S et al. Annals of Surgical Oncology, 15(3): 889-899; Saba N. F. et al. Head Neck, 31(4): 475-481 (2009).

Earlier detection of cancer improves survival rates and quality of life. To improve the likelihood of early detection and treatment, a pressing need exists for non-invasive methods for diagnosing cancer, for determining the level of risk of developing cancer, and for predicting the progression of cancer. The present invention satisfies these needs for FRα-expressing cancers.

SUMMARY OF THE INVENTION

The present invention provides methods of assessing whether a subject is afflicted with FRα-expressing cancers such as lung or ovarian cancer, methods of assessing the progression of FRα-expressing cancers such as lung or ovarian cancer in a subject afflicted with the FRα-expressing cancers, methods of stratifying an FRα-expressing cancer subject into one of at least four cancer therapy groups, methods of assessing the efficacy of MORAb-003 treatment of ovarian cancer or lung cancer and kits for assessing whether a subject is afflicted with FRα-expressing cancers such as lung or ovarian cancer or for assessing the progression of FRα-expressing cancers such as lung or ovarian cancer in a subject.

Methods of Assessing Whether a Subject is Afflicted with an FRαExpressing Cancer

In a first aspect, the present invention provides a method of assessing whether a subject is afflicted with an FRα-expressing cancer, by determining the level of folate receptor alpha (FRα) which is not bound to a cell, in a sample derived from the subject; and comparing the level of folate receptor alpha (FRα) which is not bound to a cell with the level of FRα in a control sample, wherein a difference between the level of FRα in the sample derived from the subject and the level of FRα in the control sample is an indication that the subject is afflicted with an FRα-expressing cancer; wherein the level of FRα in the sample derived from the subject is assessed by contacting the sample with an antibody that binds FRα. In a particular embodiment, the sample is either urine, serum, plasma or ascites.

In another aspect, the present invention is directed to a method of assessing whether a subject is afflicted with an FRα-expressing cancer, by determining the level of folate receptor alpha (FRα) which is not bound to a cell in a urine sample derived from the subject; and comparing the level of folate receptor alpha (FRα) which is not bound to a cell in the urine sample derived from the subject with the level of FRα in a control sample, wherein a difference between the level of FRα in the urine sample derived from the subject and the level of FRα in the control sample is an indication that the subject is afflicted with an FRα-expressing cancer. In a further aspect, the present invention provides a method of assessing whether a subject is afflicted with a cancer that expresses FRα, by determining the level of folate receptor alpha (FRα) which is not bound to a cell in a serum sample derived from the subject; and comparing the level of folate receptor alpha (FRα) which is not bound to a cell in the serum sample derived from the subject with the level of FRα in a control sample, wherein a difference between the level of FRα in the serum sample derived from the subject and the level of FRα in the control sample is an indication that the subject is afflicted with an FRα-expressing cancer.

In various embodiments of the foregoing aspects of the invention, the FRα-expressing cancer is selected from the group consisting of lung cancer, mesothelioma, ovarian cancer, renal cancer, brain cancer, cervical cancer, nasopharyngeal cancer, squamous cell carcinoma of the head and neck, endometrial cancer, breast cancer, bladder cancer, pancreatic cancer, bone cancer, pituitary cancer, colorectal cancer and medullary thyroid cancer. In a particular embodiment, the FRα-expressing cancer is ovarian cancer. In another embodiment, the FRα-expressing cancer is non-small cell lung cancer, such as an adenocarcinoma.

In another aspect, the present invention is directed to methods of assessing whether a subject is afflicted with ovarian cancer, by determining the level of folate receptor alpha (FRα) which is not bound to a cell in a urine sample derived from the subject, wherein the presence of FRα which is not bound to a cell in the urine sample at a concentration of greater than about 9100 pg/ml is an indication that the subject is afflicted with ovarian cancer.

In various aspects of the foregoing aspects of the invention, the presence of FRα in the urine sample at a concentration of greater than about 9500 pg/mL, about 10,000 pg/mL, about 11,000 pg/mL, about 12,000 pg/mL, about 13,000 pg/mL, about 14,000 pg/mL, about 15,000 pg/mL, about 16,000 pg/mL, about 17,000 pg/mL, about 18,000 pg/mL, about 19,000 pg/mL, or about 20,000 pg/mL is an indication that the subject is afflicted with ovarian cancer.

In various aspects, the level of FRα is determined by contacting the sample with an antibody that binds FRα. For example, the antibody is selected from the group consisting of:

(a) an antibody that binds the same epitope as the MORAb-003 antibody;

(b) an antibody comprising SEQ ID NO:1 (GFTFSGYGLS) as CDRH1, SEQ ID NO:2 (MISSGGSYTYYADSVKG) as CDRH2, SEQ ID NO:3 (HGDDPAWFAY) as CDRH3, SEQ ID NO:4 (SVSSSISSNNLH) as CDRL1, SEQ ID NO:5 (GTSNLAS) as CDRL2 and SEQ ID NO:6 (QQWSSYPYMYT) as CDRL3;

(d) an antibody that binds the same epitope as the MOV18 antibody;

(e) the 548908 antibody;

(f) an antibody that binds the same epitope as the 548908 antibody;

(g) the 6D398 antibody;

(h) an antibody that binds the same epitope as the 6D398 antibody;

(i) an antibody that binds the same epitope as the 26B3 antibody;

(j) an antibody comprising SEQ ID NO:55 (GYFMN) as CDRH1, SEQ ID NO:56 (RIFPYNGDTFYNQKFKG) as CDRH2, SEQ ID NO:57 (GTHYFDY) as CDRH3, SEQ ID NO:51 (RTSENIFSYLA) as CDRL1, SEQ ID NO:52 (NAKTLAE) as CDRL2 and SEQ ID NO:53 (QHHYAFPWT) as CDRL3;

(k) the 26B3 antibody;

(l) an antibody that binds the same epitope as the 19D4 antibody;

(m) an antibody comprising SEQ ID NO:39 (HPYMH) as CDRH1, SEQ ID NO:40 (RIDPANGNTKYDPKFQG) as CDRH2, SEQ ID NO:41 (EEVADYTMDY) as CDRH3, SEQ ID NO:35 (RASESVDTYGNNFIH) as CDRL1, SEQ ID NO:36 (LASNLES) as CDRL2 and SEQ ID NO:37 (QQNNGDPWT) as CDRL3;

(n) the 19D4 antibody;

(o) an antibody that binds the same epitope as the 9F3 antibody;

(p) an antibody comprising SEQ ID NO:31 (SGYYWN) as CDRH1, SEQ ID NO:32 (YIKSDGSNNYNPSLKN) as CDRH2, SEQ ID NO:33 (EWKAMDY) as CDRH3, SEQ ID NO:27 (RASSTVSYSYLH) as CDRL1, SEQ ID NO:28 (GTSNLAS) as CDRL2 and SEQ ID NO:29 (QQYSGYPLT) as CDRL3;

(q) the 9F3 antibody;

(r) an antibody that binds the same epitope as the 24F12 antibody;

(s) an antibody comprising SEQ ID NO:47 (SYAMS) as CDRH1, SEQ ID NO:48 (EIGSGGSYTYYPDTVTG) as CDRH2, SEQ ID NO:49 (ETTAGYFDY) as CDRH3, SEQ ID NO:43 (SASQGINNFLN) as CDRL1, SEQ ID NO:44 (YTSSLHS) as CDRL2 and SEQ ID NO:45 (QHFSKLPWT) as CDRL3;

(t) the 24F12 antibody;

(u) an antibody that comprises a variable region light chain selected from the group consisting of LK26HuVK (SEQ ID NO: 13); LK26HuVKY (SEQ ID NO: 14); LK26HuVKPW (SEQ ID NO: 15); and LK26HuVKPW,Y (SEQ ID NO: 16);

(v) an antibody that comprises a variable region heavy chain selected from the group consisting of LK26HuVH (SEQ ID NO: 17); LK26HuVH FAIS,N (SEQ ID NO: 18); LK26HuVH SLF (SEQ ID NO: 19); LK26HuVH I,I (SEQ ID NO: 20); and LK26KOLHuVH (SEQ ID NO: 21);

(w) an antibody that comprises the heavy chain variable region LK26KOLHuVH (SEQ ID NO: 21) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16);

(x) an antibody that comprises the heavy chain variable region LK26HuVH SLF (SEQ ID NO: 19) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16); and

(y) an antibody that comprises the heavy chain variable region LK26HuVH FAIS,N (SEQ ID NO: 18) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16).

In a particular embodiment, the antibody binds the same epitope as the MORAb-003 antibody. In another embodiment, the antibody includes SEQ ID NO:1 (GFTFSGYGLS) as CDRH1, SEQ ID NO:2 (MISSGGSYTYYADSVKG) as CDRH2, SEQ ID NO:3 (HGDDPAWFAY) as CDRH3, SEQ ID NO:4 (SVSSSISSNNLH) as CDRL1, SEQ ID NO:5 (GTSNLAS) as CDRL2 and SEQ ID NO:6 (QQWSSYPYMYT) as CDRL3. In another embodiment, the antibody is the MOV18 antibody. In yet another embodiment, the antibody binds the same epitope as the MOV18 antibody. In a further embodiment, the antibody comprises a variable region light chain selected from the group consisting of LK26HuVK (SEQ ID NO: 13); LK26HuVKY (SEQ ID NO: 14); LK26HuVKPW (SEQ ID NO: 15); and LK26HuVKPW,Y (SEQ ID NO: 16). Alternatively or in combination, the antibody includes a variable region heavy chain selected from the group consisting of LK26HuVH (SEQ ID NO: 17); LK26HuVH FAIS,N (SEQ ID NO: 18); LK26HuVH SLF (SEQ ID NO: 19); LK26HuVH I,I (SEQ ID NO: 20); and LK26KOLHuVH (SEQ ID NO: 21). In certain embodiments, the antibody includes (i) the heavy chain variable region LK26KOLHuVH (SEQ ID NO: 21) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16); the heavy chain variable region LK26HuVH SLF (SEQ ID NO: 19) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16); or the heavy chain variable region LK26HuVH FAIS,N (SEQ ID NO: 18) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16).

In a particular embodiment, the level of FRα in the sample derived from said subject is assessed by contacting the sample with a pair of antibodies selected from the group consisting of (a) MOV18 antibody immobilized to a solid support and labeled MORAB-003 antibody; (b) 9F3 antibody immobilized to a solid support and labeled 24F12 antibody; (c) 26B3 antibody immobilized to a solid support and labeled 19D4 antibody; and (d) 9F3 antibody immobilized to a solid support and labeled 26B3 antibody.

In certain embodiments, the antibody is selected from the group consisting of a murine antibody, a human antibody, a humanized antibody, a bispecific antibody, a chimeric antibody, a Fab, Fab′2, ScFv, SMIP, affibody, avimer, versabody, nanobody, and a domain antibody. Alternatively, or in combination, the antibody is labeled, for example, with a label selected from the group consisting of a radio-label, a biotin-label, a chromophore-label, a fluorophore-label, or an enzyme-label.

In certain embodiments, the level of FRα is determined by using a technique selected from the group consisting of western blot analysis, radioimmunoassay, immunofluorimetry, immunoprecipitation, equilibrium dialysis, immunodiffusion, solution phase assay, electrochemiluminescence immunoassay (ECLIA) and ELISA assay.

In various embodiments of the foregoing aspects of the invention, the control sample is a standardized control level of FRα in a healthy subject.

In certain embodiments, the sample is treated with guanidine prior to determining the level of FRα in the sample. Alternatively or in combination, the sample is diluted prior to determining the level of FRα in the sample. Alternatively, or in combination, the sample is centrifuged, vortexed, or both, prior to determining the level of FRα in the sample.

In yet another aspect, the present invention is directed to a method of assessing whether a subject is afflicted with ovarian cancer, by determining the level of folate receptor alpha (FRα) which is not bound to a cell in a sample derived from the subject; and comparing the level of folate receptor alpha (FRα) which is not bound to a cell in the sample with the level of FRα in a control sample, wherein a difference between the levels of FRα in the sample derived from the subject and in the control sample is an indication that the subject is afflicted with ovarian cancer; wherein the level of FRα in the sample derived from the subject is assessed by contacting the sample with (a) MOV18 antibody immobilized to a solid support and labeled MORAB-003 antibody, (b) 9F3 antibody immobilized to a solid support and labeled 24F12 antibody, (c) 26B3 antibody immobilized to a solid support and labeled 19D4 antibody, and (d) 9F3 antibody immobilized to a solid support and labeled 26B3 antibody. For example, the sample may be urine, serum, plasma or ascites.

Methods of Assessing the Progression of an FRαExpressing Cancer in a Subject

In a further aspect, the present invention is directed to a method of assessing the progression of an FRα-expressing cancer in a subject afflicted with an FRα-expressing cancer, by determining the level of folate receptor alpha (FRα) which is not bound to a cell, in a sample derived from the subject; and comparing the level of folate receptor alpha (FRα) which is not bound to a cell with the level of FRα in a control sample, wherein an increase in the level of FRα in the sample derived from the subject as compared with the level of FRα in the control sample is an indication that the cancer will progress rapidly; and wherein a decrease in the level of FRα in the sample derived from the subject as compared with the level of FRα in the control sample is an indication that the cancer will progress slowly or will regress, thereby assessing the progression of the FRα-expressing cancer in the subject; wherein the level of FRα which is not bound to a cell in the sample derived from the subject is assessed by contacting the sample with an antibody that binds FRα. In a particular embodiment, the sample is urine, serum, plasma or ascites.

In another aspect, the present invention provides a method of assessing the progression of an FRα-expressing cancer in a subject afflicted with an FRα-expressing cancer, by determining the level of folate receptor alpha (FRα) which is not bound to a cell in a urine sample derived from the subject; and comparing the level of folate receptor alpha (FRα) which is not bound to a cell in the urine sample derived from the subject with the level of FRα in a control sample, wherein an increase in the level of FRα in the urine sample derived from the subject as compared with the level of FRα in the control sample is an indication that the cancer will progress rapidly; and wherein a decrease in the level of FRα in the urine sample derived from the subject as compared with the level of FRα in the control sample is an indication that the cancer will progress slowly or will regress, thereby assessing the progression of the FRα-expressing cancer in the subject.

In a further aspect, the present invention provides methods of assessing the progression of an FRα-expressing cancer in a subject afflicted with an FRα-expressing cancer, by determining the level of folate receptor alpha (FRα) which is not bound to a cell in a serum sample derived from the subject; and comparing the level of folate receptor alpha (FRα) which is not bound to a cell in the serum sample derived from the subject with the level of FRα in control sample, wherein an increase in the level of FRα in the serum sample derived from the subject as compared with the level of FRα in the control sample is an indication that the cancer will progress rapidly; and wherein a decrease in the level of FRα in the serum sample derived from the subject as compared with the level of FRα in the control sample is an indication that the cancer will progress slowly or will regress, thereby assessing the progression of the FRα-expressing cancer in the subject.

In various aspects, the level of FRα is determined by contacting the sample with an antibody that binds FRα. For example, the antibody is selected from the group consisting of:

(a) an antibody that binds the same epitope as the MORAb-003 antibody;

(d) an antibody that binds the same epitope as the MOV18 antibody;

(e) the 548908 antibody;

(f) an antibody that binds the same epitope as the 548908 antibody;

(g) the 6D398 antibody;

(h) an antibody that binds the same epitope as the 6D398 antibody;

(i) an antibody that binds the same epitope as the 26B3 antibody;

(k) the 26B3 antibody;

(l) an antibody that binds the same epitope as the 19D4 antibody;

(n) the 19D4 antibody;

(o) an antibody that binds the same epitope as the 9F3 antibody;

(q) the 9F3 antibody;

(r) an antibody that binds the same epitope as the 24F12 antibody;

(t) the 24F12 antibody;

(w) an antibody that comprises the heavy chain variable region LK26KOLHuVH (SEQ ID NO: 21) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16);

(x) an antibody that comprises the heavy chain variable region LK26HuVH SLF (SEQ ID NO: 19) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16); and

(y) an antibody that comprises the heavy chain variable region LK26HuVH FAIS,N (SEQ ID NO: 18) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16).

In certain embodiments, the level of FRα is determined by using a technique selected from the group consisting of western blot analysis, radioimmunoas say, immunofluorimetry, immunoprecipitation, equilibrium dialysis, immunodiffusion, solution phase assay, electrochemiluminescence immunoassay (ECLIA) and ELISA assay.

In various embodiments of the foregoing aspects of the invention, the control sample is a standardized control level of FRα in a healthy subject. In another embodiment, the control sample is a sample previously obtained from the subject.

In a further aspect, the present invention provides methods of assessing the progression of ovarian cancer in a subject afflicted with ovarian cancer, by determining the level of folate receptor alpha (FRα) which is not bound to a cell in a sample derived from the subject; and comparing the level of folate receptor alpha (FRα) which is not bound to a cell in the sample with the level of FRα in a control sample, wherein an increase in the level of FRα in the sample derived from the subject as compared with the level of FRα in the control sample is an indication that the ovarian cancer will progress rapidly; and wherein a decrease in the level of FRα in the sample derived from the subject as compared with the level of FRα in the control sample is an indication that the ovarian cancer will progress slowly or will regress, thereby assessing the progression of ovarian cancer in the subject; wherein the level of FRα in the sample derived from the subject is assessed by contacting the sample with (a) MOV18 antibody immobilized to a solid support and labeled MORAB-003 antibody, (b) 9F3 antibody immobilized to a solid support and labeled 24F12 antibody, (c) 26B3 antibody immobilized to a solid support and labeled 19D4 antibody, and (d) 9F3 antibody immobilized to a solid support and labeled 26B3 antibody. For example, the sample may be urine, serum, plasma or ascites.

Methods of Stratifying an FRαExpressing Cancer into Cancer Therapy Groups

In a further aspect, the present invention provides a method of stratifying a subject afflicted with an FRα-expressing cancer into one of at least four cancer therapy groups by determining the level of folate receptor alpha (FRα) which is not bound to a cell, in a sample derived from the subject; and stratifying the subject into one of at least four cancer therapy groups based on the level of folate receptor alpha (FRα) which is not bound to a cell; wherein the level of FRα which is not bound to a cell in the sample derived from the subject is assessed by contacting the sample with an antibody that binds FRα. For example, the sample is selected from the group consisting of urine, serum, plasma or ascites.

In yet another aspect, the present invention provides a method of stratifying a subject afflicted with an FRα-expressing cancer into one of at least four cancer therapy groups by determining the level of folate receptor alpha (FRα) which is not bound to a cell in a urine sample derived from the subject; and stratifying the subject into one of at least four cancer therapy groups based on the level of folate receptor alpha (FRα) which is not bound to a cell in the sample. In a further aspect, the present invention is directed to methods of stratifying a subject afflicted with an FRα-expressing cancer into one of at least four cancer therapy groups by determining the level of folate receptor alpha (FRα) which is not bound to a cell in a serum sample derived from the subject; and stratifying the subject into one of at least four cancer therapy groups based on the level of folate receptor alpha (FRα) which is not bound to a cell in the serum sample.

In various aspects, the level of FRα is determined by contacting the sample with an antibody that binds FRα. For example, the antibody is selected from the group consisting of:

(a) an antibody that binds the same epitope as the MORAb-003 antibody;

(d) an antibody that binds the same epitope as the MOV18 antibody;

(e) the 548908 antibody;

(f) an antibody that binds the same epitope as the 548908 antibody;

(g) the 6D398 antibody;

(h) an antibody that binds the same epitope as the 6D398 antibody;

(i) an antibody that binds the same epitope as the 26B3 antibody;

(k) the 26B3 antibody;

(l) an antibody that binds the same epitope as the 19D4 antibody;

(n) the 19D4 antibody;

(o) an antibody that binds the same epitope as the 9F3 antibody;

(q) the 9F3 antibody;

(r) an antibody that binds the same epitope as the 24F12 antibody;

(t) the 24F12 antibody;

(w) an antibody that comprises the heavy chain variable region LK26KOLHuVH (SEQ ID NO: 21) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16);

(x) an antibody that comprises the heavy chain variable region LK26HuVH SLF (SEQ ID NO: 19) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16); and

(y) an antibody that comprises the heavy chain variable region LK26HuVH FAIS,N (SEQ ID NO: 18) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16).

In various embodiments of the foregoing aspects of the invention, the control sample is a standardized control level of FRα in a healthy subject.

In a particular embodiment, the subject is stratified in Stage I, Stage II, Stage III or Stage IV ovarian cancer.

In a further aspect, the present invention provides a method of stratifying an ovarian cancer subject into one of at least four cancer therapy groups by determining the level of folate receptor alpha (FRα) which is not bound to a cell in a sample derived from the subject; and stratifying the subject into one of at least four cancer therapy groups based on the level of folate receptor alpha (FRα) which is not bound to a cell in the sample; wherein the level of FRα in the sample derived from the subject is assessed by contacting the sample with (a) MOV18 antibody immobilized to a solid support and labeled MORAB-003 antibody, (b) 9F3 antibody immobilized to a solid support and labeled 24F12 antibody, (c) 26B3 antibody immobilized to a solid support and labeled 19D4 antibody, and (d) 9F3 antibody immobilized to a solid support and labeled 26B3 antibody. For example, the sample may be urine, serum, plasma or ascites.

Methods of Monitoring the Efficacy of MORAb-003 Treatment of Ovarian Cancer or Lung Cancer

In one aspect, the present invention provides a method of monitoring the efficacy of MORAb-003 treatment of ovarian cancer or lung cancer in a subject suffering from ovarian cancer or lung cancer, by determining the level of folate receptor alpha (FRα) which is not bound to a cell, in a sample derived from the subject, wherein the subject has been previously administered MORAb-003; and comparing the level of folate receptor alpha (FRα) which is not bound to a cell with the level of FRα in a control sample, wherein an increase in the level of FRα in the sample derived from the subject as compared with the level of FRα in the control sample is an indication that the MORAb-003 treatment is not efficacious; and wherein a decrease in the level of FRα in the sample derived from the subject as compared with the level of FRα in the control sample is an indication that the MORAb-003 treatment is efficacious. In particular embodiments, the level of FRα which is not bound to a cell in the sample derived from the subject is assessed by contacting the sample with an antibody that binds FRα. For example, the sample may be urine, serum, plasma or ascites.

In a further aspect, the present invention provides a method of monitoring the efficacy of MORAb-003 treatment of ovarian cancer or lung cancer in a subject suffering from ovarian cancer or lung cancer, by determining the level of folate receptor alpha (FRα) which is not bound to a cell in a urine sample derived from the subject,

wherein the subject has been previously administered MORAb-003; and comparing the level of folate receptor alpha (FRα) which is not bound to a cell in the urine sample derived from the subject with the level of FRα in a control sample, wherein an increase in the level of FRα in the urine sample derived from the subject as compared with the level of FRα in the control sample is an indication that the MORAb-003 treatment is not efficacious; and wherein a decrease in the level of FRα in the urine sample derived from the subject as compared with the level of FRα in the control sample is an indication that the MORAb-003 treatment is efficacious.

In yet another aspect, the present invention is directed to a method of monitoring the efficacy of MORAb-003 treatment of ovarian cancer or lung cancer in a subject suffering from ovarian cancer or lung cancer, by determining the level of folate receptor alpha (FRα) which is not bound to a cell in a serum sample derived from the subject, wherein the subject has been previously administered MORAb-003; and comparing the level of folate receptor alpha (FRα) which is not bound to a cell in the serum sample derived from the subject with the level of FRα in a control sample, wherein an increase in the level of FRα in the serum sample derived from the subject as compared with the level of FRα in the control sample is an indication that the MORAb-003 treatment is not efficacious; and wherein a decrease in the level of FRα in the serum sample derived from the subject as compared with the level of FRα in the control sample is an indication that the MORAb-003 treatment is efficacious.

In various aspects, the level of FRα is determined by contacting the sample with an antibody that binds FRα. For example, the antibody is selected from the group consisting of:

(a) an antibody that binds the same epitope as the MORAb-003 antibody;

(d) an antibody that binds the same epitope as the MOV18 antibody;

(e) the 548908 antibody;

(f) an antibody that binds the same epitope as the 548908 antibody;

(g) the 6D398 antibody;

(h) an antibody that binds the same epitope as the 6D398 antibody;

(i) an antibody that binds the same epitope as the 26B3 antibody;

(k) the 26B3 antibody;

(l) an antibody that binds the same epitope as the 19D4 antibody;

(n) the 19D4 antibody;

(o) an antibody that binds the same epitope as the 9F3 antibody;

(q) the 9F3 antibody;

(r) an antibody that binds the same epitope as the 24F12 antibody;

(t) the 24F12 antibody;

(w) an antibody that comprises the heavy chain variable region LK26KOLHuVH (SEQ ID NO: 21) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16);

(x) an antibody that comprises the heavy chain variable region LK26HuVH SLF (SEQ ID NO: 19) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16); and

(y) an antibody that comprises the heavy chain variable region LK26HuVH FAIS,N (SEQ ID NO: 18) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16).

In certain embodiments, the level of FRα is determined by using a technique selected from the group consisting of western blot analysis, radioimmunoas say, immunofluorimetry, immunoprecipitation, equilibrium dialysis, immunodiffusion, solution phase assay, electrochemiluminescence immunoassay (ECLIA) and ELISA assay.

Methods of Predicting Whether a Subject Will Respond to MORAb-003 Treatment

In one aspect, the present invention provides a method for predicting whether a subject suffering from an FRα expressing cancer, such as ovarian cancer or lung cancer, will respond to treatment with MORAb-003, by determining the level of folate receptor alpha (FRα) which is not bound to a cell in a sample derived from the subject; and comparing the level of folate receptor alpha (FRα) which is not bound to a cell in the sample derived from the subject with the level of FRα in a control sample, wherein a difference between the level of FRα in the sample derived from the subject and the level of FRα in the control sample is an indication that the subject will respond to treatment with MORAb-003.

In one aspect, the present invention provides a method for predicting whether a subject suffering from an FRα expressing cancer, such as ovarian cancer or lung cancer, will respond to treatment with MORAb-003, by determining the level of folate receptor alpha (FRα) which is not bound to a cell in a urine sample derived from the subject; and comparing the level of folate receptor alpha (FRα) which is not bound to a cell in the urine sample derived from the subject with the level of FRα in a control sample, wherein a difference between the level of FRα in the urine sample derived from the subject and the level of FRα in the control sample is an indication that the subject will respond to treatment with MORAb-003.

In further embodiments, the FRα-expressing cancer is selected from the group consisting of lung cancer, mesothelioma, ovarian cancer, renal cancer, brain cancer, cervical cancer, nasopharyngeal cancer, squamous cell carcinoma of the head and neck, endometrial cancer, breast cancer, bladder cancer, pancreatic cancer, bone cancer, pituitary cancer, colorectal cancer and medullary thyroid cancer. In a particular embodiment, the FRα-expressing cancer is ovarian cancer. In another embodiment, the FRα-expressing lung cancer is non-small cell lung cancer, such as adenocarcinoma.

In a further aspect, the present invention provides methods for predicting whether a subject suffering from ovarian cancer will respond to treatment with MORAb-003, by determining the level of folate receptor alpha (FRα) which is not bound to a cell in a urine sample derived from the subject, wherein the presence of FRα which is not bound to a cell in the urine sample at a concentration of greater than about 9100 pg/ml is an indication that the subject will respond to treatment with MORAb-003.

In various embodiments of the foregoing aspects of the invention, the presence of FRα in the urine sample at a concentration of greater than about 9500 pg/mL, about 10,000 pg/mL, about 11,000 pg/mL, about 12,000 pg/mL, about 13,000 pg/mL, about 14,000 pg/mL, about 15,000 pg/mL, about 16,000 pg/mL, about 17,000 pg/mL, about 18,000 pg/mL, about 19,000 pg/mL, or about 20,000 pg/mL is an indication that the subject is afflicted with ovarian cancer.

In various embodiments of the foregoing aspects of the invention, the level of FRα is determined by contacting the sample with an antibody that binds FRα. For example, the antibody is selected from the group consisting of:

(a) an antibody that binds the same epitope as the MORAb-003 antibody;

(d) an antibody that binds the same epitope as the MOV18 antibody;

(e) the 548908 antibody;

(f) an antibody that binds the same epitope as the 548908 antibody;

(g) the 6D398 antibody;

(h) an antibody that binds the same epitope as the 6D398 antibody;

(i) an antibody that binds the same epitope as the 26B3 antibody;

(k) the 26B3 antibody;

(l) an antibody that binds the same epitope as the 19D4 antibody;

(n) the 19D4 antibody;

(o) an antibody that binds the same epitope as the 9F3 antibody;

(q) the 9F3 antibody;

(r) an antibody that binds the same epitope as the 24F12 antibody;

(t) the 24F12 antibody;

(v) an antibody that comprises a variable region heavy chain selected from the group consisting of LK26HuVH (SEQ ID NO: 17); LK26HuVH FAIS,N (SEQ ID NO: 18); LK26HuVH SLF (SEQ ID NO: 19); LK26HuVH LI (SEQ ID NO: 20); and LK26KOLHuVH (SEQ ID NO: 21);

(w) an antibody that comprises the heavy chain variable region LK26KOLHuVH (SEQ ID NO: 21) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16);

(x) an antibody that comprises the heavy chain variable region LK26HuVH SLF (SEQ ID NO: 19) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16); and

(y) an antibody that comprises the heavy chain variable region LK26HuVH FAIS,N (SEQ ID NO: 18) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16).

In certain embodiments, the level of FRα is determined by using a technique selected from the group consisting of western blot analysis, radioimmunoas say, immunofluorimetry, immunoprecipitation, equilibrium dialysis, immunodiffusion, solution phase assay, electrochemiluminescence immunoassay (ECLIA) and ELISA assay.

In various embodiments of the foregoing aspects of the invention, the control sample is a standardized control level of FRα in a healthy subject.

In a further aspect, the present invention provides a method for predicting whether a subject suffering from an FRα expressing cancer, such as ovarian cancer or lung cancer, will respond to treatment with MORAb-003, by determining the level of folate receptor alpha (FRα) which is not bound to a cell in a sample derived from the subject; and comparing the level of folate receptor alpha (FRα) which is not bound to a cell in the sample with the level of FRα in a control sample, wherein a difference between the levels of FRα in the sample derived from the subject and in the control sample is an indication that the subject will respond to treatment with MORAb-003; wherein the level of FRα in the sample derived from the subject is assessed by contacting the sample with (a) MOV 18 antibody immobilized to a solid support and labeled MORAB-003 antibody, (b) 9F3 antibody immobilized to a solid support and labeled 24F12 antibody, (c) 26B3 antibody immobilized to a solid support and labeled 19D4 antibody, and (d) 9F3 antibody immobilized to a solid support and labeled 26B3 antibody. For example, the sample may be urine, serum, plasma or ascites.

In various embodiments of the foregoing aspects of the invention, the MORAb-003 for treatment is (a) an antibody that comprises the heavy chain amino acid sequence as set forth in SEQ ID NO:7 and the light chain amino acid sequence as set forth in SEQ ID NO:8; (b) an antibody that binds the same epitope as the MORAb-003 antibody; or (c) an antibody comprising SEQ ID NO:1 (GFTFSGYGLS) as CDRH1, SEQ ID NO:2 (MISSGGSYTYYADSVKG) as CDRH2, SEQ ID NO:3 (HGDDPAWFAY) as CDRH3, SEQ ID NO:4 (SVSSSISSNNLH) as CDRL1, SEQ ID NO:5 (GTSNLAS) as CDRL2 and SEQ ID NO:6 (QQWSSYPYMYT) as CDRL3.

Methods of Treating a Subject Having Ovarian Cancer or Lung Cancer

In another aspect, the present invention provides methods of treating a subject having ovarian cancer or lung cancer by determining the level of folate receptor alpha (FRα) which is not bound to a cell, in a sample derived from said subject (for example, urine, serum, plasma or ascites); and comparing the level of folate receptor alpha (FRα) which is not bound to a cell with the level of FRα in a control sample, wherein a difference between the level of FRα in the sample derived from said subject and the level of FRα in the control sample is an indication that the subject is afflicted with ovarian cancer or lung cancer; and administering a therapeutically effective amount of MORAb-003 to said subject.

In another aspect, the present invention provides methods of treating a subject having ovarian cancer or lung cancer by determining the level of folate receptor alpha (FRα) which is not bound to a cell, in a urine sample derived from said subject; and comparing the level of folate receptor alpha (FRα) which is not bound to a cell with the level of FRα in a control sample, wherein a difference between the level of FRα in the urine sample derived from said subject and the level of FRα in the control sample is an indication that the subject is afflicted with ovarian cancer or lung cancer; and administering a therapeutically effective amount of MORAb-003 to said subject.

In another aspect, the present invention provides methods of treating a subject having ovarian cancer or lung cancer by determining the level of folate receptor alpha (FRα) which is not bound to a cell, in a serum sample derived from said subject; and comparing the level of folate receptor alpha (FRα) which is not bound to a cell with the level of FRα in a control sample, wherein a difference between the level of FRα in the serum sample derived from said subject and the level of FRα in the control sample is an indication that the subject is afflicted with ovarian cancer or lung cancer; and administering a therapeutically effective amount of MORAb-003 to said subject.

In a further aspect, the present invention provides methods for treating a subject suffering from ovarian cancer by determining the level of folate receptor alpha (FRα) which is not bound to a cell in a urine sample derived from the subject, wherein the presence of FRα which is not bound to a cell in the urine sample at a concentration of greater than about 9100 pg/ml is an indication that the subject will respond to treatment with MORAb-003; and administering a therapeutically effective amount of MORAb-003 to said subject.

In particular embodiments, the level of FRα which is not bound to a cell in the sample derived from said subject is assessed by contacting the sample with an antibody that binds FRα.

(a) an antibody that binds the same epitope as the MORAb-003 antibody;

(d) an antibody that binds the same epitope as the MOV18 antibody;

(e) the 548908 antibody;

(f) an antibody that binds the same epitope as the 548908 antibody;

(g) the 6D398 antibody;

(h) an antibody that binds the same epitope as the 6D398 antibody;

(i) an antibody that binds the same epitope as the 26B3 antibody;

(k) the 26B3 antibody;

(l) an antibody that binds the same epitope as the 19D4 antibody;

(n) the 19D4 antibody;

(o) an antibody that binds the same epitope as the 9F3 antibody;

(q) the 9F3 antibody;

(r) an antibody that binds the same epitope as the 24F12 antibody;

(t) the 24F12 antibody;

(w) an antibody that comprises the heavy chain variable region LK26KOLHuVH (SEQ ID NO: 21) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16);

(x) an antibody that comprises the heavy chain variable region LK26HuVH SLF (SEQ ID NO: 19) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16); and

(y) an antibody that comprises the heavy chain variable region LK26HuVH FAIS,N (SEQ ID NO: 18) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16).

In certain embodiments, the level of FRα is determined by using a technique selected from the group consisting of western blot analysis, radioimmunoas say, immunofluorimetry, immunoprecipitation, equilibrium dialysis, immunodiffusion, solution phase assay, electrochemiluminescence immunoassay (ECLIA) and ELISA assay.

In various embodiments of the foregoing aspects of the invention, the control sample is a standardized control level of FRα in a healthy subject.

In a further aspect, the present invention provides a method for treating a subject suffering from ovarian cancer or lung cancer, by determining the level of folate receptor alpha (FRα) which is not bound to a cell in a sample derived from the subject; and comparing the level of folate receptor alpha (FRα) which is not bound to a cell in the sample with the level of FRα in a control sample, wherein a difference between the levels of FRα in the sample derived from the subject and in the control sample is an indication that the subject will respond to treatment with MORAb-003; wherein the level of FRα in the sample derived from the subject is assessed by contacting the sample with (a) MOV18 antibody immobilized to a solid support and labeled MORAB-003 antibody, (b) 9F3 antibody immobilized to a solid support and labeled 24F12 antibody, (c) 26B3 antibody immobilized to a solid support and labeled 19D4 antibody, and (d) 9F3 antibody immobilized to a solid support and labeled 26B3 antibody. For example, the sample may be urine, serum, plasma or ascites.

Kits of the Invention

In one aspect, the present invention provides a kit for assessing whether a subject is afflicted with an FRα-expressing cancer or for assessing the progression of an FRα-expressing cancer in a subject, the kit including means for determining the level of folate receptor alpha (FRα) which is not bound to a cell in a sample derived from the subject; and instructions for use of the kit to assess whether the subject is afflicted with an FRα-expressing cancer or to assess the progression of an FRα-expressing cancer. For example, the FRα-expressing cancer is selected from the group consisting of lung cancer, mesothelioma, ovarian cancer, renal cancer, brain cancer, cervical cancer, nasopharyngeal cancer, squamous cell carcinoma of the head and neck, endometrial cancer, breast cancer, bladder cancer, pancreatic cancer, bone cancer, pituitary cancer, colorectal cancer and medullary thyroid cancer. In a particular embodiment, the FRα-expressing cancer is ovarian cancer. In yet another embodiment, the FRα-expressing cancer is non-small cell lung cancer, for example, adenocarcinoma. In a further embodiment, the sample is either urine, serum, plasma or ascites.

In a further embodiment, the means includes a folate receptor alpha (FRα) binding agent, for example, an antibody. In a further embodiment, the antibody is selected from the group consisting of

(a) an antibody that binds the same epitope as the MORAb-003 antibody;

(d) an antibody that binds the same epitope as the MOV18 antibody;

(e) the 548908 antibody;

(f) an antibody that binds the same epitope as the 548908 antibody;

(g) the 6D398 antibody;

(h) an antibody that binds the same epitope as the 6D398 antibody;

(i) an antibody that binds the same epitope as the 26B3 antibody;

(k) the 26B3 antibody;

(l) an antibody that binds the same epitope as the 19D4 antibody;

(n) the 19D4 antibody;

(o) an antibody that binds the same epitope as the 9F3 antibody;

(q) the 9F3 antibody;

(r) an antibody that binds the same epitope as the 24F12 antibody;

(t) the 24F12 antibody;

(w) an antibody that comprises the heavy chain variable region LK26KOLHuVH (SEQ ID NO: 21) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16);

(x) an antibody that comprises the heavy chain variable region LK26HuVH SLF (SEQ ID NO: 19) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16); and

(y) an antibody that comprises the heavy chain variable region LK26HuVH FAIS,N (SEQ ID NO: 18) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16).

In certain embodiments, the antibody is labeled including, but not limited to, a radio-label, a biotin-label, a chromophore-label, a fluorophore-label, or an enzyme-label.

In yet another embodiment, the kit includes a means for obtaining a sample from the subject.

The present invention is further illustrated by the following detailed description and drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic depiction of an electrochemiluminescence immunoassay (ECLIA) method for assessing the FRα in urine as described in the Examples. MOV18 antibody attached to solid supports bound FRα in urine. The FRα was subsequently detected by binding to Ru-labeled MORAb-003 antibody.

FIG. 2 shows the distribution of FRα levels in the urine of ovarian cancer subjects and normal control subjects as measured by ECLIA (see Example 1).

FIG. 3 depicts the detection of FRα in urine of ovarian cancer patients (pale band on lane 1, clear band on lane 2) using immunoblotting (see Example 5).

FIG. 4 shows the distribution of FRα levels in the urine of ovarian cancer subjects and normal control subjects as measured by ECLIA after the urine was treated with guanidine, as described in Example 7.

FIG. 5 depicts an ROC curve showing the sensitivity and specificity of the ECLIA measurement of FRα levels in urine after the urine was treated with guanidine, as described in Example 7. The area under the curve (AUC) measures the accuracy of the test in separating ovarian cancer from control subjects. A cutoff value (above which the test results were considered abnormal) of 9100 pg/mL was used.

FIG. 6 shows the distribution of FRα levels in ovarian cancer (OC) and normal control subjects after correction for creatinine levels. There is a statistically significant difference between ovarian cancer patients and controls in creatinine-corrected levels of FRα (p=0.007) (see Example 8).

FIG. 7 depicts an ROC analysis of creatinine-corrected FRα levels determined using electrochemiluminescence assay (ECLIA) of guanidine-treated urine samples (see Example 8).

FIG. 8 is a schematic depiction of the enzyme immunoassay (EIA) method used for assessing the level of FRα (i.e., FRα) in samples, as described in Example 9. MOV-18 served as the capture antibody, which bound FRα from biological fluids. The FRα was detected by binding to biotinylated MORAb-003, which was detected using avidin conjugated to horseradish peroxidase (avidin-HRP).

FIG. 9 depicts results obtained for the measurement of FRα in serum using one- and two-step incubation procedures, as described in Example 9.

FIG. 10 is a schematic depiction of the three different combinations of capture and detector antibodies that were used with the enzyme immunoassay (EIA) method for assessing the level of FRα in human plasma, as described in Example 11.

FIG. 11 shows the plasma concentrations of FRα (pg/mL) for individual subjects determined using EIA with three combinations of capture and detector antibodies, as described in Example 11.

FIG. 12 depicts the relationship between OD values and FRα concentrations (see Example 11).

FIG. 13 shows the distribution of plasma FRα concentrations in subjects with ovarian cancer and normal control subjects as determined using EIA (see Example 12).

FIG. 14 depicts the correlation between FRα plasma concentrations determined using EIA and ECLIA (see Example 12).

FIG. 15 shows correlations between ECLIA measures of FRα levels in serum and urine. The correlation for lung cancer patients was r=0.24 (upper panel) and the correlation for ovarian cancer patients was r=−0.76 (lower panel) (see Example 13).

FIG. 16 shows the correlation of serum versus plasma FRα levels for assays conducted using pair 1 (see Example 16).

FIG. 17 shows the correlation of serum versus plasma FRα levels for assays conducted using pair 2 (see Example 16).

FIG. 18 shows the correlation of serum FRα levels for assays conducted using pair 1 versus pair 2 (see Example 16).

FIG. 19 shows the correlation of plasma FRα levels for assays conducted using pair 1 versus pair 2 (see Example 16).

FIG. 20 shows the intraday correlation of serum FRα levels for assays conducted using pair 2 (Example 16).

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based, at least in part, on the unexpected discovery that folate receptor alpha (FRα), not bound to a cell, is found at elevated levels in the body fluids, for example, urine or serum, of a subject having an FRα-expressing cancer such as lung or ovarian cancer as compared to a control sample. Moreover, the present invention is based, at least in part, on the identification of an immunological assay that exhibits the necessary sensitivity for assessing FRα levels in samples, where prior attempts to do so repeatedly failed. As a result, the present invention provides methods for diagnosing an FRα-expressing cancer by assessing levels of an FRα not bound to a cell in samples derived from the subject. Indeed, the present invention overcomes the challenges observed during prior attempts to develop an FRα based diagnostic assay for FRα-expressing cancers such as ovarian cancer by providing an immunological assay capable of accurately assessing levels of FRα not bound to a cell in samples.

Accordingly, methods and kits for assessing whether a subject has or is at risk for developing an FRα-expressing cancer and, further, for assessing the progression of FRα-expressing cancer are provided. In various embodiments, the methods involve the comparison of levels of FRα not bound to a cell in samples, for example, urine and serum, as compared to control levels, in assessing the presence, degree or risk of development of ovarian cancer in the subject. In particular embodiments, the methods involve the use of the MORAb-003 antibody, antibodies that bind the same epitope as the MORAb-003 antibody or antibodies having SEQ ID NO:1 (GFTFSGYGLS) as CDRH1, SEQ ID NO:2 (MISSGGSYTYYADSVKG) as CDRH2, SEQ ID NO:3 (HGDDPAWFAY) as CDRH3, SEQ ID NO:4 (SVSSSISSNNLH) as CDRL1, SEQ ID NO:5 (GTSNLAS) as CDRL2 and SEQ ID NO:6 (QQWSSYPYMYT) as CDRL3, in assessing the levels of FRα not bound to a cell in a sample, e.g., urine or serum. Alternatively or in addition, the MOV 18 antibody or an antibody that binds the same epitope of the MOV18 antibody, the 548908 antibody, an antibody that binds the same epitope of the 548908 antibody, the 6D398 antibody or an antibody that binds the same epitope of the 548908 antibody may be used in accordance with the methods of the present invention.

Various aspects of the invention are described in further detail in the following subsections:

I. DEFINITIONS

As used herein, each of the following terms has the meaning associated with it in this section.

The articles “a” and “an” are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

As used herein, the term “subject” refer to human and non-human animals, including veterinary subjects. The term “non-human animal” includes all vertebrates, e.g., mammals and non-mammals, such as non-human primates, mice, rabbits, sheep, dog, cat, horse, cow, chickens, amphibians, and reptiles. In a preferred embodiment, the subject is a human.

The terms “cancer” or “tumor” are well known in the art and refer to the presence, e.g., in a subject, of cells possessing characteristics typical of cancer-causing cells, such as uncontrolled proliferation, immortality, metastatic potential, rapid growth and proliferation rate, and certain characteristic morphological features. Cancer cells are often in the form of a tumor, but such cells may exist alone within a subject, or may be non-tumorigenic cancer cells, such as leukemia cells. As used herein, the term “cancer” includes pre-malignant as well as malignant cancers.

As used herein, an “FRα-expressing cancer” includes any type of cancer characterized in that the cancer cells express FRα. In particular embodiments, the FRα expressing cancer includes cancerous conditions characterized in that the cancer cells are capable of secreting, shedding, exporting or releasing FRα in such a manner that elevated levels of FRα are detectable in a biological sample from the subject. FRα-expressing cancers include, but are not limited to, lung cancer (e.g., bronchioalveolar carcinomas, carcinoid tumors, and non-small cell lung cancers, such as adenocarcinomas); mesothelioma; ovarian cancer; renal cancer; brain cancer (e.g., anaplastic ependymoma and cerebellar juvenile pilocytic astrocytoma); cervical cancer; nasopharyngeal cancer; mesodermally derived tumor; squamous cell carcinoma of the head and neck; endometrial cancer; endometrioid adenocarcinomas of the ovary, serous cystadenocarcinomas, breast cancer; bladder cancer; pancreatic cancer; bone cancer (e.g., high-grade osteosarcoma); pituitary cancer (e.g., pituitary adenoma). See e.g., U.S. Pat. No. 7,754,698; U.S. Patent Application No. 2005/0232919; WO 2009/132081; Bueno R et al. J of Thoracic and Cardiovascular Surgery, 121(2): 225-233 (2001); Elkanat H & Ratnam M. Frontiers in Bioscience, 11, 506-519 (2006); Franklin, W A et al. Int J Cancer, Suppl 8: 89-95 (1994); Hartman L. C. et al. Int J Cancer 121: 938-942 (2007); Iwakiri S et al. Annals of Surgical Oncology, 15(3): 889-899; Weitman, S D et al. Cancer Res 52: 3396-3401 (1992); Saba N. F. et al. Head Neck, 31(4): 475-481 (2009); Yang R et al. Clin Cancer Res 13: 2557-2567 (2007). In a particular embodiment, the FRα-expressing cancer is ovarian cancer. In another embodiment, the FRα-expressing cancer is lung cancer such as non-small cell lung cancer. In other embodiments, the FRα-expressing cancer is colorectal cancer and medullary thyroid cancer.

As used herein, a subject who is “afflicted with an FRα-expressing cancer” is one who is clinically diagnosed with such a cancer by a qualified clinician (for example, by the methods of the present invention), or one who exhibits one or more signs or symptoms (for example, elevated levels of FRα in biological fluids) of such a cancer and is subsequently clinically diagnosed with such a cancer by a qualified clinician (for example, by the methods of the present invention). A non-human subject that serves as an animal model of FRα-expressing cancer may also fall within the scope of the term a subject “afflicted with an FRα-expressing cancer.”

The term “ovarian cancer” refers to the art recognized disease and includes each of epithelial ovarian cancer (EOC; >90% of ovarian cancer in Western countries), germ cell tumors (circa 2-3% of ovarian cancer), and stromal ovarian cancer. Ovarian cancer is stratified into different groups based on the differentiation of the tumor tissue. In grade I, the tumor tissue is well differentiated. In grade II, tumor tissue is moderately well differentiated. In grade III, the tumor tissue is poorly differentiated. This grade correlates with a less favorable prognosis than grades I and II.

Ovarian cancer is stratified into different stages based on the spread of the cancer. Stage I is generally confined within the capsule surrounding one (stage IA) or both (stage IB) ovaries, although in some stage I (i.e. stage IC) cancers, malignant cells may be detected in ascites, in peritoneal rinse fluid, or on the surface of the ovaries. Stage II involves extension or metastasis of the tumor from one or both ovaries to other pelvic structures. In stage IIA, the tumor extends or has metastasized to the uterus, the fallopian tubes, or both. Stage IIB involves extension of the tumor to the pelvis. Stage IIC is stage IIA or IIB in which malignant cells may be detected in ascites, in peritoneal rinse fluid, or on the surface of the ovaries. In stage III, the tumor comprises at least one malignant extension to the small bowel or the omentum, has formed extrapelvic peritoneal implants of microscopic (stage IIIA) or macroscopic (<2 centimeter diameter, stage IIIB; >2 centimeter diameter, stage IIIC) size, or has metastasized to a retroperitoneal or inguinal lymph node (an alternate indicator of stage IIIC). In stage IV, distant (i.e. non-peritoneal) metastases of the tumor can be detected.

The durations of the various stages of ovarian cancer are not presently known, but are believed to be at least about a year each (Richart et al., 1969, Am. J. Obstet. Gynecol. 105:386). Prognosis declines with increasing stage designation. For example, 5-year survival rates for human subjects diagnosed with stage I, II, III, and IV ovarian cancer are 80%, 57%, 25%, and 8%, respectively.

Each of the foregoing types, groups and stages of ovarian cancer are encompassed by the term “ovarian cancer” as used herein.

As used herein, the term “lung cancer” refers to a disease in tissues of the lung involving uncontrolled cell growth, which, in some cases, leads to metastasis. Lung cancer is the most common cause of cancer-related death in men and women. The majority of primary lung cancers are carcinomas of the lung, derived from epithelial cells. The main types of lung cancer are small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC). In a particular embodiment, the FRα-expressing cancer is a non-small cell lung cancer.

Small cell lung cancer or small cell lung carcinoma (SCLC) is a malignant cancer of the lung, wherein the cancer cells have a flat shape and scanty cytoplasm; therefore, SCLC is sometimes called “oat cell carcinoma.” SCLC is generally more metastatic than NSCLC and is sometimes seen in combination with squamous cell carcinomas.

As used herein, the term “non-small cell lung cancer,” also known as non-small cell lung carcinoma (NSCLC), refers to epithelial lung cancer other than small cell lung carcinoma (SCLC). There are three main sub-types: adenocarcinoma, squamous cell lung carcinoma, and large cell lung carcinoma. Other less common types of non-small cell lung cancer include pleomorphic, carcinoid tumor, salivary gland carcinoma, and unclassified carcinoma. Adenocarcinomas account for approximately 40% of lung cancers, and are the most common type of lung cancer in people who have never smoked. Squamous cell carcinomas account for about 25% of lung cancers. Squamous cell carcinoma of the lung is more common in men than in women and is even more highly correlated with a history of tobacco smoking than are other types of lung carcinoma. There are at least four variants (papillary, small cell, clear cell, and basaloid) of squamous cell carcinoma of the lung. Large cell lung carcinomas are a heterogeneous group of malignant neoplasms originating from transformed epithelial cells in the lung. Large cell lung carcinomas are carcinomas that lack light microscopic characteristics of small cell carcinoma, squamous cell carcinoma, or adenocarcinoma.

Different staging systems are used for SCLC and NSCLC. SCLC is categorized as limited disease confined to the ipsilateral hemithorax or as extensive disease with metastasis beyond the ipsilateral hemithorax.

NSCLC may be categorized using the tumor-nodes-metastasis (TNM) staging system. See Spira J & Ettinger, D.S. Multidisciplinary management of lung cancer, N Engl J Med, 350:382-(2004) (hereinafter Spira); Greene F L, Page D L, Fleming I D, Fritz A G, Balch C M, Haller D G, et al (eds). AJCC Cancer Staging Manual. 6th edition. New York: Springer-Verlag, 2002:167-77 (hereinafter Greene); Sobin L H, Wittekind C H (eds). International Union Against Cancer. TNM classification of malignant tumours. 6th edition. New York: Wiley-Liss (2002) (hereinafter Sobin). In addition, NSCLC is typically treated according to the stage of cancer determined by the following classification scheme (see http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/Patient/page2#Keypoint10).

In the occult (hidden) stage, cancer cells are found in sputum (mucus coughed up from the lungs), but no tumor can be found in the lung by imaging or bronchoscopy, or the tumor is too small to be checked.

In stage 0 (carcinoma in situ), abnormal cells are found in the lining of the airways. These abnormal cells may become cancer and spread into nearby normal tissue.

Stage 0 is also called carcinoma in situ.

Stage I, in which cancer has formed, is divided into stages IA and IB.

In Stage IA, the tumor is in the lung only and is 3 centimeters or smaller.

In Stage IB, the cancer has not spread to the lymph nodes and one or more of the following is true: (i) The tumor is larger than 3 centimeters but not larger than 5 centimeters; (ii) cancer has spread to the main bronchus and is at least 2 centimeters below where the trachea joins the bronchus; (iii) cancer has spread to the innermost layer of the membrane that covers the lung; (iv) part of the lung has collapsed or developed pneumonitis (inflammation of the lung) in the area where the trachea joins the bronchus.

In Stage IIA, cancer has spread to certain lymph nodes on the same side of the chest as the primary tumor; the cancer is (a) 5 cm or smaller, (b) has spread to the main bronchus, and/or (c) has spread to the innermost layer of the lung lining. OR, cancer has not spread to lymph nodes; the cancer is (d) larger than 5 cm but not larger than 7 cm, (e) has spread to the main bronchus, and/or (f) has spread to the innermost layer of the lung lining. Part of the lung may have collapsed or become inflamed. Stage IIA is divided into two sections depending on the size of the tumor, where the tumor is found, and whether there is cancer in the lymph nodes. In the first section, cancer has spread to lymph nodes on the same side of the chest as the tumor. The lymph nodes with cancer are within the lung or near the bronchus. Also, one or more of the following is true: (i) the tumor is not larger than 5 centimeters, (ii) cancer has spread to the main bronchus and is at least 2 centimeters below where the trachea joins the bronchus, (iii) cancer has spread to the innermost layer of the membrane that covers the lung, (iv) part of the lung has collapsed or developed pneumonitis (inflammation of the lung) in the area where the trachea joins the bronchus. In the second section, cancer has not spread to lymph nodes and one or more of the following is true: (i) the tumor is larger than 5 centimeters but not larger than 7 centimeters, (ii) cancer has spread to the main bronchus and is at least 2 centimeters below where the trachea joins the bronchus, (iii) cancer has spread to the innermost layer of the membrane that covers the lung, (iv) part of the lung has collapsed or developed pneumonitis (inflammation of the lung) in the area where the trachea joins the bronchus.

In Stage IIB, cancer has spread to certain lymph nodes on the same side of the chest as the primary tumor; the cancer is (a) larger than 5 cm but not larger than 7 cm, (b) has spread to the main bronchus, and/or (c) has spread to the innermost layer of the lung lining. Part of the lung may have collapsed or become inflamed. Alternatively, (d) the cancer is larger than 7 cm; (e) has spread to the main bronchus, (f) the diaphragm, (g) the chest wall or the lining of the chest wall; and/or (h) has spread to the membrane around the heart. There may be one or more separate tumors in the same lobe of the lung; cancer may have spread to the nerve that controls the diaphragm; the whole lung may have collapsed or become inflamed. Stage IIB is divided into two sections depending on the size of the tumor, where the tumor is found, and whether there is cancer in the lymph nodes. In the first section, cancer has spread to nearby lymph nodes on the same side of the chest as the tumor. The lymph nodes with cancer are within the lung or near the bronchus. Also, one or more of the following is true: (i) the tumor is larger than 5 centimeters but not larger than 7 centimeters, (ii) cancer has spread to the main bronchus and is at least 2 centimeters below where the trachea joins the bronchus, (iii) cancer has spread to the innermost layer of the membrane that covers the lung, (iv) part of the lung has collapsed or developed pneumonitis (inflammation of the lung) in the area where the trachea joins the bronchus. In the second section, cancer has not spread to lymph nodes and one or more of the following is true: (i) the tumor is larger than 7 centimeters, (ii) cancer has spread to the main bronchus (and is less than 2 centimeters below where the trachea joins the bronchus), the chest wall, the diaphragm, or the nerve that controls the diaphragm, (iii) cancer has spread to the membrane around the heart or lining the chest wall, (iv) the whole lung has collapsed or developed pneumonitis (inflammation of the lung), (v) there are one or more separate tumors in the same lobe of the lung.

Stage IIIA is divided into three sections depending on the size of the tumor, where the tumor is found, and which lymph nodes have cancer (if any). In the first section of Stage IIIA, cancer has spread to lymph nodes on the same side of the chest as the tumor. The lymph nodes with cancer are near the sternum (chest bone) or where the bronchus enters the lung. Also, the tumor may be any size; part of the lung (where the trachea joins the bronchus) or the whole lung may have collapsed or developed pneumonitis (inflammation of the lung); there may be one or more separate tumors in the same lobe of the lung; and cancer may have spread to any of the following: (i) main bronchus, but not the area where the trachea joins the bronchus, (ii) chest wall, (iii) diaphragm and the nerve that controls it, (iv) membrane around the lung or lining the chest wall, (iv) membrane around the heart. In the second section of Stage IIIA, cancer has spread to lymph nodes on the same side of the chest as the tumor. The lymph nodes with cancer are within the lung or near the bronchus. Also, the tumor may be any size; the whole lung may have collapsed or developed pneumonitis (inflammation of the lung); there may be one or more separate tumors in any of the lobes of the lung with cancer; and cancer may have spread to any of the following: (i) main bronchus, but not the area where the trachea joins the bronchus, (ii) chest wall, (iii) diaphragm and the nerve that controls it, (iv) membrane around the lung or lining the chest wall, (v) heart or the membrane around it, (vi) major blood vessels that lead to or from the heart, (vi) trachea, (vii) esophagus, (viii) nerve that controls the larynx (voice box), (ix) sternum (chest bone) or backbone, (x) carina (where the trachea joins the bronchi). In the third section of Stage IIIA, cancer has not spread to the lymph nodes and the tumor may be any size, and cancer has spread to any of the following: (i) heart, (ii) major blood vessels that lead to or from the heart, (iii) trachea, (iv) esophagus, (v) nerve that controls the larynx (voice box), (vi) sternum (chest bone) or backbone, (vi) carina (where the trachea joins the bronchi).

Stage IIIB is divided into two sections depending on the size of the tumor, where the tumor is found, and which lymph nodes have cancer. In the first section, cancer has spread to lymph nodes above the collarbone or to lymph nodes on the opposite side of the chest as the tumor; the tumor may be any size; part of the lung (where the trachea joins the bronchus) or the whole lung may have collapsed or developed pneumonitis (inflammation of the lung); there may be one or more separate tumors in any of the lobes of the lung with cancer; and cancer may have spread to any of the following: (i) main bronchus, (ii) chest wall, (iii) diaphragm and the nerve that controls it, (iv) membrane around the lung or lining the chest wall, (iv) heart or the membrane around it, (v) major blood vessels that lead to or from the heart, (vi) trachea, (vii) esophagus, (viii) nerve that controls the larynx (voice box), (ix) sternum (chest bone) or backbone, (x) carina (where the trachea joins the bronchi). In the second section of Stage IIIB, cancer has spread to lymph nodes on the same side of the chest as the tumor; the lymph nodes with cancer are near the sternum (chest bone) or where the bronchus enters the lung; the tumor may be any size; there may be separate tumors in different lobes of the same lung; and cancer has spread to any of the following: (i) heart, (ii) major blood vessels that lead to or from the heart, (iii) trachea, (iv) esophagus, (v) nerve that controls the larynx (voice box), (vi) sternum (chest bone) or backbone, (vii) carina (where the trachea joins the bronchi).

In Stage IV, the tumor may be any size and cancer may have spread to lymph nodes. One or more of the following is true: there are one or more tumors in both lungs; cancer is found in fluid around the lungs or the heart; cancer has spread to other parts of the body, such as the brain, liver, adrenal glands, kidneys, or bone.

Accordingly, in various embodiments of the foregoing invention, the lung cancer may be stratified into any of the preceding stages (e.g., occult, stage 0, stage IA, stage IB, stage IIA, stage IIB, stage IIIA, stage IIIB or stage IV) based on assessing of the levels of FRα not bound to a cell, such as a normal or cancerous cell, in a sample (for example, urine or serum) of a subject.

As used herein, the term “folate receptor alpha” (also referred to as FRα, FR-alpha, FOLR-1 or FOLR1) refers to the alpha isoform of the high affinity receptor for folate. Membrane bound FRα is attached to the cell surface by a glycosyl phosphatidylinositol (GPI) anchor), recycles between extracellular and endocytic compartments and is capable of transporting folate into the cell. FRα is expressed in a variety of epithelial tissues including those of the female reproductive tract, placenta, breast, kidney proximal tubules, choroid plexus, lung and salivary glands. Soluble forms of FRα may be derived by the action of proteases or phospholipase on membrane anchored folate receptors.

The consensus nucleotide and amino acid sequences for human FRα are set forth herein as SEQ ID NOs: 24 and 25, respectively. Variants, for example, naturally occurring allelic variants or sequences containing at least one amino acid substitution, are encompassed by the terms as used herein.

As used herein, the term “not bound to a cell” refers to FRα that is not attached to the cellular membrane of a cell, such as a cancerous cell. In a particular embodiment, the FRα not bound to a cell is unbound to any cell and is freely floating or solubilized in biological fluids, e.g., urine or serum. For example, the FRα may be shed, secreted or exported from normal or cancerous cells, for example, from the surface of cancerous cells, into biological fluids.

The “level” of folate receptor alpha not bound to a cell, as used herein, refers to the level of folate receptor alpha protein as determined using any method known in the art for the measurement of protein levels. Such methods include, for example, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, fluid or gel precipitin reactions, absorption spectroscopy, a colorimetric assays, spectrophotometric assays, flow cytometry, immunodiffusion (single or double), solution phase assay, immunoelectrophoresis, Western blotting, radioimmunoassay (RIA), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, and electrochemiluminescence immunoassay (exemplified below), and the like. In a preferred embodiment, the level is determined using antibody-based techniques, as described in more detail herein.

It is generally preferable to immobilize either an antibody or binding protein specific for FRα not bound to a cell on a solid support for Western blots and immunofluorescence techniques. Suitable solid phase supports or carriers include any support capable of binding an antigen or an antibody. Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite.

One skilled in the art will know many other suitable carriers for binding antibody or antigen, and will be able to adapt such support for use with the present invention. For example, protein isolated from a subject sample (e.g., urine or serum) can be run on a polyacrylamide gel electrophoresis and immobilized onto a solid phase support such as nitrocellulose. The support can then be washed with suitable buffers followed by treatment with the labeled antibody. The solid phase support can then be washed with the buffer a second time to remove unbound antibody. The amount of bound label on the solid support can then be detected by conventional means. Means of detecting proteins using electrophoretic techniques are well known to those of skill in the art (see generally, R. Scopes (1982) Protein Purification, Springer-Verlag, N.Y.; Deutscher, (1990) Methods in Enzymology Vol. 182: Guide to Protein Purification, Academic Press, Inc., N.Y.).

Other standard methods include immunoassay techniques which are well known to one of ordinary skill in the art and may be found in Principles And Practice Of Immunoassay, 2nd Edition, Price and Newman, eds., MacMillan (1997) and Antibodies, A Laboratory Manual, Harlow and Lane, eds., Cold Spring Harbor Laboratory, Ch. 9 (1988), each of which is incorporated herein by reference in its entirety.

Antibodies used in immunoassays to determine the level of expression of folate receptor alpha may be labeled with a detectable label. The term “labeled”, with regard to the binding agent or antibody, is intended to encompass direct labeling of the binding agent or antibody by coupling (i.e., physically linking) a detectable substance to the binding agent or antibody, as well as indirect labeling of the binding agent or antibody by reactivity with another reagent that is directly labeled. An example of indirect labeling includes detection of a primary antibody using a fluorescently labeled secondary antibody. In one embodiment, the antibody is labeled, e.g., radio-labeled, chromophore-labeled, fluorophore-labeled, or enzyme-labeled. In another embodiment, the antibody is an antibody derivative (e.g., an antibody conjugated with a substrate or with the protein or ligand of a protein-ligand pair (e.g., biotin-streptavidin), or an antibody fragment (e.g., a single-chain antibody, an isolated antibody hypervariable domain) which binds specifically with FRα not bound to a cell.

In one embodiment of the invention, proteomic methods, e.g., mass spectrometry, are used. Mass spectrometry is an analytical technique that consists of ionizing chemical compounds to generate charged molecules (or fragments thereof) and measuring their mass-to-charge ratios. In a typical mass spectrometry procedure, a sample is obtained from a subject, loaded onto the mass spectrometry, and its components (e.g., FRα) are ionized by different methods (e.g., by impacting them with an electron beam), resulting in the formation of charged particles (ions). The mass-to-charge ratio of the particles is then calculated from the motion of the ions as they transit through electromagnetic fields.

For example, matrix-associated laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) or surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) which involves the application of a sample, such as urine or serum, to a protein-binding chip (Wright, G. L., Jr., et al. (2002) Expert Rev Mol Diagn 2:549; Li, J., et al. (2002) Clin Chem 48:1296; Laronga, C., et al. (2003) Dis Markers 19:229; Petricoin, E. F., et al. (2002) 359:572; Adam, B. L., et al. (2002) Cancer Res 62:3609; Tolson, J., et al. (2004) Lab Invest 84:845; Xiao, Z., et al. (2001) Cancer Res 61:6029) can be used to determine the level of FRα.

Furthermore, in vivo techniques for determination of the level of FRα not bound to a cell include introducing into a subject a labeled antibody directed against FRα, which binds to and transforms FRα into a detectable molecule. The presence, level, or location of the detectable FRα not bound to a cell in a subject may be determined using standard imaging techniques.

The term “sample” as used herein refers to a collection of similar fluids, cells, or tissues isolated from a subject, as well as fluids, cells, or tissues present within a subject. In preferred embodiments the sample is a biological fluid containing FRα not bound to a cancerous cell. Biological fluids are typically liquids at physiological temperatures and may include naturally occurring fluids present in, withdrawn from, expressed or otherwise extracted from a subject or biological source. Certain biological fluids derive from particular tissues, organs or localized regions and certain other biological fluids may be more globally or systemically situated in a subject or biological source. Examples of biological fluids include blood, serum and serosal fluids, plasma, lymph, urine, cerebrospinal fluid, saliva, ocular fluids, cystic fluid, tear drops, feces, sputum, mucosal secretions of the secretory tissues and organs, vaginal secretions, gynecological fluids, ascites fluids such as those associated with non-solid tumors, fluids of the pleural, pericardial, peritoneal, abdominal and other body cavities, fluids collected by bronchial lavage and the like. In a particular embodiment, the sample is urine or serum. In another embodiment, the sample does not include ascites or is not an ascite sample. In another embodiment, the sample does not include peritoneal fluid or is not peritoneal fluid.

In one embodiment, the sample is removed from the subject. In another embodiment, the sample is present within the subject. Biological fluids may also include liquid solutions contacted with a subject or biological source, for example, cell and organ culture medium including cell or organ conditioned medium, lavage fluids and the like.

In some embodiments, only a portion of the sample is subjected to an assay for determining the level of FRα not bound to a cell, or various portions of the sample are subjected to various assays for determining the level of FRα not bound to a cell. Also, in many embodiments, the sample may be pre-treated by physical or chemical means prior to the assay. For example, in embodiments discussed in more detail in the Examples section, samples, for example, urine samples, were subjected to centrifugation, dilution and/or treatment with a solubilizing substance (e.g., guanidine treatment) prior to assaying the samples for FRα not bound to a cell. Such techniques serve to enhance the accuracy, reliability and reproducibility of the assays of the present invention.

The term “control sample,” as used herein, refers to any clinically relevant control sample, including, for example, a sample from a healthy subject not afflicted with ovarian cancer, a sample from a subject having a less severe or slower progressing ovarian cancer than the subject to be assessed, a sample from a subject having some other type of cancer or disease, and the like. A control sample may include a sample derived from one or more subjects. A control sample may also be a sample made at an earlier timepoint from the subject to be assessed. For example, the control sample could be a sample taken from the subject to be assessed before the onset of the FRα expressing cancer such as lung or ovarian cancer, at an earlier stage of disease, or before the administration of treatment or of a portion of treatment. The control sample may also be a sample from an animal model, or from a tissue or cell lines derived from the animal model, of the FRα expressing cancer such as lung or ovarian cancer. The level of FRα not bound to a cell in a control sample that consists of a group of measurements may be determined based on any appropriate statistical measure, such as, for example, measures of central tendency including average, median, or modal values.

The term “control level” refers to an accepted or pre-determined level of FRα which is used to compare with the level of FRα in a sample derived from a subject. In one embodiment, the control level of FRα is based on the level of FRα not bound to a cell in sample(s) from a subject(s) having slow disease progression. In another embodiment, the control level of FRα not bound to a cell is based on the level in a sample from a subject(s) having rapid disease progression. In another embodiment, the control level of FRα is based on the level of FRα not bound to a cell in a sample(s) from an unaffected, i.e., non-diseased, subject(s), i.e., a subject who does not have an FRα expressing cancer such as lung or ovarian cancer. In yet another embodiment, the control level of FRα is based on the level of FRα not bound to a cell in a sample from a subject(s) prior to the administration of a therapy for ovarian cancer. In another embodiment, the control level of FRα is based on the level of FRα not bound to a cell in a sample(s) from a subject(s) having an FRα expressing cancer such as lung or ovarian cancer that is not contacted with a test compound. In another embodiment, the control level of FRα is based on the level of FRα not bound to a cell in a sample(s) from a subject(s) not having an FRα expressing cancer such as lung or ovarian cancer that is contacted with a test compound. In one embodiment, the control level of FRα is based on the level of FRα not bound to a cell in a sample(s) from an animal model of an FRα expressing cancer such as lung or ovarian cancer, a cell, or a cell line derived from the animal model of an FRα expressing cancer such as lung or ovarian cancer.

In one embodiment, the control is a standardized control, such as, for example, a control which is predetermined using an average of the levels of FRα not bound to a cell from a population of subjects having no FRα expressing cancer such as lung or ovarian cancer. In still other embodiments of the invention, a control level of FRα is based on the level of FRα not bound to a cell in a non-cancerous sample(s) derived from the subject having an FRα expressing cancer such as lung or ovarian cancer. For example, when a laparotomy or other medical procedure reveals the presence of ovarian cancer in one portion of the ovaries, the control level of FRα may be determined using the non-affected portion of the ovaries, and this control level may be compared with the level of FRα in an affected portion of the ovaries. Similarly, when a biopsy or other medical procedure reveals the presence of a lung cancer in one portion of the lungs, the control level of FRα may be determined using the non-affected portion of the lungs, and this control level may be compared with the level of FRα in an affected portion of the lungs.

As used herein, “a difference” between the level of folate receptor alpha not bound to a cell in a sample from a subject (i.e., a test sample) and the level of folate receptor alpha not bound to a cell in a control sample refers broadly to any clinically relevant and/or statistically significant difference in the level of folate receptor alpha in the two samples. In an exemplary embodiment, the difference is selected based on a cutoff value determined using a receiver operating characteristic (ROC) analysis, an example of which is presented in Example 6.

In other embodiments, the difference must be greater than the limits of detection of the method for determining the level of FRα not bound to a cell. It is preferred that the difference be at least greater than the standard error of the assessment method, and preferably a difference of at least about 2-, about 3-, about 4-, about 5-, about 6-, about 7-, about 8-, about 9-, about 10-, about 15-, about 20-, about 25-, about 100-, about 500-, about 1000-fold or greater than the standard error of the assessment method. The difference may be assessed by any appropriate comparison, including any appropriate parametric or nonparametric descriptive statistic or comparison. For example, “an increase” in the level of FRα not bound to a cell may refer to a level in a test sample that is about two, and more preferably about three, about four, about five, about six, about seven, about eight, about nine, about ten or more times more than the level of FRα in the control sample. An increase may also refer to a level in a test sample that is preferably at least about 1.5, and more preferably about two, about three, about four, about five or more standard deviations above the average level of FRα in the control sample. Likewise, “a decrease” in the level of FRα not bound to a cell may refer to a level in a test sample that is preferably at least about two, and more preferably about three, about four, about five, about six, about seven, about eight, about nine, about ten or more times less than the level of FRα in the control sample. A decrease may also refer to a level in a test sample that is preferably at least about 1.5, and more preferably about two, about three, about four, about five or more standard deviations below the average level of FRα in the control sample.

As used herein, the term “contacting the sample” with an FRα binding agent, e.g., an anti-FRα antibody, includes exposing the sample, or any portion thereof with the agent or antibody, such that at least a portion of the sample comes into contact with the agent or antibody. The sample or portion thereof may be altered in some way, such as by subjecting it to physical or chemical treatments (e.g., dilution or guanidine treatment), prior to the act of contacting it with the agent or antibody.

The term “antibody” as used herein, comprises four polypeptide chains, two heavy (H) chains and two light (L) chains, interconnected by disulfide bonds, as well as any functional (i.e., antigen-binding) fragment, mutant, variant, or derivation thereof, which retains the essential epitope binding features of an Ig molecule. Such mutant, variant, or derivative antibody formats are known in the art, and include molecules such as Fab fragments, Fab′ fragments, F(ab′)₂fragments, Fd fragments, Fabc fragments, Sc antibodies (single chain antibodies), diabodies, individual antibody light chains, individual antibody heavy chains, chimeric fusions between antibody chains and the like. Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass.

Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CH1, CH2 and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, and define the antibody's isotype as IgG, IgM, IgA, IgD and IgE, respectively.

The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.

The term “antigen-binding portion” of an antibody, as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., FRα not bound to a cell). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term “antigen-binding portion” of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the V_L, V_H, CL and CH1 domains; (ii) a F(ab′)₂fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the V_Hand CH1 domains; (iv) a Fv fragment consisting of the V_Land V_Hdomains of a single arm of an antibody, (v) a dAb including VH and VL domains; (vi) a dAb fragment (Ward et al. (1989) Nature 341, 544-546), which consists of a V_Hdomain; (vii) a dAb which consists of a VH or a VL domain; and (viii) an isolated complementarity determining region (CDR) or (ix) a combination of two or more isolated CDRs which may optionally be joined by a synthetic linker. Furthermore, although the two domains of the Fv fragment, V_Land V_H, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the V_Land V_Hregions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al. (1988) Science 242, 423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85, 5879-5883). Such single chain antibodies are also intended to be encompassed within the term “antigen-binding portion” of an antibody. These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies. Antigen-binding portions can be produced by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact immunoglobulins.

The term “antibody”, as used herein, includes polyclonal antibodies, monoclonal antibodies, murine antibodies, chimeric antibodies, humanized antibodies, and human antibodies, and those that occur naturally or are recombinantly produced according to methods well known in the art.

In one embodiment, an antibody for use in the methods of the invention is a bispecific antibody. A “bispecific antibody” is an artificial hybrid antibody having two different heavy/light chain pairs and two different binding sites. Bispecific antibodies can be produced by a variety of methods including fusion of hybridomas or linking of Fab′ fragments. See, e.g., Songsivilai & Lachmann, (1990) Clin. Exp. Immunol. 79, 315-321; Kostelny et al. (1992) J. Immunol. 148, 1547-1553.

In another embodiment, an antibody for use in the methods of the invention is a camelid antibody as described in, for example, PCT Publication WO 94/04678, the entire contents of which are incorporated herein by reference.

A region of the camelid antibody that is the small, single variable domain identified as V_HHcan be obtained by genetic engineering to yield a small protein having high affinity for a target, resulting in a low molecular weight, antibody-derived protein known as a “camelid nanobody”. See U.S. Pat. No. 5,759,808; see also Stijlemans et al., 2004 J. Biol. Chem. 279: 1256-1261; Dumoulin et al., 2003 Nature 424: 783-788; Pleschberger et al., 2003 Bioconjugate Chem. 14: 440-448; Cortez-Retamozo et al., 2002 Int. J. Cancer 89: 456-62; and Lauwereys et al., 1998 EMBO J. 17: 3512-3520. Engineered libraries of camelid antibodies and antibody fragments are commercially available, for example, from Ablynx, Ghent, Belgium. Accordingly, a feature of the present invention is a camelid nanobody having high affinity for FRα.

In other embodiments of the invention, an antibody for use in the methods of the invention is a diabody, a single chain diabody, or a di-diabody.

Diabodies are bivalent, bispecific molecules in which V_Hand V_Ldomains are expressed on a single polypeptide chain, connected by a linker that is too short to allow for pairing between the two domains on the same chain. The V_Hand V_Ldomains pair with complementary domains of another chain, thereby creating two antigen binding sites (see e.g., Holliger et al., 1993 Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak et al., 1994 Structure 2:1121-1123). Diabodies can be produced by expressing two polypeptide chains with either the structure V_HA-V_LBand V_HB-V_LA(V_H-V_Lconfiguration), or V_LA-V_HBand V_LB-V_HA(V_L-V_Hconfiguration) within the same cell. Most of them can be expressed in soluble form in bacteria.

Single chain diabodies (scDb) are produced by connecting the two diabody-forming polypeptide chains with linker of approximately 15 amino acid residues (see Holliger and Winter, 1997 Cancer Immunol. Immunother., 45(3-4):128-30; Wu et al., 1996 Immunotechnology, 2(1):21-36). scDb can be expressed in bacteria in soluble, active monomeric form (see Holliger and Winter, 1997 Cancer Immunol. Immunother., 45(34): 128-30; Wu et al., 1996 Immunotechnology, 2(1):21-36; Pluckthun and Pack, 1997 Immunotechnology, 3(2): 83-105; Ridgway et al., 1996 Protein Eng., 9(7):617-21).

A diabody can be fused to Fc to generate a “di-diabody” (see Lu et al., 2004 J. Biol. Chem., 279(4):2856-65).

FRα binding molecules that exhibit functional properties of antibodies but derive their framework and antigen binding portions from other polypeptides (e.g., polypeptides other than those encoded by antibody genes or generated by the recombination of antibody genes in vivo) may also be used in the methods of the present invention. The antigen binding domains (e.g., FRα binding domains) of these binding molecules are generated through a directed evolution process. See U.S. Pat. No. 7,115,396. Molecules that have an overall fold similar to that of a variable domain of an antibody (an “immunoglobulin-like” fold) are appropriate scaffold proteins. Scaffold proteins suitable for deriving antigen binding molecules include fibronectin or a fibronectin dimer, tenascin, N-cadherin, E-cadherin, ICAM, titin, GCSF-receptor, cytokine receptor, glycosidase inhibitor, antibiotic chromoprotein, myelin membrane adhesion molecule PO, CD8, CD4, CD2, class I MHC, T-cell antigen receptor, CD1, C2 and I-set domains of VCAM-1, I-set immunoglobulin domain of myosin-binding protein C, I-set immunoglobulin domain of myosin-binding protein H, I-set immunoglobulin domain of telokin, NCAM, twitchin, neuroglian, growth hormone receptor, erythropoietin receptor, prolactin receptor, interferon-gamma receptor, β-galactosidase/glucuronidase, β-glucuronidase, transglutaminase, T-cell antigen receptor, superoxide dismutase, tissue factor domain, cytochrome F, green fluorescent protein, GroEL, and thaumatin.

“Specific binding” when used in the context of antibodies, or antibody fragments, represents binding via domains encoded by immunoglobulin genes or fragments of immunoglobulin genes to one or more epitopes of a protein of interest, but which do not substantially recognize and bind other molecules in a sample containing a mixed population of antigenic molecules. Typically, an antibody binds to a cognate antigen with a Kd of less than about 1×10⁻⁸M, as measured by a surface plasmon resonance assay or a cell binding assay.

As used herein, a folate receptor alpha “binding agent” includes an antibody that binds FRα not bound to a cell as well as non-antibody binding agents. To generate non-antibody binding agents or binding molecules, a library of clones can be created in which sequences in regions of the scaffold protein that form antigen binding surfaces (e.g., regions analogous in position and structure to CDRs of an antibody variable domain immunoglobulin fold) are randomized. Library clones are tested for specific binding to the antigen of interest (e.g., FRα) and for other functions (e.g., inhibition of biological activity of FRα). Selected clones can be used as the basis for further randomization and selection to produce derivatives of higher affinity for the antigen.

High affinity binding molecules are generated, for example, using the tenth module of fibronectin III (¹⁰Fn3) as the scaffold, described in U.S. Pat. Nos. 6,818,418 and 7,115,396; Roberts and Szostak, 1997 Proc. Natl. Acad. Sci USA 94:12297; U.S. Pat. No. 6,261,804; U.S. Pat. No. 6,258,558; and Szostak et al. WO98/31700, the entire contents of each of which are incorporated herein by reference.

Non-antibody binding molecules can be produced as dimers or multimers to increase avidity for the target antigen. For example, the antigen binding domain is expressed as a fusion with a constant region (Fc) of an antibody that forms Fc-Fc dimers. See, e.g., U.S. Pat. No. 7,115,396, the entire contents of which are incorporated herein by reference.

An “antigen” is a molecule recognized by the immune system; the term originally came from “antibody generator” and includes a molecule that binds specifically to an antibody. At the molecular level, an antigen is characterized by its ability to be bound at the antigen-binding site of an antibody. In the present invention, the antigen is FRα, such as FRα which is not bound to a cell FRα or a portion thereof.

As used herein, the term “epitope” refers to the molecular surface features of an antigen, e.g., FRα, capable of being bound by an antibody. Antigenic molecules, normally being “large” biological polymers, usually present several surface features that can act as points of interaction for specific antibodies. Any such distinct molecular feature constitutes an epitope. Most antigens therefore have the potential to be bound by several distinct antibodies, each of which is typically specific to a particular epitope. In one embodiment of the present invention, a binding agent, e.g., antibody, binds to an epitope on FRα which is available in the form of the receptor which is not bound to a cell but not in the membrane bound form of the receptor. For example, the antibody may bind to the same epitope on FRα to which MORAB-003 binds.

As used herein, the phrase “progression of an FRα-expressing cancer in a subject afflicted with an FRα-expressing cancer” includes the progression of such a cancer from a less severe to a more severe state. This could include an increase in the number or severity of tumors, the degree of metastasis, the speed with which the cancer is growing and spreading, and the like. For example, “the progression of ovarian cancer” includes the progression of such a cancer from a less severe to a more severe state, such as the progression from Stage I to Stage II, from Stage II to Stage III, etc. Alternatively, the phrase “progression of an FRα-expressing cancer in a subject afflicted with an FRα-expressing cancer” may refer to the regression of an FRα-expressing cancer from a more severe state to a less severe state. For example, in one embodiment, “the progression of ovarian cancer” refers to the regression from Stage IV to Stage III, from Stage III to Stage II, etc. In other embodiments, the “progression of an FRα-expressing cancer in a subject afflicted with an FRα-expressing cancer” may refer to the survival rate determined from the beginning of symptoms of the FRα-expressing cancer, or to the survival rate from the time of diagnosis of the FRα-expressing cancer.

As used herein, the term “stratifying” refers to characterizing an FRα expressing cancer, for example, ovarian or lung cancer, into an appropriate stage based, for example, on the degree of the spread of the cancer, as well accepted stratifications in the art. For example, stratifying includes characterizing the FRα expressing cancer into Stage I, Stage II, Stage III or Stage IV. In certain embodiments, Stage I refers to cancers that are localized to one part of the body. In certain embodiments, Stages II and III refer to cancers that are locally advanced, wherein a distinction between the stages are often specific to the particular cancer. Finally, Stage IV refers to cancers that have often metastasized, or spread to other organs or throughout the body.

As used herein, the term “survival” refers to the continuation of life of a subject which has been treated for cancer. In one embodiment, survival refers to the failure of a tumor to recur. As used herein, the term “recur” refers to the re-growth of tumor or cancerous cells in a subject in whom primary treatment for the tumor has been administered. The tumor may recur in the original site or in another part of the body. In one embodiment, a tumor that recurs is of the same type as the original tumor for which the subject was treated. For example, if a subject had an ovarian cancer tumor, was treated and subsequently developed another ovarian cancer tumor, the tumor has recurred. In addition, a cancer can recur in a different organ or tissue than the one where it originally occurred.

II. METHODS AND KITS OF THE INVENTION

The present invention is based, at least in part, on the unexpected discovery that folate receptor alpha (FRα), not bound to a cell, is found at elevated levels in the body fluids, for example, urine or serum, of a subject having an FRα-expressing cancer as compared to a control sample. Moreover, the present invention is based, at least in part, on the identification of an immunological assay that exhibits the necessary sensitivity for assessing levels of FRα not bound to a cells in samples, where prior attempts to do so had repeatedly failed. Indeed, the present invention overcomes the challenges observed during prior attempts to develop an FRα-based diagnostic assay for FRα-expressing cancer such as lung or ovarian cancer by providing an immunological assay capable of accurately assessing levels of FRα not bound to a cell in a sample, e.g., urine or serum.

Accordingly, methods and kits for assessing whether a subject has or is at risk for developing an FRα-expressing cancer and, further, for assessing the progression of an FRα-expressing cancer are provided. In various embodiments, the methods involve the comparison of levels of FRα not bound to a cell in samples, for example, urine and serum, as compared to control levels, in assessing the presence, degree or risk of development of ovarian cancer in the subject.

A. Diagnostic Methods, Prognostic Methods, Risk Assessment Methods, and Stratification Methods

Specifically, the present invention provides diagnostic methods for assessing whether a subject is afflicted with an FRα-expressing cancer, such as lung or ovarian cancer, prognostic methods for predicting the progression of an FRα-expressing cancer such as lung or ovarian cancer, and risk assessment methods for assessing the level of risk that a subject will develop the FRα-expressing cancer. Furthermore, the invention provides stratification methods for stratifying an FRα-expressing cancer such as lung or ovarian cancer subject into cancer therapy groups. The various aspects and embodiments of the invention discussed here are intended to be non-limiting and to encompass all possible combinations of the specific embodiments mentioned, which may apply to any of the methods and kits discussed herein or claimed below.

The methods of the present invention can be practiced in conjunction with any other method used by the skilled practitioner to diagnose an FRα-expressing cancer, predict the progression of an FRα-expressing cancer, or to assess the level of risk that a subject will develop an FRα-expressing cancer.

In one aspect, the invention provides a method of assessing whether a subject is afflicted with an FRα-expressing cancer, by determining the level of folate receptor alpha (FRα) which is not bound to a cell, in a sample (such as urine or serum) derived from the subject; and comparing the level of folate receptor alpha (FRα) which is not bound to a cell with the level of FRα in a control sample, wherein a difference between the level of FRα in the sample derived from the subject and the level of FRα in the control sample is an indication that the subject is afflicted with an FRα-expressing cancer. In a particular embodiment, the level of FRα in the sample derived from the subject is assessed by contacting the sample with an antibody that binds FRα not bound to a cell and is selected from the group consisting of (a) an antibody that binds the same epitope as the MORAb-003 antibody; and (b) an antibody comprising SEQ ID NO:1 (GFTFSGYGLS) as CDRH1, SEQ ID NO:2 (MISSGGSYTYYADSVKG) as CDRH2, SEQ ID NO:3 (HGDDPAWFAY) as CDRH3, SEQ ID NO:4 (SVSSSISSNNLH) as CDRL1, SEQ ID NO:5 (GTSNLAS) as CDRL2 and SEQ ID NO:6 (QQWSSYPYMYT) as CDRL3. In one embodiment, the sample is selected from the group consisting of urine and serum.

In another aspect, the present invention provides a method of assessing whether a subject is afflicted with an FRα-expressing cancer such as lung cancer or ovarian cancer, the method comprising determining the level of folate receptor alpha (FRα) not bound to a cell in a urine sample derived from the subject; and comparing the level of folate receptor alpha (FRα) in the urine sample derived from the subject with the level of FRα in a control sample, wherein a difference between the level of FRα in the urine sample derived from the subject and the level of FRα in the control sample is an indication that the subject is afflicted with an FRα-expressing cancer.

In another aspect, the invention provides a method of assessing whether a subject is afflicted with an FRα-expressing cancer, by determining the level of folate receptor alpha (FRα) not bound to a cell in a serum sample derived from the subject; and comparing the level of folate receptor alpha (FRα) in the serum sample derived from the subject with the level of FRα in a control sample, wherein a difference between the level of FRα in the serum sample derived from the subject and the level of FRα in the control sample is an indication that the subject is afflicted with an FRα-expressing cancer. In particular embodiments, the subject has not been treated with an agent, such as a steroid, that enhances the levels of FRα in serum. In a specific embodiment, the FRα-expressing cancer is ovarian cancer and the subject has not been treated with an agent, such as a steroid, that enhances the levels of FRα in serum.

In the methods and kits of the present invention, FRα-expressing cancers include cancers characterized in that the cancer cells express FRα. In particular embodiments, the FRα is released from the cancer cells, for example, from the surface of the cancer cell, and into the biological fluids of the subject. FRα-expressing cancers include lung cancer (e.g., bronchioalveolar carcinomas, carcinoid tumors, and non-small cell lung cancers, such as adenocarcinomas); mesothelioma; ovarian cancer; renal cancer; brain cancer (e.g., anaplastic ependymoma and cerebellar juvenile pilocytic astrocytoma); cervical cancer; nasopharyngeal cancer; mesodermally derived tumor; squamous cell carcinoma of the head and neck; endometrial cancer; endometrioid adenocarcinomas of the ovary, serous cystadenocarcinomas, breast cancer; bladder cancer; pancreatic cancer; bone cancer (e.g., high-grade osteosarcoma); and pituitary cancer (e.g., pituitary adenoma). In a particular embodiment, the FRα-expressing cancer is ovarian cancer.

In certain embodiments of the methods and kits of the present invention, the FRα-expressing cancer is lung cancer. In more specific embodiments, the lung cancer is non-small cell lung carcinoma (NSCLC). In one such embodiment, the NSCLC is selected from the group consisting of adenocarcinoma, squamous cell lung carcinoma, large cell lung carcinoma, pleomorphic NSCLC, carcinoid tumor, salivary gland carcinoma, and unclassified carcinoma. In a preferred embodiment, the NSCLC is adenocarcinoma. In alternative embodiments, the lung cancer is small cell lung carcinoma (SCLC). In another embodiment, the lung cancer is bronchioalveolar carcinoma. In yet another embodiment, the lung cancer is a lung carcinoid tumor.

The present invention also provides methods to assess whether a subject is afflicted with ovarian cancer by determining the level of folate receptor alpha (FRα) not bound to a cell in a urine sample derived from the subject, wherein the presence of FRα in the urine sample at a concentration of greater than about 3000 a.u./ml is an indication that the subject is afflicted with ovarian cancer. In particular embodiments, the presence of FRα in the urine sample at a concentration of greater than about 4000 a.u./ml, about 5000 a.u./ml, about 6000 a.u./ml, about 7000 a.u./ml, about 8000 a.u./ml, about 9000 a.u./ml, about 10,000 a.u./ml, about 11,000 a.u./ml, about 12,000 a.u./ml, about 13,000 a.u./ml, about 14,000 a.u./ml, about 15,000 a.u./ml, about 16,000 a.u./ml, about 17,000 a.u./ml, about 18,000 a.u./ml, about 19,000 a.u./ml, about 20,000 a.u./ml, about 21,000 a.u./ml, about 22,000 a.u./ml, about 23,000 a.u./ml, about 24,000 a.u./ml, about 25,000 a.u./ml, about 26,000 a.u./ml, about 27,000 a.u./ml, about 28,000 a.u./ml, about 29,000 a.u./ml or about 30,000 a.u./ml is an indication that the subject is afflicted with ovarian cancer.

In yet another aspect, the present invention provides a method of assessing whether a subject is afflicted with ovarian cancer, by determining the level of folate receptor alpha (FRα) in a urine sample derived from the subject, wherein the presence of FRα in the urine sample at a concentration of greater than about 9100 pg/ml is an indication that the subject is afflicted with ovarian cancer or wherein a concentration of less than about 9100 pg/ml is an indication that the subject is not afflicted with ovarian cancer. For example, the presence of FRα in the urine sample at a concentration of greater than about 9500 pg/mL, about 10,000 pg/mL, about 11,000 pg/mL, about 12,000 pg/mL, about 13,000 pg/mL, about 14,000 pg/mL, about 15,000 pg/mL, about 16,000 pg/mL, about 17,000 pg/mL, about 18,000 pg/mL, about 19,000 pg/mL, about 20,000 pg/mL, about 21,000 pg/mL, about 22,000 pg/mL, about 23,000 pg/mL, about 24,000 pg/mL, about 25,000 pg/mL, about 26,000 pg/mL, about 27,000 pg/mL, about 28,000 pg/mL, about 29,000 pg/mL, about 30,000 pg/mL, about 40,000 pg/mL, about 50,000 pg/mL, about 60,000 pg/mL, about 70,000 pg/mL, about 80,000 pg/ml, about 90,000 pg/ml, about 100,000 pg/ml or about 150,000 pg/ml is an indication that the subject is afflicted with ovarian cancer.

In certain embodiments of the foregoing aspects of the invention, the levels of FRα not bound to a cell in a sample (e.g., a sample such as a urine sample or serum sample) derived from a subject are compared with the levels of FRα in a control sample, wherein a difference between the levels is an indication that the subject is afflicted with an FRα-expressing cancer such as lung or ovarian cancer. In a particular embodiment, the difference constitutes an increase in the level of FRα not bound to a cell in the sample derived from the subject as compared with the level of FRα in the control sample, wherein this increase is indicative of the presence or growth of FRα-expressing cancer. Alternatively, the difference constitutes a decrease in the level of FRα, wherein the decrease is indicative of the absence or regression of FRα-expressing cancer. As used herein, “a difference” between the level of folate receptor alpha not bound to a cell in a sample from a subject (i.e., a test sample) and the level of folate receptor alpha in a control sample refers broadly to any clinically relevant change (including an increase or a decrease) and/or statistically significant difference in the level of folate receptor alpha in the two samples. In an exemplary embodiment, the difference is selected based on a cutoff value determined using a receiver operating characteristic (ROC) analysis, an example of which is presented in Example 6. The optimal cutoff value may vary depending on the assay methods and conditions employed. In other embodiments, the difference must be greater than the limits of detection of the method for determining the level of FRα not bound to a cell. It is preferred that the difference be at least greater than the standard error of the assessment method, and preferably a difference of at least about 2-, about 3-, about 4-, about 5-, about 6-, about 7-, about 8-, about 9-, about 10-, about 15-, about 20-, about 25-, about 100-, about 500-, about 1000-fold or greater than the standard error of the assessment method. The difference may be assessed by any appropriate comparison, including any appropriate parametric or nonparametric descriptive statistic or comparison. For example, “an increase” in the level of FRα may refer to a level that exceeds a cutoff value determined using an ROC analysis. It may also refer to a level in a test sample that is two, and more preferably about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 150%, about 200%, about 300%, about 400%, about 500%, about 600%, about 700%, about 800%, about 900% or about 1000% more than the level of FRα in the control sample. An increase may also refer to a level in a test sample that is preferably at least about 1.5, and more preferably about two, about three, about four, about five or more standard deviations above the average level of FRα in the control sample. Likewise, “a decrease” in the level of FRα not bound to a cell may refer to a level in a test sample that does not exceed a cutoff value determined using an ROC analysis. It may also refer to a level in a test sample that is about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% less than the level of FRα in the control sample. A decrease may also refer to a level in a test sample that is preferably at least about 1.5, and more preferably about two, about three, about four, about five or more standard deviations below the average level of FRα in the control sample.

Samples useful in the methods and kits of the invention include any tissue, cell, biopsy, or bodily fluid that may contain detectable levels of FRα not bound to a cell. In one embodiment, a sample may be a tissue, a cell, whole blood, plasma, buccal scrape, saliva, cerebrospinal fluid, stool, or bronchoalveolar lavage. In some embodiments, the sample is FRα-expressing tumor sample or a sample of tissues or cells where FRα-expressing cancer may be found. In preferred embodiments, the sample is a urine or serum sample.

Body samples may be obtained from a subject by a variety of techniques known in the art including, for example, by the use of a biopsy or by scraping or swabbing an area or by using a needle to aspirate bodily fluids. Methods for collecting various body samples are well known in the art.

Samples suitable for detecting and quantitating the FRα protein level may be fresh, frozen, or fixed according to methods known to one of skill in the art. Suitable tissue samples are preferably sectioned and placed on a microscope slide for further analyses. Solid samples, i.e., tissue samples, may be solubilized and/or homogenized and subsequently analyzed as soluble extracts. Liquid samples may also be subjected to physical or chemical treatments. In some embodiments, urine samples are treated by centrifugation, vortexing, dilution and/or treatment with a solubilizing substance (such as, for example, guanidine treatment).

In one embodiment, a freshly obtained biopsy sample is frozen using, for example, liquid nitrogen or difluorodichloromethane. The frozen sample is mounted for sectioning using, for example, OCT, and serially sectioned in a cryostat. The serial sections are collected on a glass microscope slide. For immunohistochemical staining the slides may be coated with, for example, chrome-alum, gelatine or poly-L-lysine to ensure that the sections stick to the slides. In another embodiment, samples are fixed and embedded prior to sectioning. For example, a tissue sample may be fixed in, for example, formalin, serially dehydrated and embedded in, for example, paraffin.

Once the sample is obtained, any method known in the art to be suitable for detecting and quantitating FRα not bound to a cell may be used (either at the nucleic acid or, preferably, at the protein level), as described in section (B) below. Exemplary methods are well known in the art and include but are not limited to western blots, northern blots, southern blots, immunohistochemistry, solution phase assay, ELISA, e.g., amplified ELISA, immunoprecipitation, immunofluorescence, flow cytometry, immunocytochemistry, mass spectrometrometric analyses, e.g., MALDI-TOF and SELDI-TOF, nucleic acid hybridization techniques, nucleic acid reverse transcription methods, and nucleic acid amplification methods.

In many embodiments, the level of FRα not bound to a cell in the sample (such as, for example, urine or serum) is assessed by contacting the sample with an antibody that binds FRα. Antibodies that bind FRα are known in the art and include (i) the murine monoclonal LK26 antibody (the heavy and light chains thereof are presented herein as SEQ ID NOs: 22 and 23), as described in European Patent Application No. 86104170.5 (Rettig) (the entire contents of which are incorporated herein by reference); (ii) the MORAB-003 antibody, as described in International Publication No. WO2004/113388 and U.S. Pat. No. 5,646,253, the entire contents of each of which are incorporated herein by reference. The monoclonal antibodies MOV18 and MOv19 also bind different epitopes on the FRα molecule (previously known as gp38/FBP). Miotti, S. et al. Int J Cancer, 38: 297-303 (1987). For example, the MOV18 antibody binds the epitope set forth herein as SEQ ID NO:26 (TELLNVXMNAK*XKEKPXPX*KLXXQX) (note that at position 12, a tryptophan or histidine residue is possible, and at position 21, an aspartic acid or glutamic acid residue is possible), as taught in Coney et al. Cancer Res, 51: 6125-6132 (1991).

As used herein, the term “MORAb-003” refers to an antibody that specifically binds FRα and which comprises the mature heavy chain amino acid sequence as set forth in SEQ ID NO:7 and the mature light chain sequence of SEQ ID NO:8. The corresponding pre-protein amino acid sequences for MORAb-003 are set forth in SEQ ID NOs: 9 (heavy chain) and 10 (light chain). The MORAb-003 antibody comprises the following CDRs: SEQ ID NO:1 as CDRH1, SEQ ID NO:2 as CDRH2, SEQ ID NO:3 as CDRH3, SEQ ID NO:4 as CDRL1, SEQ ID NO:5 as CDRL2, and SEQ ID NO:6 as CDRL3. MORAb-003 antibody producing cells have been deposited with the American Type Culture Collection (10801 University Blvd., Manassas, Va. 20110-2209) on Apr. 24, 2006 and have been assigned Accession No. PTA-7552.

Other antibodies that bind FRα and for use in the methods of the present invention include 9F3.H9.H3.H3.B5.G2 (also referred to as 9F3),19D4.B7 (also referred to as 19D4), 24F12.B1 (also referred to as 24F12), and 26B3.F2 (also referred to as 26B3). The amino acid sequences of these antibodies, their CDRs, and their heavy and light chain variable domains, as well as polynucleotide sequences that may encode them, are provided in Table 33. In some embodiments, these antibodies are murine IgG, or derivatives thereof. In other embodiments, the antibodies are human, humanized, or chimeric.

9F3

In some embodiments, the antibody that binds FRα is an antibody or antigen-binding fragment that includes a light chain CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:27. In some embodiments, the antibody that binds FRα includes a light chain CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO:28. In some embodiments, the antibody that binds FRα includes a light chain CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO 29. In some embodiments, the antibody that binds FRα includes a heavy chain CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO 31. In some embodiments, the antibody that binds FRα includes a heavy chain CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO:32. In some embodiments, the antibody that binds FRα includes a heavy chain CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:33. The antibody that binds FRα may include a light chain having a CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:27; a CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO:28; and a CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:29. The antibody that binds FRα may include a heavy chain having a CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:31; a CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO: 32; and a CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:33. The antibody that binds FRα may include a light chain having a CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:27; a CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO:28; and a CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:29, and also have a heavy chain having a CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:31; a CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO:32; and a CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:33.

The antibody that binds FRα may include a light chain variable domain that includes an amino acid sequence substantially the same as, or identical to, SEQ ID NO:30. The antibody that binds FRα may include a heavy chain variable domain that includes an amino acid sequence substantially the same as, or identical to, SEQ ID NO:34. The antibody that binds FRα may include a light and a heavy chain variable domains, wherein the light chain variable domain includes an amino acid sequence substantially the same as, or identical to, SEQ ID NO:30, and the heavy chain variable domain includes an amino acid sequence substantially the same as, or identical to, SEQ ID NO:34. In some embodiments the antibody that binds FRα is the 9F3.H9.H3.H3.B5.G2 (9F3) antibody or an antigen-binding fragment thereof, capable of binding either a native or nonreduced form of FRα. In some embodiments, the antibody has a murine IgG2a constant region.

In some embodiments, the antibody that binds FRα is an antibody that is produced by antibody-producing cells deposited with the American Type Culture Collection (10801 University Blvd., Manassas, Va. 20110-2209) on May 19, 2011 and have been assigned Accession No. PTA-11887. In some embodiments, the antibody that binds FRα comprises one or more of the light and heavy chain CDRs of the antibodies produced by the deposited antibody-producing cells. In some embodiments, antibody that binds FRα comprises the light and heavy chain variable regions of the antibodies produced by the deposited antibody-producing cells.

19D4

In some embodiments, the antibody that binds FRα is an antibody or antigen-binding fragment that includes a light chain CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:35. In some embodiments, the antibody that binds FRα includes a light chain CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO:36. In some embodiments, the antibody that binds FRα includes a light chain CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:37. In some embodiments, the antibody that binds FRα includes a heavy chain CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:39. In some embodiments, the antibody that binds FRα includes a heavy chain CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO:40. In some embodiments, the antibody that binds FRα includes a heavy chain CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:41. The antibody that binds FRα may include a light chain having a CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:35; a CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO:36; and a CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:37. The antibody that binds FRα may include a heavy chain having a CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:39; a CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO: 40; and a CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:41. The antibody that binds FR^cmay include a light chain having a CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:35; a CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO:36; and a CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:37, and also have a heavy chain having a CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:39; a CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO:40; and a CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:41.

The antibody that binds FRα may include a light chain variable domain that includes an amino acid sequence substantially the same as, or identical to, SEQ ID NO:38. The antibody that binds FRα may include a heavy chain variable domain that includes an amino acid sequence substantially the same as, or identical to, SEQ ID NO:42. The antibody that binds FRα may include a light and a heavy chain variable domains, wherein the light chain variable domain includes an amino acid sequence substantially the same as, or identical to, SEQ ID NO:38, and the heavy chain variable domain includes an amino acid sequence substantially the same as, or identical to, SEQ ID NO:42. In some embodiments, the antibody that binds FRα is the 19D4.B7 (19D4) antibody or an antigen-binding fragment thereof, capable of binding either a native or nonreduced form of FRα. In some embodiments, the antibody has a murine IgG2a constant region.

In some embodiments, the antibody that binds FRα is an antibody that is produced by antibody-producing cells deposited with the American Type Culture Collection (10801 University Blvd., Manassas, Va. 20110-2209) on May 19, 2011 and have been assigned Accession No. PTA-11884. In some embodiments, the antibody that binds FRα comprises one or more of the light and heavy chain CDRs of the antibodies produced by the deposited antibody-producing cells. In some embodiments, antibody that binds FRα comprises the light and heavy chain variable regions of the antibodies produced by the deposited antibody-producing cells.

24F12

In some embodiments, the antibody that binds FRα is an antibody or antigen-binding fragment that includes a light chain CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:43. In some embodiments, the antibody that binds FRα includes a light chain CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO:44. In some embodiments, the antibody that binds FRα includes a light chain CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:45. In some embodiments, the antibody that binds FRα includes a heavy chain CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:47. In some embodiments, the antibody that binds FRα includes a heavy chain CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO:48. In some embodiments, the antibody that binds FRα includes a heavy chain CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:49. The antibody that binds FRα may include a light chain having a CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:43; a CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO:44; and a CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:45. The antibody that binds FRα may include a heavy chain having a CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:47; a CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO: 48; and a CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:49. The antibody that binds FRα may include a light chain having a CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:43; a CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO:44; and a CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:45, and also have a heavy chain having a CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:47; a CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO:48; and a CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:49.

The antibody that binds FRα may include a light chain variable domain that includes an amino acid sequence substantially the same as, or identical to, SEQ ID NO:46. The antibody that binds FRα may include a heavy chain variable domain that includes an amino acid sequence substantially the same as, or identical to, SEQ ID NO:50. The antibody that binds FRα may include a light and a heavy chain variable domains, wherein the light chain variable domain includes an amino acid sequence substantially the same as, or identical to, SEQ ID NO:46, and the heavy chain variable domain includes an amino acid sequence substantially the same as, or identical to, SEQ ID NO:50. In some embodiments the antibody that binds FRα is the 24F12.B1 (24F12) antibody or an antigen-binding fragment thereof, capable of binding either a native or nonreduced form of FRα. In some embodiments, the antibody has a murine IgG1 constant region.

In some embodiments, the antibody that binds FRα is an antibody that is produced by antibody-producing cells deposited with the American Type Culture Collection (10801 University Blvd., Manassas, Va. 20110-2209) on May 19, 2011 and have been assigned Accession No. PTA-11886. In some embodiments, the antibody that binds FRα comprises one or more of the light and heavy chain CDRs of the antibodies produced by the deposited antibody-producing cells. In some embodiments, antibody that binds FRα comprises the light and heavy chain variable regions of the antibodies produced by the deposited antibody-producing cells.

26B3

In some embodiments, the antibody that binds FRα is an antibody or antigen-binding fragment that includes a light chain CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:51. In some embodiments, the antibody that binds FRα includes a light chain CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO:52. In some embodiments, the antibody that binds FRα includes a light chain CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:53. In some embodiments, the antibody that binds FRα includes a heavy chain CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:55. In some embodiments, the antibody that binds FRα includes a heavy chain CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO:56. In some embodiments, the antibody that binds FRα includes a heavy chain CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:57. The antibody that binds FRα may include a light chain having a CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:51; a CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO:52; and a CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:53. The antibody that binds FRα may include a heavy chain having a CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:55; a CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO:56; and a CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:57. The antibody that binds FRα may include a light chain having a CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:51; a CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO:52; and a CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:53, and also have a heavy chain having a CDR1 amino acid sequence substantially the same as, or identical to, SEQ ID NO:55; a CDR2 amino acid sequence substantially the same as, or identical to, SEQ ID NO:56; and a CDR3 amino acid sequence substantially the same as, or identical to, SEQ ID NO:57.

The antibody that binds FRα may include a light chain variable domain that includes an amino acid sequence substantially the same as, or identical to, SEQ ID NO:54. The antibody that binds FRα may include a heavy chain variable domain that includes an amino acid sequence substantially the same as, or identical to, SEQ ID NO:58. The antibody that binds FRα may include a light and a heavy chain variable domains, wherein the light chain variable domain includes an amino acid sequence substantially the same as, or identical to, SEQ ID NO:54, and the heavy chain variable domain includes an amino acid sequence substantially the same as, or identical to, SEQ ID NO:58. In some embodiments the antibody that binds FRα is the 26B3.F2 (26B3) antibody or an antigen-binding fragment thereof, capable of binding either a native or nonreduced form of FRα. In some embodiments, the antibody has a murine IgG1 constant region.

In some embodiments, the antibody that binds FRα is an antibody that is produced by antibody-producing cells deposited with the American Type Culture Collection (10801 University Blvd., Manassas, Va. 20110-2209) on May 19, 2011 and have been assigned Accession No. PTA-11885. In some embodiments, the antibody that binds FRα comprises one or more of the light and heavy chain CDRs of the antibodies produced by the deposited antibody-producing cells. In some embodiments, antibody that binds FRα comprises the light and heavy chain variable regions of the antibodies produced by the deposited antibody-producing cells.

Antigen binding arrangements of CDRs may be engineered using antibody-like proteins as CDR scaffolding. Engineered antigen-binding proteins are included within the scope of antibodies that bind FRα.

Other reagent antibodies that bind FRα are known in the art, and presently, multiple such reagent antibodies are commercially available (based on search of anti-FRα antibodies at http://www.biocompare.com), as listed in the table below.

Product
Company
Quantity
Applications
Reactivity

Mouse Anti-Human
Abnova
50
μg
Detection Antibody, Western
Human

FRα Purified - MaxPab
Corporation

Blot (Transfected lysate)

Polyclonal Antibody,

Unconjugated

Mouse Anti-Human
Abnova
50
μg
Detection Antibody, Western
Human

FRα Purified MaxPab
Corporation

Blot (Transfected lysate)

Polyclonal Antibody,

Unconjugated

Rabbit Anti-Human
Abnova
100
μg
Detection Antibody, Western
Human

FRα Purified MaxPab
Corporation

Blot (Transfected lysate)

Polyclonal Antibody,

Unconjugated

Rabbit Anti-FRα
Aviva Systems
50
μg
Western Blot
Human,

Polyclonal Antibody,
Biology

Mouse, Rat

Unconjugated

Rabbit Anti-Human
GeneTex
100
μL
Western blot. The usefulness of
Human

FRα Polyclonal

this product in other

Antibody, Unconjugated

applications has not been

determined.

Goat Anti-Bovine Folate
LifeSpan
10
mg
ELISA (1:4000-1:20000),
Bovine

Receptor Alpha (FRα)
BioSciences

Immunofluorescence,

Polyclonal, Biotin

Immunohistochemistry,

Conjugated

Western Blot

Goat Anti-Bovine Folate
LifeSpan
Not
ELISA (1:5000-1:25000),
Bovine

Receptor Alpha (FRα)
BioSciences
provided
Western Blot

Polyclonal, Biotin

Conjugated

Goat Anti-Bovine Folate
LifeSpan
20
mg
ELISA (1:2000 - 1:10000),
Bovine

Receptor Alpha (FRα)
BioSciences

Immunohistochemistry,

Polyclonal, Hrp

Western Blot

Conjugated

Goat Anti-Bovine Folate
LifeSpan
1000
μg
ELISA (1:2000-1:12000), Gel
Bovine

Receptor Alpha (FRα)
BioSciences

Shift, Immunohistochemistry

Polyclonal, Hrp

(1:100-1:200),

Conjugated

Immunohistochemistry

Goat Anti-Bovine Folate
LifeSpan
2000
μg
ELISA, Western Blot
Bovine

Receptor Alpha (FRα)
BioSciences
(200
μl)

Polyclonal, Hrp

Conjugated

Goat Anti-Bovine Folate
LifeSpan
Not
ELISA, Immunohistochemistry
Bovine

Receptor Alpha (FRα)
BioSciences
provided
(Frozen sections),

Polyclonal, Hrp

Immunohistochemistry

Conjugated

(Parrafin), Western Blot

Goat Anti-Bovine Folate
LifeSpan
50
mg
ELISA (1:10000-1:40000),
Bovine

Receptor Alpha (FRα)
BioSciences

Immunoprecipitation, Western

Polyclonal,

Blot

Unconjugated

Goat Anti-Bovine Folate
LifeSpan
10000
μg
ELISA (1:10000 - 1:40000),
Bovine

Receptor Alpha (FRα)
BioSciences

Immunoprecipitation, Western

Polyclonal,

Blot

Unconjugated

Goat Anti-Bovine Folate
LifeSpan
1
ml
ELISA (1:3000-1:9000),
Bovine

Receptor Alpha (FRα)
BioSciences

Immunoprecipitation, Western

Polyclonal,

Blot

Unconjugated

Goat Anti-Bovine Folate
LifeSpan
Not
ELISA (1:3000-1:9000),
Bovine

Receptor Alpha (FRα)
BioSciences
provided
Immunoprecipitation, Western

Polyclonal,

Blot

Unconjugated

Folate Receptor Alpha

(FRα)

Mouse Anti-Bovine
LifeSpan
200
μg
ELISA
Bovine

Folate Receptor Alpha
BioSciences

(FRα) Monoclonal,

Unconjugated

Mouse Anti-Bovine
LifeSpan
200
μg
ELISA
Human

Folate Receptor Alpha
BioSciences

(FRα) Monoclonal,
Folate Receptor

Unconjugated
Alpha (FRα)

Mouse Anti-Bovine
LifeSpan
200
μg
ELISA
Human

Folate Receptor Alpha
BioSciences

(FRα) Monoclonal,

Unconjugated

Mouse Anti-Bovine
LifeSpan
200
μg
ELISA
Not

Folate Receptor Alpha
BioSciences

provided

(FRα) Monoclonal,

Unconjugated

Mouse Anti-Human
LifeSpan
100
μl
ELISA (1-10 μg/ml), Flow
Monkey

Folate Receptor Alpha
BioSciences

Cytometry,

(FRα) Monoclonal,

Immunocytochemistry,

Unconjugated, Clone

Immunohistochemistry (Frozen

6d398

sections)

Rabbit Anti-Bovine
LifeSpan
1
ml
ELISA
Bovine

Folate Receptor Alpha
BioSciences

(FRα) Polyclonal,

Unconjugated

Rabbit Anti-Bovine
LifeSpan
Not
Not provided
Bovine

Folate Receptor Alpha
BioSciences
provided

(FRα) Polyclonal,

Unconjugated

Mouse Anti-Human
Novus
0.05
ml
Western Blot, ELISA

FRα Polyclonal
Biologicals

antibody, Unconjugated,

Clone folate receptor 1

(adult)

Mouse Anti-Human
Novus
0.05
mg
ELISA, Western Blot
Human

FRα Polyclonal,
Biologicals

Unconjugated

Goat Anti-Human FRα
R&D Systems
50
μg
Western Blot
Human

Affinity purified

Polyclonal antibody,

Biotin Conjugated

Goat Anti-Human FRα
R&D Systems
100
μg
Flow Cytometry, Western Blot
Human

Affinity purified

Polyclonal antibody,

Unconjugated

Mouse Anti-Human
R&D Systems
100
Tests
Flow Cytometry
Human

FRα Monoclonal

Antibody,

Allophycocyanin

Conjugated, Clone

548908

Mouse Anti-Human
R&D Systems
100
Tests
Flow Cytometry
Human

FRα Monoclonal

Antibody, Phycoerythrin

Conjugated, Clone

548908

Mouse Anti-Human
R&D Systems
100
μg
Flow Cytometry,
Human

FRα Monoclonal

Immunocytochemistry,

antibody, Unconjugated,

Western Blot

Clone 548908

Mouse Anti-Human
United States
100
μg
ELISA, Flow Cytometry,
Human

FRα Monoclonal
Biological

Immunocytochemistry,

Antibody, Unconjugated

Western Blot

In a preferred embodiment, the antibody that binds FRα comprises at least one of the following CDRs, as derived from the murine LK26 heavy and light chains: SEQ ID NO:1 (GFTFSGYGLS) as CDRH1, SEQ ID NO:2 (MISSGGSYTYYADSVKG) as CDRH2, SEQ ID NO:3 (HGDDPAWFAY) as CDRH3, SEQ ID NO:4 (SVSSSISSNNLH) as CDRL1, SEQ ID NO:5 (GTSNLAS) as CDRL2 and SEQ ID NO:6 (QQWSSYPYMYT) as CDRL3. See U.S. Pat. No. 5,646,253, the contents of which, as they relate to the anti-FRα antibodies that may be used in the present invention, are incorporated herein by reference. Further mutations may be made in the framework regions as taught in U.S. Pat. No. 5,646,253, the contents of which are hereby incorporated by reference.

In another preferred embodiment, the antibody includes a variable region light chain selected from the group consisting of LK26HuVK (SEQ ID NO: 13) LK26HuVKY (SEQ ID NO: 14), LK26HuVKPW (SEQ ID NO: 15), and LK26HuVKPW,Y (SEQ ID NO: 16); and a variable region heavy chain selected from the group consisting of LK26HuVH (SEQ ID NO: 17); LK26HuVH FAIS,N (SEQ ID NO: 18); LK26HuVH SLF (SEQ ID NO: 19); LK26HuVH I,I (SEQ ID NO: 20); and LK26KOLHuVH (SEQ ID NO: 21). See U.S. Pat. No. 5,646,253 and U.S. Pat. No. 6,124,106. In another embodiment, the antibody comprises the heavy chain variable region LK26KOLHuVH (SEQ ID NO: 21) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16). In another embodiment, the antibody comprises the heavy chain variable region LK26HuVH SLF (SEQ ID NO: 19) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16). In a further embodiment, the antibody comprises the heavy chain variable region LK26HuVH FAIS,N (SEQ ID NO: 18) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 16).

In some embodiments, samples may need to be modified in order to make FRα accessible to antibody binding. In a particular aspect of the immunocytochemistry or immunohistochemistry methods, slides may be transferred to a pretreatment buffer and optionally heated to increase antigen accessibility. Heating of the sample in the pretreatment buffer rapidly disrupts the lipid bi-layer of the cells and makes the antigens (may be the case in fresh specimens, but not typically what occurs in fixed specimens) (i.e., the FRα protein) more accessible for antibody binding. The term “pretreatment buffer” are used interchangeably herein to refer to a buffer that is used to prepare cytology or histology samples for immunostaining, particularly by increasing FRα protein accessibility for antibody binding. The pretreatment buffer may comprise a pH-specific salt solution, a polymer, a detergent, or a nonionic or anionic surfactant such as, for example, an ethyloxylated anionic or nonionic surfactant, an alkanoate or an alkoxylate or even blends of these surfactants or even the use of a bile salt. The pretreatment buffer may, for example, be a solution of 0.1% to 1% of deoxycholic acid, sodium salt, or a solution of sodium laureth-13-carboxylate (e.g., Sandopan LS) or and ethoxylated anionic complex. In some embodiments, the pretreatment buffer may also be used as a slide storage buffer. In a particular embodiment, the sample, for example, the urine sample, is centrifuged, vortexed, diluted and/or subjected to guanidine treatment.

Any method for making FRα protein more accessible for antibody binding may be used in the practice of the invention, including the antigen retrieval methods known in the art. See, for example, Bibbo, et al. (2002) Acta. Cytol. 46:25-29; Saqi, et al. (2003) Diagn. Cytopathol. 27:365-370; Bibbo, et al. (2003) Anal. Quant. Cytol. Histol. 25:8-11, the entire contents of each of which are incorporated herein by reference.

Following pretreatment to increase FRα protein accessibility, samples may be blocked using an appropriate blocking agent, e.g., a peroxidase blocking reagent such as hydrogen peroxide. In some embodiments, the samples may be blocked using a protein blocking reagent to prevent non-specific binding of the antibody. The protein blocking reagent may comprise, for example, purified casein. An antibody, particularly a monoclonal or polyclonal antibody, that specifically binds to FRα is then incubated with the sample.

Techniques for detecting antibody binding are well known in the art. Antibody binding to FRα may be detected through the use of chemical reagents that generate a detectable signal that corresponds to the level of antibody binding and, accordingly, to the level of FRα protein expression. In one of the immunohistochemistry or immunocytochemistry methods of the invention, antibody binding is detected through the use of a secondary antibody that is conjugated to a labeled polymer. Examples of labeled polymers include but are not limited to polymer-enzyme conjugates. The enzymes in these complexes are typically used to catalyze the deposition of a chromagen at the antigen-antibody binding site, thereby resulting in cell staining that corresponds to expression level of the biomarker of interest. Enzymes include, but are not limited to, horseradish peroxidase (HRP) and alkaline phosphatase (AP).

In one immunohistochemistry or immunocytochemistry method of the invention, antibody binding to the FRα protein is detected through the use of an HRP-labeled polymer that is conjugated to a secondary antibody. Antibody binding can also be detected through the use of a species-specific probe reagent, which binds to monoclonal or polyclonal antibodies, and a polymer conjugated to HRP, which binds to the species specific probe reagent. Slides are stained for antibody binding using any chromagen, e.g., the chromagen 3,3-diaminobenzidine (DAB), and then counterstained with hematoxylin and, optionally, a bluing agent such as ammonium hydroxide or TBS/Tween-20. Other suitable chromagens include, for example, 3-amino-9-ethylcarbazole (AEC). In some aspects of the invention, slides are reviewed microscopically by a cytotechnologist and/or a pathologist to assess cell staining, e.g., fluorescent staining (i.e., FRα expression). Alternatively, samples may be reviewed via automated microscopy or by personnel with the assistance of computer software that facilitates the identification of positive staining cells.

In a preferred embodiment of the invention, the antibody is labeled. For example, detection of antibody binding can be facilitated by coupling the anti-FRα antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ³⁵S, ¹⁴C, or ³H. In a particular embodiment, the antibody is labeled with a radio-label, chromophore-label, fluorophore-label, or enzyme-label.

In one embodiment of the invention frozen samples are prepared as described above and subsequently stained with antibodies against FRα diluted to an appropriate concentration using, for example, Tris-buffered saline (TBS). Primary antibodies can be detected by incubating the slides in biotinylated anti-immunoglobulin. This signal can optionally be amplified and visualized using diaminobenzidine precipitation of the antigen. Furthermore, slides can be optionally counterstained with, for example, hematoxylin, to visualize the cells.

In another embodiment, fixed and embedded samples are stained with antibodies against FRα and counterstained as described above for frozen sections. In addition, samples may be optionally treated with agents to amplify the signal in order to visualize antibody staining. For example, a peroxidase-catalyzed deposition of biotinyl-tyramide, which in turn is reacted with peroxidase-conjugated streptavidin (Catalyzed Signal Amplification (CSA) System, DAKO, Carpinteria, Calif.) may be used.

One of skill in the art will recognize that the concentration of a particular antibody used to practice the methods of the invention will vary depending on such factors as time for binding, level of specificity of the antibody for FRα, and method of sample preparation. Moreover, when multiple antibodies are used, the required concentration may be affected by the order in which the antibodies are applied to the sample, e.g., simultaneously as a cocktail or sequentially as individual antibody reagents. Furthermore, the detection chemistry used to visualize antibody binding to FRα must be optimized to produce the desired signal to noise ratio.

In one embodiment of the invention, proteomic methods, e.g., mass spectrometry, are used for detecting and quantitating the FRα protein. For example, matrix-associated laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) or surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) which involves the application of a sample, such as serum, to a protein-binding chip (Wright, G. L., Jr., et al. (2002) Expert Rev Mol Diagn 2:549; Li, J., et al. (2002) Clin Chem 48:1296; Laronga, C., et al. (2003) Dis Markers 19:229; Petricoin, E. F., et al. (2002) 359:572; Adam, B. L., et al. (2002) Cancer Res 62:3609; Tolson, J., et al. (2004) Lab Invest 84:845; Xiao, Z., et al. (2001) Cancer Res 61:6029) can be used to detect and quantitate the FRα protein. Mass spectrometric methods are described in, for example, U.S. Pat. Nos. 5,622,824, 5,605,798 and 5,547,835, the entire contents of each of which are incorporated herein by reference.

The present invention is further predicated, at least in part, on the identification of FRα as a prognostic biomarker, i.e., as a biomarker of the progression and/or severity, of an FRα-expressing cancer such as ovarian cancer or non-small cell lung cancer. Accordingly, the present invention provides methods of assessing the progression of an FRα-expressing cancer in a subject afflicted with ovarian cancer by comparing the level of FRα in a sample derived from a subject with the level of FRα in a control sample, wherein a difference in the level of FRα in the sample (such as a urine or serum sample) derived from the subject compared with the control sample is an indication that the cancer will progress rapidly. Similarly, methods of assessing the level of risk that a subject will develop an FRα-expressing cancer involve comparing the level of FRα in a sample derived from a subject with the level of FRα in a control sample, wherein a difference in the level of FRα in the sample (such as urine or serum sample) derived from the subject compared with the control sample is an indication that the subject has a higher level of risk of developing an FRα-expressing cancer as compared to normal risk in a healthy individual.

In one embodiment, the difference is an increase. In another embodiment, the difference is a decrease. In some types of cancers (e.g., squamous cell carcinoma of the head and neck, ovarian cancer), a higher level of FRα expression is associated with a worse prognosis, whereas in other types of cancers (e.g., non-small-cell lung cancers), a higher level of FRα expression is associated with a better prognosis. Thus, in one specific embodiment, the FRα-expressing cancer is ovarian cancer or squamous cell carcinoma of the head and neck and the difference is an increase. In another specific embodiment, the FRα-expressing cancer is a non small-cell lung cancer, and the difference is a decrease.

In certain aspects, the invention provides methods of assessing the progression of an FRα-expressing cancer in a subject afflicted with an FRα-expressing cancer by comparing the level of FRα in a sample derived from a subject with the level of FRα in a control sample, wherein an increase in the level of FRα in the sample (such as a urine or serum sample) derived from the subject compared with the control sample is an indication that the cancer will progress rapidly, or a decrease in the level of FRα in the sample derived from the subject as compared with the level of FRα in the control sample is an indication that the cancer will progress slowly or will regress. Similarly, methods of assessing the level of risk that a subject will develop an FRα-expressing cancer involve comparing the level of FRα in a sample derived from a subject with the level of FRα in a control sample, wherein an increase in the level of FRα in the sample (such as urine or serum sample) derived from the subject compared with the control sample is an indication that the subject has a higher level of risk of developing an FRα-expressing cancer as compared to normal risk in a healthy individual, or a decrease in the level of FRα in the sample derived from the subject as compared with the level of FRα in the control sample is an indication that the subject has a lower level of risk of developing an FRα-expressing cancer as compared to a normal risk in a healthy individual.

Any clinically relevant or statistically significant increase or decrease, using any analytical method known in the art, may be utilized in the prognostic, risk assessment and other methods of the invention. In one embodiment, an increase in the level of FRα in the level of FRα refers to a level that exceeds a cutoff value determined using an ROC analysis as exemplified in Example 6. In another embodiment, a decrease in the level of FRα refers to a level in a test sample that does not exceed a cutoff value determined using an ROC analysis.

In other embodiments, the increase or decrease must be greater than the limits of detection of the method for determining the level of FRα. In further embodiments, the increase or decrease be at least greater than the standard error of the assessment method, and preferably a difference of at least about 2-, about 3-, about 4-, about 5-, about 6-, about 7-, about 8-, about 9-, about 10-, about 15-, about 20-, about 25-, about 100-, about 500-, about 1000-fold or greater than the standard error of the assessment method. In some embodiments, the increase or decrease is assessed using parametric or nonparametric descriptive statistics, comparisons, regression analyses, and the like.

In other embodiments, the increase or decrease is a level in the sample derived from the subject that is about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 150%, about 200%, about 300%, about 400%, about 500%, about 600%, about 700%, about 800%, about 900% or about 1000% more or less than the level of FRα in the control sample. In alternative embodiments, the increase or decrease is a level in the sample derived from the subject that is at least about 1.5, and more preferably about two, about three, about four, about five or more standard deviations above or below the average level of FRα in the control sample. As used herein, the phrase “progression of an FRα-expressing cancer in a subject afflicted with an FRα-expressing cancer” may refer to the progression of an FRα-expressing cancer from a less severe to a more severe cancer state. This could include an increase in the number or severity of tumors, the degree of metastasis, the speed with which the cancer is growing and spreading, and the like. In certain embodiments, the progression is a progression from a less severe stage to a more severe stage, wherein the stage is assessed according to a staging scheme known in the art. In one embodiment, wherein the FRα-expressing cancer is ovarian cancer, the progression refers to a progression from Stage I to Stage II, from Stage II to Stage III, etc. In another embodiment, wherein the FRα-expressing cancer is non-small cell lung cancer (NSCLC), the progression refers to a progression from Stage 0 to Stage IA, Stage IA to Stage IB, Stage IB to Stage IIA, Stage IIA to Stage IIB, Stage IIB to Stage IIC, etc. In another embodiment, wherein the FRα-expressing cancer is non-small cell lung cancer (NSCLC), the progression refers to a progression from a less severe to a more severe stage as determined under the TNM classification system. See Spira; Greene; Sobin.

Alternatively, the phrase “progression of an FRα-expressing cancer in a subject afflicted with an FRα-expressing cancer” may refer to a regression of an FRα-expressing cancer from a more severe state to a less severe state, such as a decrease in the number or severity of tumors, the degree of metastasis, the speed with which the cancer is growing and spreading, and the like. In certain embodiments, the progression is a progression from a more severe stage to a less severe stage, wherein the stage is assessed according to a staging scheme known in the art. In one embodiment, wherein the FRα-expressing cancer is ovarian cancer, the progression refers to a regression from Stage IV to Stage III, from Stage III to Stage II, etc. In another embodiment, wherein the FRα-expressing cancer is non-small cell lung cancer (NSCLC), the progression refers to a progression from Stage IV to Stage IIIB, Stage IIIB to Stage IIIA, Stage IIIA to Stage IIB, etc. In another embodiment, wherein the FRα-expressing cancer is non-small cell lung cancer (NSCLC), the progression refers to a progression from a more severe to a less severe stage as determined under the TNM classification system. See Spira; Greene; Sobin.

In further embodiments, the level of FRα may be used to calculate the likelihood that a subject is afflicted with an FRα-expressing cancer, the progression of an FRα-expressing cancer in a subject, the level of risk of developing an FRα-expressing cancer, the risk of cancer recurrence in a subject being treated for an FRα-expressing, the survival of a subject being treated for an FRα-expressing cancer, the efficacy of a treatment regimen for treating an FRα-expressing cancer, and the like, using the methods of the invention, which may include methods of regression analysis known to one of skill in the art. For example, suitable regression models include, but are not limited to CART (e.g., Hill, T, and Lewicki, P. (2006) “STATISTICS Methods and Applications” StatSoft, Tulsa, Okla.), Cox (e.g., www.evidence-based-medicine.co.uk), exponential, normal and log normal (e.g., www.obgyn.cam.ac.uk/mrg/statsbook/stsurvan.html), logistic (e.g., www.en.wikipedia.org/wiki/Logistic_regression), parametric, non-parametric, semi-parametric (e.g., www.socserv.mcmaster.ca/jfox/Books/Companion), linear (e.g., www.en.wikipedia.org/wiki/Linear_regression), or additive (e.g., www.en.wikipedia.org/wiki/Generalized_additive_model).

In one embodiment, a regression analysis includes the level of FRα. In further embodiments, a regression analysis may include additional clinical and/or molecular co-variates. Such clinical co-variates include, but are not limited to, age of the subject, tumor stage, tumor grade, tumor size, treatment regime, e.g., chemotherapy and/or radiation therapy, clinical outcome (e.g., relapse, disease-specific survival, therapy failure), and/or clinical outcome as a function of time after diagnosis, time after initiation of therapy, and/or time after completion of treatment. Molecular co-variates can include, but are not limited to additional molecular marker values. For example, in embodiments wherein the FRα-expressing cancer is ovarian cancer, such markers may include, e.g., serum CAl25 levels, serum DF3 levels, and/or plasma LPA levels.

In other aspects, the invention provides methods for monitoring the effectiveness of a therapy or treatment regimen. For example, the present invention provides methods for monitoring the efficacy of MORAb-003 treatment of ovarian cancer or lung cancer in a subject suffering from ovarian cancer or lung cancer. Specifically, the methods involve determining the level of folate receptor alpha (FRα) which is not bound to a cell, in a sample derived from said subject, wherein said subject has been previously administered MORAb-003; and comparing the level of folate receptor alpha (FRα) which is not bound to a cell with the level of FRα in a control sample, wherein an increase or no change in the level of FRα in the sample derived from said subject as compared with the level of FRα in the control sample is an indication that the MORAb-003 treatment is not efficacious; and wherein a decrease in the level of FRα in the sample derived from said subject as compared with the level of FRα in the control sample is an indication that the MORAb-003 treatment is efficacious.

For example, the control sample may be derived from a subject not subjected to the treatment regimen and a test sample may be derived from a subject subjected to at least a portion of the treatment regimen. Alternatively, the test sample and the control sample may be derived from the same subject. For example, the test sample may be a sample derived from a subject after administration of a therapeutic, such as MORAb-003. The control sample may be a sample derived from a subject prior to administration of therapeutic or at an earlier stage of therapeutic regimen. Accordingly, a decrease in the level of expression of FRα in the test sample, relative to the control sample, is an indication that therapy has decreased the progression of the FRα-expressing cancer, for example, ovarian cancer. For FRα-expressing cancers wherein a higher level of FRα is associated with a worse prognosis, such as e.g., ovarian cancer or squamous cell carcinoma of the head and neck, a decrease in the level of expression of FRα in the test sample, relative to the control sample, is an indication that therapy is effective in slowing the progression of the FRα-expressing cancer, or in causing a regression of the cancer, in the subject afflicted with the FRα-expressing cancer. In a preferred embodiment, the FRα-expressing cancer is ovarian cancer.

In various embodiments of this aspect of the invention, the sample may be urine, serum, plasma or ascites. In particular embodiments, the sample is urine or serum. Moreover, the FRα may be determined by contacting the sample with an antibody that binds FRα, optionally, using antibodies as described herein and assay methods as described herein.

In various embodiments, the MORAb-003 treatment antibody is (a) an antibody that comprises the heavy chain amino acid sequence as set forth in SEQ ID NO:7 and the light chain amino acid sequence as set forth in SEQ ID NO:8; (b) an antibody that binds the same epitope as the MORAb-003 antibody; or (c) an antibody comprising SEQ ID NO:1 (GFTFSGYGLS) as CDRH1, SEQ ID NO:2 (MISSGGSYTYYADSVKG) as CDRH2, SEQ ID NO:3 (HGDDPAWFAY) as CDRH3, SEQ ID NO:4 (SVSSSISSNNLH) as CDRL1, SEQ ID NO:5 (GTSNLAS) as CDRL2 and SEQ ID NO:6 (QQWSSYPYMYT) as CDRL3.

In a particular embodiment, the FRα-expressing cancer is ovarian cancer. In other embodiments, the FRα-expressing cancer is lung cancer. In more specific embodiments, the lung cancer is non-small cell lung cancer (NSCLC). In one such embodiment, the NSCLC is selected from the group consisting of adenocarcinoma, squamous cell lung carcinoma, large cell lung carcinoma, pleomorphic NSCLC, carcinoid tumor, salivary gland carcinoma, and unclassified carcinoma. In a preferred embodiment, the NSCLC is adenocarcinoma. In alternative embodiments, the lung cancer is small cell lung carcinoma (SCLC). In another embodiment, the lung cancer is bronchioalveolar carcinoma. In yet another embodiment, the lung cancer is a lung carcinoid tumor.

In another aspect, the invention provides methods of stratifying a subject with an FRα-expressing cancer into cancer therapy groups based on the determined level of FRα in a sample. In a preferred embodiment, the method involves stratifying a subject with an FRα-expressing cancer into one of at least four cancer therapy groups. In other embodiments, the method involves stratifying a subject with an FRα-expressing cancer into one of at least about two, about three, about four, about five, about six, about seven, about eight, about nine, or about ten cancer therapy groups.

According to the present invention, the levels of FRα may be associated with the severity, i.e., the stage, of the FRα expressing cancer. For example, ovarian cancer is stratified into different stages based on the severity of the cancer, as set forth herein. Accordingly, the present invention provides methods for stratifying ovarian cancer into Stage I, for example, Stage IA, Stage IB or Stage IC; Stage II, for example, Stage IIA, Stage IIB or Stage IIC; Stage III, for example, Stage IIIA, Stage IIIB or Stage IIIC; or Stage IV ovarian cancer.

SCLS or NSCLC may be stratified into different stages based on the severity of the cancer, as set forth herein. Accordingly, the present invention provides methods for stratifying the lung cancer, for example, SCLS or NSCLC, into the occult (hidden) stage; stage 0; Stage I, for example, stages IA and IB; Stage II, for example, stages IIA and IIB; Stage III, for example, stages IIIA and IIIB; or Stage IV lung cancer.

In yet another aspect, the present invention is predicated, at least in part, on the finding that FRα can serve as a predictive biomarker for treatment of FRα expressing cancers. Specifically, the methods of the present invention provide for assessing whether a subject will respond to treatment, for example, with MORAb-003, and whether and when to initiate treatment, for example, with MORAb-003, by assessing the levels of FRα in a subject.

In one aspect, the present invention provides a method for predicting whether a subject suffering from an FRα expressing cancer, for example, ovarian or lung cancer, will respond to treatment with MORAb-003, by determining the level of folate receptor alpha (FRα) which is not bound to a cell in a sample derived from said subject; and comparing the level of folate receptor alpha (FRα) which is not bound to a cell in the sample derived from said subject with the level of FRα in a control sample, wherein a difference between the level of FRα in the sample derived from said subject and the level of FRα in the control sample is an indication that the subject will respond to treatment with MORAb-003.

In certain embodiments, the degree of difference between the levels of FRα not bound to a cancer cell in the test sample as compared to the control sample is indicative that the subject will respond to treatment with MORAb-003. For example, a difference of at least about 2-, about 3-, about 4-, about 5-, about 6-, about 7-, about 8-, about 9-, about 10-, about 15-, about 20-, about 25-, about 100-, about 500-, about 1000-fold or greater than the standard error of the assessment method is indicative that the subject will respond to treatment with MORAb-003. Alternatively or in combination, a difference of at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 150%, about 200%, about 300%, about 400%, about 500%, about 600%, about 700%, about 800%, about 900% or about 1000% is indicative that the subject will respond to treatment with MORAb-003. Alternatively or in combination, a difference of at least about 1.5, and more preferably about two, about three, about four, about five or more standard deviations is indicative that the subject will respond to treatment with MORAb-003.

In various embodiments, the MORAb-003 treatment antibody is (a) an antibody that binds the same epitope as the MORAb-003 antibody; or (b) an antibody comprising SEQ ID NO:1 (GFTFSGYGLS) as CDRH1, SEQ ID NO:2 (MISSGGSYTYYADSVKG) as CDRH2, SEQ ID NO:3 (HGDDPAWFAY) as CDRH3, SEQ ID NO:4 (SVSSSISSNNLH) as CDRL1, SEQ ID NO:5 (GTSNLAS) as CDRL2 and SEQ ID NO:6 (QQWSSYPYMYT) as CDRL3.

In various embodiments, the sample is urine, plasma, serum or ascites. In particular embodiments, the sample is urine or serum. In further embodiments, the FRα-expressing cancer is selected from the group consisting of lung cancer, mesothelioma, ovarian cancer, renal cancer, brain cancer, cervical cancer, nasopharyngeal cancer, squamous cell carcinoma of the head and neck, endometrial cancer, breast cancer, bladder cancer, pancreatic cancer, bone cancer, pituitary cancer, colorectal cancer and medullary thyroid cancer. In a particular embodiment, the FRα-expressing cancer is ovarian cancer. In another embodiment, the FRα-expressing cancer is non-small cell lung cancer, such as adenocarcinoma.

B. Anti-FRαAntibody Based Assays for Detecting FRα-Expressing Cancers

There are a variety of assay formats known to those of ordinary skill in the art for using an antibody to detect a polypeptide in a sample, including but not limited to enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immunofluorimetry, immunoprecipitation, solution phase assay, equilibrium dialysis, immunodiffusion and other techniques. See, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988; Weir, D. M., Handbook of Experimental Immunology, 1986, Blackwell Scientific, Boston. For example, the assay may be performed in a Western blot format, wherein a protein preparation from the biological sample is submitted to gel electrophoresis, transferred to a suitable membrane and allowed to react with the antibody. The presence of the antibody on the membrane may then be detected using a suitable detection reagent, as is well known in the art and described below.

In another embodiment, the assay involves the use of an antibody immobilized on a solid support to bind to the target FRα polypeptide and remove it from the remainder of the sample. The bound FRα polypeptide may then be detected using a second antibody reactive with a distinct FRα polypeptide antigenic determinant, for example, a reagent that contains a detectable reporter moiety. As a non-limiting example, according to this embodiment the immobilized antibody and the second antibody which recognize distinct antigenic determinants may be any two of the monoclonal antibodies described herein selected from MORAb-003, MOV18, 548908, 6D398 or variants thereof as described herein. Alternatively, a competitive assay may be utilized, in which FRα is labeled with a detectable reporter moiety and allowed to bind to the immobilized anti-FRα antibody after incubation of the immobilized antibody with the sample. The extent to which components of the sample inhibit the binding of the labeled polypeptide to the antibody is indicative of the reactivity of the sample with the immobilized antibody, and as a result, indicative of the level of FRα in the sample.

The solid support may be any material known to those of ordinary skill in the art to which the antibody may be attached, such as a test well in a microtiter plate, a nitrocellulose filter or another suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic such as polystyrene or polyvinylchloride. The antibody may be immobilized on the solid support using a variety of techniques known to those in the art, which are amply described in the patent and scientific literature.

In certain preferred embodiments, the assay for detection of FRα in a sample is a two-antibody sandwich assay. This assay may be performed by first contacting a FRα specific antibody (e.g., MORAb-003, MOV18, 548908, 6D398 or variants thereof as described herein) that has been immobilized on a solid support, commonly the well of a microtiter plate, with the biological sample, such that a soluble molecule naturally occurring in the sample and having an antigenic determinant that is reactive with the antibody is allowed to bind to the immobilized antibody (e.g., a 30 minute incubation time at room temperature is generally sufficient) to form an antigen-antibody complex or an immune complex. Unbound constituents of the sample are then removed from the immobilized immune complexes. Next, a second antibody specific for FRα is added, wherein the antigen combining site of the second antibody does not competitively inhibit binding of the antigen combining site of the immobilized first antibody to FRα (e.g., MORAb-003, MOV18, 548908, 6D398 or variants thereof as described herein, that is not the same as the monoclonal antibody immobilized on the solid support). The second antibody may be detectably labeled as provided herein, such that it may be directly detected. Alternatively, the second antibody may be indirectly detected through the use of a detectably labeled secondary (or “second stage”) anti-antibody, or by using a specific detection reagent as provided herein. The subject invention method is not limited to any particular detection procedure, as those having familiarity with immunoassays will appreciate that there are numerous reagents and configurations for immunologically detecting a particular antigen (e.g., FRα) in a two-antibody sandwich immunoassay.

In certain preferred embodiments of the invention using the two-antibody sandwich assay described above, the first, immobilized antibody specific for FRα is a polyclonal antibody and the second antibody specific for FRα is a polyclonal antibody. In certain other embodiments of the invention, the first, immobilized antibody specific for FRα is a monoclonal antibody and the second antibody specific for FRα is a polyclonal antibody. In certain other embodiments of the invention the first, immobilized antibody specific for FRα is a polyclonal antibody and the second antibody specific for FRα is a monoclonal antibody. In certain other embodiments of the invention, the first, immobilized antibody specific for FRα is a monoclonal antibody and the second antibody specific for FRα is a monoclonal antibody. For example, in these embodiments it should be noted that monoclonal antibodies MORAb-003, MOV18, 548908, 6D398 or variants thereof as described herein, as provided herein recognize distinct and noncompetitive antigenic determinants (e.g., epitopes) on FRα polypeptides, such that any pairwise combination of these monoclonal antibodies may be employed. In other preferred embodiments of the invention, the first, immobilized antibody specific for FRα and/or the second antibody specific for FRα may be any of the kinds of antibodies known in the art and referred to herein, for example, by way of illustration and not limitation, Fab fragments, F(ab′)₂fragments, immunoglobulin V-region fusion proteins or single chain antibodies. Those familiar with the art will appreciate that the present invention encompasses the use of other antibody forms, fragments, derivatives and the like in the methods disclosed and claimed herein.

In certain particularly preferred embodiments, the second antibody may contain a detectable reporter moiety or label such as an enzyme, dye, radionuclide, luminescent group, fluorescent group or biotin, or the like. The amount of the second antibody that remains bound to the solid support is then determined using a method appropriate for the specific detectable reporter moiety or label. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Antibody-enzyme conjugates may be prepared using a variety of coupling techniques (for review see, e.g., Scouten, W. H., Methods in Enzymology 135:30-65, 1987). Spectroscopic methods may be used to detect dyes (including, for example, colorimetric products of enzyme reactions), luminescent groups and fluorescent groups. Biotin may be detected using avidin or streptavidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic, spectrophotometric or other analysis of the reaction products. Standards and standard additions may be used to determine the level of mesothelin polypeptide in a sample, using well known techniques.

A method of screening for the presence of an FRα expressing cancer according to the present invention may be further enhanced by the detection of more than one tumor associated marker in a biological sample from a subject. Accordingly, in certain embodiments the present invention provides a method of screening that, in addition to detecting reactivity of FRα not bound to a cell, also includes detection of at least one additional soluble marker of a malignant condition using established methods as known in the art and provided herein. As noted above, there are currently a number of soluble tumor associated antigens that are detectable in samples of readily obtained biological fluids.

C. Kits of the Invention

The invention also provides kits for assessing whether a subject is afflicted with an FRα-expressing cancer, for assessing the progression of an FRα-expressing cancer, for assessing the level of risk that a subject will develop an FRα-expressing cancer, or for monitoring the effectiveness of a therapy or treatment regimen for an FRα-expressing cancer. These kits include means for determining the level of expression of FRα and instructions for use of the kit to assess the progression of an FRα-expressing cancer, to assess the level of risk that a subject will develop an FRα-expressing cancer, or to monitor the effectiveness of a therapy or treatment regimen for an FRα-expressing cancer.

The kits of the invention may optionally comprise additional components useful for performing the methods of the invention. By way of example, the kits may comprise means for obtaining a sample from a subject, a control sample, e.g., a sample from a subject having slowly progressing cancer and/or a subject not having cancer, one or more sample compartments, and instructional material which describes performance of a method of the invention and tissue specific controls/standards.

The means for determining the level of FRα include known methods in the art for assessing protein levels, as discussed above, and specific preferred embodiments, for example, utilizing the MORAb-003 antibody, as discussed herein. Thus, for example, in one embodiment, the level of FRα is assessed by contacting a sample derived from a subject (such as urine or serum) with a folate receptor alpha (FRα) binding agent. In a preferred embodiment, the binding agent is an antibody. Many of the types of antibodies that bind FRα are discussed above in the methods of the invention and may also be utilized in the kits of the invention.

The means for determining the level of FRα can further include, for example, buffers or other reagents for use in an assay for determining the level of FRα. The instructions can be, for example, printed instructions for performing the assay and/or instructions for evaluating the level of expression of FRα.

The kits of the inventions may also include means for isolating a sample from a subject. These means can comprise one or more items of equipment or reagents that can be used to obtain a fluid or tissue from a subject. The means for obtaining a sample from a subject may also comprise means for isolating blood components, such as serum, from a blood sample. Preferably, the kit is designed for use with a human subject.

III. SCREENING ASSAYS

In further embodiments, the invention also provides methods (also referred to herein as “screening assays”) for identifying modulators, i.e., candidate or test compounds or agents (e.g., proteins, peptides, peptidomimetics, peptoids, small molecules or other drugs), which modulate the growth, progression and/or aggressiveness of cancer, e.g., an FRα-expressing cancer, or a cancer cell, e.g., an ovarian cancer cell, by monitoring and comparing the levels of FRα in a sample. Such assays typically comprise a test compound, or a combination of test compounds, whose activity against cancer or a cancer cell is to be evaluated. Compounds identified via assays such as those described herein may be useful, for example, for modulating, e.g., inhibiting, ameliorating, treating, or preventing aggressiveness of an FRα-expressing cancer or a cancer cell, e.g., an ovarian cancer cell. By monitoring the level of FRα in a sample, one can determine whether the FRα-expressing cancer is progressing or regressing and whether the test compound has the desired effect. For example, in embodiments wherein the FRα-expressing cancer is a cancer for which higher levels of FRα are associated with a worse prognosis, a decrease in the level of FRα after administration of the test compound(s) would be indicative of the efficacy of the test compound. By contrast, an increase in the level of FRα after administration of the test compound(s) would indicate that the test compound is not effective in treating ovarian cancer. By contrast, in embodiments wherein the FRα-expressing cancer is a cancer for which higher levels of FRα are associated with a better prognosis, an increase in the level of FRα after administration of the test compound(s) would be indicative of the efficacy of the test compound. By contrast, an decrease in the level of FRα after administration of the test compound(s) would indicate that the test compound is not effective in treating ovarian cancer.

The test compounds used in the screening assays of the present invention may be obtained from any available source, including systematic libraries of natural and/or synthetic compounds. Test compounds may also be obtained by any of the numerous approaches in combinatorial library methods known in the art, including biological libraries; peptoid libraries (libraries of molecules having the functionalities of peptides, but with a novel, non-peptide backbone which are resistant to enzymatic degradation but which nevertheless remain bioactive; see, e.g., Zuckermann et al., 1994, J. Med. Chem. 37:2678-85); spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the ‘one-bead one-compound’ library method; and synthetic library methods using affinity chromatography selection. The biological library and peptoid library approaches are limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, 1997, Anticancer Drug Des. 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90:6909; Erb et al. (1994) Proc. Natl. Acad. Sci. USA 91:11422; Zuckermann et al. (1994). J. Med. Chem. 37:2678; Cho et al. (1993) Science 261:1303; Carrell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2059; Carell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2061; and in Gallop et al. (1994) J. Med. Chem. 37:1233.

Libraries of compounds may be presented in solution (e.g., Houghten, 1992, Biotechniques 13:412-421), or on beads (Lam, 1991, Nature 354:82-84), chips (Fodor, 1993, Nature 364:555-556), bacteria and/or spores, (Ladner, U.S. Pat. No. 5,223,409), plasmids (Cull et al, 1992, Proc Natl Acad Sci USA 89:1865-1869) or on phage (Scott and Smith, 1990, Science 249:386-390; Devlin, 1990, Science 249:404-406; Cwirla et al, 1990, Proc. Natl. Acad. Sci. 87:6378-6382; Felici, 1991, J. Mol. Biol. 222:301-310; Ladner, supra.).

The present invention is further illustrated by the following examples which should not be construed as further limiting. The contents of all references, patents and published patent applications cited throughout this application, as well as the Figures, are expressly incorporated herein by reference in their entirety.

EXAMPLES
Example 1
Determination of FRαLevels in Urine Samples from Human Subjects with and without Ovarian Cancer as Measured by Electrochemiluminescence Immunoassay (ECLIA)
Materials and Methods

Urine samples were obtained from human subjects, including subjects afflicted with ovarian cancer and normal control subjects not afflicted with ovarian cancer. The levels of FRα in urine samples were determined using an electrochemiluminescence immunoassay (ECLIA) according to the following procedure (see Namba et al. (1999) Analytical Science 15:1087-1093):

i. Antibody Coating to Micro Beads

The monoclonal anti-folate receptor alpha antibody was coated over the surface of micro beads (Dynabeads M-450 Epoxy, Dynal). Thirty six milligrams of micro beads were mixed with 1.2 mL of antibody MOV18 (0.36 mg/mL, Enzo Life Science) in 0.15 mol/L phosphate buffer saline pH 7.8 (PBS), followed by gentle mixing for 16 hours at room temperature. The micro beads were then washed 5 times with 50 mM HEPES buffer containing 0.1% normal rabbit serum (NRS), 150 mmol/L NaCl, 0.01% Tween 20 pH 7.5 (wash buffer). Thereafter, the coated micro beads were suspended in 1.2 mL 50 mM HEPES buffer containing 20% NRS, 150 mmol/L NaCl and 0.01% Tween 20 pH 7.5 (reaction buffer) to block the unbound surface, followed by gentle mixing for 3.5 hours at room temperature. Finally, the micro beads were washed 5 times with wash buffer and re-suspended with 1.2 mL 50 mM HEPES buffer containing 10% NRS, 150 mmol/L NaCl, 10 mmol/L EDTA-2Na and 0.01% Tween 20 pH 7.5 (reaction buffer) so that the concentration of micro beads was 30 mg/mL. The micro beads were stored at 4° C. until use.

ii. Antibody Labeling with Ruthenium-Chelate-NHS (Ru)

One milliliter of MORAB-003 (1 mg/mL) in PBS was mixed with 14 μL of Ru (10 mg/mL), initial molar ratio of antibody to Ru was 1:20, followed by shaking for 30 minutes at room temperature in the dark. The reaction was terminated by adding 25 μL of 2 mol/L glycine solution followed by incubation for 20 minutes. The labeled antibody was purified by gel filtration using Sephadex G-25 (GE Healthcare) eluted with PBS. The first eluted yellow fraction was collected and the concentration of antibody and Ru were determined by means of the Pierce BCA protein assay kit (Thermo Scientific) and absorption at 455 nm respectively. The final molar ratio was calculated by the formula: Final molar ratio=[(absorption at 455)/13700]/[Ab(mg/mL/150000)]. The labeled antibody was stored at 4° C. until use.

iii. One Step Immunoassay

The antibody coated micro beads were set on the reagent table of the Picolumi 8220 (Sanko, Tokyo, Japan) after adjusting the concentration of the beads to 1.5 mg/ml (working solution) in reaction buffer. The Ru labeled antibody was set on the reagent table of the Picolumi 8220 after adjusting the concentration of antibody to 2 μg/ml (working solution) in reaction buffer.

Ten microliters of urine (diluted 1:51 in reaction buffer) or standard FRα (prepared in reaction buffer) and 100 μL of reaction buffer were dispensed into a reaction tube (Sanko, Tokyo, Japan) and set on Picolumi 8220.

The following steps were automatically run by Picolumi 8220. Twenty five microliters of beads (working solution) and 180 μL of Ru labeled antibody (working solution) were dispensed. After 26 minutes of incubation at 30+/−2° C., the beads were washed and suspended with 300 μL of electrolyte solution (Sanko, Tokyo, Japan). The washed beads were subsequently transferred to the electrode and electrochemiluminescence (ECL) emission was measured.

All ECL measurements were carried out in duplicate.

Results

Table 1 depicts the urine levels of FRα in individual subjects with ovarian cancer and non-afflicted female control subjects.

TABLE 1

FRα levels in urine of subjects with ovarian

cancer and normal female control subjects

Group
Sample #
FRα (pg/mL)

ovarian cancer
1
27800

2
40242

3
85580

4
4994

5
2017

6
3781

7
29469

8
47456

9
4479

10
11920

11
18352

12
162017

13
30630

14
14431

15
11801

16
13470

17
11563

18
22185

19
52106

normal control
20
8491

21
4885

22
3595

23
21301

24
22757

25
16578

26
6081

27
4195

28
12169

29
20639

FIG. 2 depicts the distribution of FRα levels in urine in subjects with ovarian cancer and in normal female control subjects, as set forth in Table 1.

Table 2 summarizes the number of subjects (n), mean, standard deviation (SD), maximum (Max.) and minimum (Min.) values for the levels of FRα in the ovarian cancer group and the normal female control group.

TABLE 2

Summary of urine FRα measurement

FRα (pg/mL)

ovarian cancer
normal female

N
19
10

Mean
31279
12069

SD
37895
7654

Max.
162017
22757

Min.
2017
3595

Discussion

A high level of FRα was detected in the urine of subjects with ovarian cancer. Moreover, the levels of FRα differed significantly between ovarian cancer and normal female control groups (p=0.03, one-sided).

Example 2
Dilution Linearity Determination of FRα Levels in Serially Diluted Urine Samples Measured by Electrochemiluminescence Immunoassay (ECLIA)

Dilution Linearity is a measure of accuracy of an assay. Two urine samples were serially diluted by a factor of 10 and 100. The FRα levels of each sample were measured as set forth in Example 1 and compared to assess the percent error. Percent error was calculated as follows:

$\frac{[\begin{matrix} [(FR α in undiluted sample) * (dilution factor)] - \\ (FR α in undiluted sample) \end{matrix}] * 100}{(FR α in undiluted sample)}$

The results are set forth in Table 3:

TABLE 3

Dilution Linearity for Urine

Dilution
FRα
Error

Sample
factor
(pg/mL)
(%)

1
1
25037
—

10
2601
4

100
279
11

2
1
16649
—

10
1696
2

100
173
4

The foregoing results demonstrate dilution linearity in assessing the levels of FRα in human urine samples and that, within acceptable errors, urine can be diluted up to a factor of at least 100 while retaining accurate levels of FRα. Accordingly, dilution of the urine samples may be considered prior to determining levels of FRα.

Example 3
Centrifugation of Urine Samples Addressing Reproducibility

The reproducibility of the ECLIA assay for a particular urine sample was also tested. For example, as reflected in Table 4, ECLIA assays of the same sample resulted in varying results.

TABLE 4

Reproducibility without

sample centrifugation

ECL Counts

Sample
Test 1
Test 2

1
29380
15046

2
20912
17227

The presence of insoluble material (precipitates) in urine samples was hypothesized to be responsible for the variability seen in measuring the levels of FRα. As a result, centrifugation of samples in order to remove urine sediment, prior to measurement of FRα levels, was considered as an option to enhance the accuracy and reproducibility of the assay.

Table 5 depicts the results obtained when three samples were centrifuged prior to performance of the ECLIA assay.

TABLE 5

Reproducibility with sample centrifugation

FRα concentration (ng/mL)

Test
Sample 1
Sample 2
Sample 3

1
10.4
9.2
13.3

2
10.5
8.9
14.0

3
10.3
9.2
13.4

Mean
10.4
9.1
13.6

SD
0.1
0.1
0.3

CV(%)
1.0
1.1
2.2

As set forth above, the results indicate that centrifugation provided more consistent measurements of FRα concentration.

Additionally, two samples were subjected to (i) centrifugation (at 2000×g for 2 min) and the supernatant removed for measurement of FRα (depicted as sample “A” below in Table 6) and (ii) centrifugation followed by vortexing (depicted as sample “B” below in Table 6), prior to measurement of FRα levels by the ECLIA assay set forth in Example 1. The results are reflected in Table 6 below.

TABLE 6

Effect of centrifugation on FRα levels in urine

Sediment after

FRα
Difference

Sample
centrifugation
A/B
(pg/mL)
(%)

1
Yes
A
13678
—

(++)

B
16559
21

2
Yes
A
12271
—

(+)

B
13206
8

Difference (%) was determined as follows:

$\frac{[(Level of FR α in “ B ”) - (Level of FR α in “ A ”)] * 100}{(Level of FR α in “ A ”)}$

As shown in Table 6, the levels of FRα as determined by the ECLIA assay vary depending on whether urine was clarified by centrifugation to remove precipitates or whether urine was vortexed to suspend or disperse sediments. Accordingly, in certain embodiments centrifuging or vortexing of urine samples may be performed prior to determining levels of FRα.

Example 4
Determination of FRα Levels in Centrifuged Urine Samples From Human Subjects with and without Ovarian Cancer Measured by Electrochemiluminescence Immunoassay (ECLIA)

Based on the results of Example 3, the assay for assessing FRα levels in subjects was modified to introduce a centrifugation step. FRα levels were determined on the same samples utilized in Example 1, including the group of subjects with ovarian cancer and the group of normal female control subjects.

Materials and Methods

The methodology utilized was as described in Example 1, except that the urine samples were centrifuged for 10000×g for 1 minute and the resulting supernatant subsequently diluted by 1:51 in reaction buffer.

Results

Table 7 depicts the levels of FRα in centrifuged and non-centrifuged urine samples from subjects afflicted with ovarian cancer and healthy female control subjects.

TABLE 7

Urine FRα1 level in ovarian cancer and normal control group

FRα (pg/mL)
sediment

Sample
Without
With
after

Group
#
centrifugation
centrifugation
centrifugation

ovarian cancer
1
27800
23960
+

2
40242
37852
+

3
85580
78976
+

4
4994
3766
+

5
2017
1512
−

6
3781
3443
−

7
29469
25728
+

8
47456
16556
+

9
4479
3357
−

10
11920
5020
+

11
18352
16695
−

12
162017
82705
+

13
30630
4496
+

14
14431
8786
+

15
11801
10582
−

16
13470
5611
+

17
11563
5463
+

18
22185
14443
+

19
52106
38327
−

normal control
20
8491
6867
+

21
4885
3754
−

22
3595
3529
−

23
21301
15047
+

24
22757
4850
+

25
16578
14366
+

26
6081
5201
−

27
4195
3135
−

28
12169
499
+

29
20639
2439
+

According to the results set forth in Table 7, centrifugation resulted in a decrease in the measurement of FRα levels in some samples, as previously demonstrated in Table 6.

Example 5
Detection of FRα in Urine Sediment by Immunoblotting

Based on the results shown in Examples 3 and 4, the presence or absence of FRα in urine sediment/precipitate was assessed using western blotting.

Materials and Methods

Urine samples from 2 ovarian cancer patients for whom FRα concentrations were measured at 18,747 pg/mL and 145,564 pg/mL, respectively (See Table 10 supra), were subjected to the following procedures. Control samples consisted of HeLa cell lysate 10 μg, liver tissue lysate 20 μg, and ovarian cancer tissue lysate 20 μg.

- 900 μL urine was centrifuged for 2 minutes at 10000 g
- supernatant was removed
- the remaining pellet was dissolved in 15 μL of PAGE sample buffer (containing 292 mM LDS) and subsequently boiled at 70° C. for 10 min
- The entire sample (approx. 20 μL) was loaded onto the NuPAGE bis-tris gel (Invitrogen)
- After electrophoresis, proteins were transferred to PVDF membrane
- 1% skim milk/0.05% Tween 20/PBS was added for blocking
- The membrane was washed with 0.05% Tween 20/PBS
- 0.5 mL of monoclonal antibody 548908 (R&D Systems) at 2 μg/ml was added and incubated for 60 minutes at room temperature
- The membrane was washed with 0.05% Tween 20/PBS
- 10 mL of anti-mouse IgG-HRP (DAKO p0447, 1:2000) was added and allowed to incubate for 60 minutes
- The membrane was washed with 0.05% Tween 20/PBS
- Pierce ECL Substrate was added to the membrane
- The membrane was removed from the substrates and then imaged using the LAS-3000 (FUJIFILM) system

Results

The resulting immunoblot is shown in FIG. 3. In this figure, lanes 1-5 correspond to FRα detected from the following sources:

(1) urine from ovarian cancer patient with a measured FRα level of 18,747 pg/mL

(2) urine from ovarian cancer patient with a measured FRα level of 145,564 pg/mL

(3) HeLa cell lysate: 10 μg

(4) Liver tissue lysate: 20 μg

(5) ovarian cancer tissue lysate: 20 μg

Lane 6 in the western blot represents molecular weight markers and demonstrates that the observed band in lanes 1, 2, 3 and 5 runs at the expected molecular weight for FRα.

Lanes 3 and 5 are positive control samples and lane 4 is a negative control sample. The faint band on lane 1 and the clear band on lane 2 demonstrate that FRα can be detected in the urine sediment of ovarian cancer patients by western blotting.

Example 6
Determination of FRα levels in Guanidine-Treated Normal Human Urine Samples by Electrochemiluminescence Immunoassay (ECLIA)

Based on the results of Example 4 in which centrifugation resulted in decreased FRα levels, and the results of Example 5 where the urine sediment obtained from centrifugation was shown to contain immunoreactive FRα, methods were sought to solubilize the sediments of urine to obtain more quantitative and accurate measurements of FRα.

In this regard, treatment of normal female urine samples with guanidine prior to assessing FRα levels was attempted.

The methodology utilized was as described in Example 1, except that the urine samples were mixed in a 1:1 ratio with either 6 M guanidine in buffer (PBS) or buffer alone. Subsequently, the urine samples were diluted by 1:51 in reaction buffer.

The results of this assay are shown in Table 8.

TABLE 8

Normal urine FRα level with or without guanidine treatment

Guanidine
FRα

Sample
treatment
(pg/mL)

Std Ag
Yes
83964

No
82512

Normal Urine
1
Yes
9431

No
7796

2
Yes
5713

No
4066

3
Yes
9687

No
9428

The results of this experiment indicate that guanidine does not interfere with FRα measurements. As can be seen for the pure antigen control (Std Ag), this methodology of guanidine treatment and subsequent dilution has no effect on the measurement of FRα. Further, it will be noted that in all three (3) urine samples assessed, the levels of FRα were higher in the samples treated (solubilized) with guanidine relative to the samples not treated with guanidine.

The reliability of guanidine pre-treatment of urine samples was further assessed by exposing three samples to guanidine and measuring the FRα concentration of each guanidine treated sample 3 times using the ECLIA assay. The results are reflected in Table 9 below:

TABLE 9

Intra-assay reproducibility of guanidine treated urine

FRα (pg/mL)

Test
Sample 1
Sample 2
Sample 3

1
9210
5477
9889

2
9638
5405
10047

3
10192
5812
10944

Mean
9680
5565
10293

SD
492
217
569

CV(%)
5.1
3.9
5.5

As set forth above, the results indicate that guanidine treatment of urine prior to FRα assay provided consistent measurements of FRα concentration with very low CV's.

Example 7
Determination of FRα Levels in Guanidine-Treated Urine Samples from Human Subjects with and without Ovarian Cancer Measured by Electrochemiluminescence Immunoassay (ECLIA)

Based on the results of Example 6 in which guanidine treatment was shown not to interfere with FRα assays, a modified assay protocol was employed to measure FRα in the urine samples from the subjects with and without ovarian cancer in Example 1.

The following assay protocol was employed:

Materials and Methods

The methodology utilized was as described in Example 1, except that the urine samples were mixed in a 1:1 ratio with a 6 M guanidine buffer and subsequently diluted by 1:26 in reaction buffer.

Results

Table 10 depicts the levels of FRα in guanidine treated urine samples from subjects afflicted with ovarian cancer and healthy female control subjects.

TABLE 10

Urine FRα level in ovarian cancer

and normal control group

Group
Sample #
FRα (pg/mL)

ovarian
1
27015

cancer
2
37315

3
79579

4
285

5
1864

6
2902

7
27914

8
51864

9
2699

10
9455

11
18396

12
145564

13
19046

14
10440

15
10977

16
9199

17
18223

18
18747

19
51098

normal
20
8012

control
21
3797

22
3323

23
20976

24
6941

25
14512

26
7286

27
2789

28
2617

29
7233

FIG. 4 shows the distribution of FRα levels in the urine of ovarian cancer afflicted subjects and normal female control subjects using the modified protocol with guanidine treatment. A statistically significant difference between groups was observed. Table 11 summarizes these results.

TABLE 11

Summary of urine FRα measurement

FRα (pg/mL)

ovarian cancer
normal control

n
19
10

Mean
28557
7749

SD
34990
5850

Max.
145564
20976

Min.
285
2617

Using the data from this experiment, a receiver operating characteristic (ROC) analysis was performed. FIG. 5 shows an ROC curve of the sensitivity and specificity of the ECLIA measurement of FRα levels in urine after the urine was treated with guanidine. AUC is the area under the curve, which measures the accuracy of the test in separating ovarian cancer from control subjects.

Using an arbitrary cutoff value of 9100 pg FRα/mL, the AUC was 0.70 with a positive predictive value of 70% and a negative predictive value of 80%, as shown in Table 12. Using this cutoff value, 15/19 ovarian cancer patients had a concentration of FRα above 9100 pg/mL and 8/10 normal subjects had a concentration of FRα less than 9100 pg/mL.

TABLE 12

Guanidine treatment for urine measurement

ovarian cancer
control

Number of Samples
19
10

Positive
15
2

Predictive value (%)
78.9
80.0

Example 8
Creatinine Correction of FRα Concentrations Determined in Guanidine-Treated Urine Samples by Electrochemiluminescence Immunoassay (ECLIA)

Concentrations of FRα were previously determined using ECLIA of guanidine-treated urine samples from ovarian cancer patients and normal female controls (See Example 7, Table 10). Here, these FRα concentrations were corrected for urine creatinine levels in order to normalize for the glomerular filtration rate. The resulting values were subjected to an ROC analysis.

Methods

The urine creatinine level was determined by the Ministry of Health, Labour and Welfare approved test kit, determiner L CRE (Kyowa Medex, Japan). The corrected value for urine FRα concentration was calculated as follows:

$\begin{matrix} Urine FR α Creatinine correction (ng / g) = \frac{(Urine FR α (ng / L) \times 1000)}{(Urine Creatinine (mg / dL) \times 10)} \\ = \frac{(Urine FR α (ng / L) \times 1000)}{Urine Creatinine (mg / L)} \\ = \frac{Urine FR α (ng / L)}{Urine Creatinine (g / L)} \\ = \frac{Urine FR α (ng)}{Urine Creatinine (g)} or \\ = \frac{1 / 1000 \times (Urine FR α (μg)}{Urine Creatinine (g)} \end{matrix}$

Results

Table 13 presents the resulting creatinine-corrected FRα levels.

TABLE 13

Creatinine-corrected FRα levels determined using

ECLIA of guanidine-treated urine samples

Sample
FRα
Corrected FRα (μg

Group
#
(pg/mL)
FRα/g creatinine)

ovarian cancer
1
27015
11.6

2
37315
37.8

3
79579
33.9

4
285
0.6

5
1864
6.7

6
2902
7.1

7
27914
54.9

8
51864
17.1

9
2699
13.5

9
9455
14.5

10
18396
23.1

11
145564
66.0

12
19046
9.1

13
10440
8.5

14
10977
7.4

15
9199
5.9

16
18223
13.0

17
18747
9.6

normal control
18
3797
7.7

19
3323
7.9

20
20976
10.7

21
6941
4.3

22
14512
8.6

23
7286
13.8

24
2789
4.3

25
2617
1.9

26
7233
3.1

FIG. 6 shows the distribution of FRα levels in ovarian cancer (OC) and normal female control subjects after correction for urine creatinine levels. There is a statistically significant difference between ovarian cancer patients and controls in creatinine-corrected levels of FRα (p=0.007).

The summary data for ovarian cancer and normal control subjects are provided in Table 14.

TABLE 14

Summary statistics for creatinine-corrected FRα levels

FRα (μg/g-creatinine)

ovarian cancer
normal control

n
18
9

Mean
18.9
6.9

SD
17.9
3.9

Max.
66.0
13.8

Min.
0.6
1.9

The creatinine-corrected FRα levels were further subjected to an ROC analysis. The ROC curve is shown in FIG. 7. Table 15 presents the sensitivity, specificity, and area under the curve (AUC) for various cutoff values of the creatinine-corrected test.

TABLE 15

Sensitivity, specificity, and AUC for various cutoff

values of the creatinine-corrected FRα test

Cut-off
Sensitivity
Specificity
AUC

3.0
94.4%
11.1%
0.67

4.0
94.4%
22.2%
0.70

5.0
94.4%
44.4%
0.78

6.0
88.9%
44.4%
0.74

9.0
66.7%
77.8%
0.70

As previously noted, there is a clear discrimination between urines of ovarian cancer patients and those from healthy female control subjects.

Example 9
Enzyme Immunoassay (EIA) and Optimization Thereof
1. Enzyme Immunoassay (EIA)
Antibody Coating to Microtiter Plates

The monoclonal anti-folate receptor alpha antibody was coated on the surface of microtiter plates (Nunc-immunoplate, Thermo Scientific) as follows. One hundred microliter of antibody (absorbance 0.02 at 280 nm) in 50 mmol/L carbonate buffer pH 9.4 was dispensed into wells, followed by coating for 16 hours at 4° C. The microplates were then washed 2 times with PBS containing 0.05% Tween20 (PBS-T). Thereafter 0.15 mL of PBS containing 20% normal rabbit serum pH 7.8 was dispensed into wells to block the unbounded surface, followed by blocking for 1 hour at room temperature. Finally, the microplates were washed 2 times with PBS-T. The antibody coated plates were dried and kept at 4° C. in aluminum bags until use.

Biotin Labeling

Biotin labeling was conducted according to the manufacturers recommendations for the EZ-Link Sulfo-NHS-LC-LC-Biotin (Product No. 21338, Thermo Scientific). Briefly, 1 mg of antibody in 0.4 mL of PBS was mixed with 0.013 mL of 10 mM Sulfo-NHS-LC-LC-Biotin, with an initial molar ratio of antibody to biotin of 1:20, followed by incubation for 30 min at room temperature. The biotin coupled antibody was purified by gel filtration using a PD-10 column (GE Healthcare) eluted with PBS to remove non-reacted biotin. In order to determine the level of biotin incorporation, the EZ Biotin quantitation kit (Product No. 28005, Thermo Scientific) was used. The biotin labeled antibody was stored at −80° C. until use.

Two Step Immunoassay

For the first reaction, 40 μL of plasma or standard antigen and 60 μL of 50 mM HEPES buffer containing 10% NRS, 150 mmol/L NaCl, 10 mmol/L EDTA-2Na, 0.01% Tween 20 pH 7.5 (reaction buffer) was dispensed into antibody coated wells. The plate was incubated for 18 hours at 4° C., and subsequently washed 5 times with PBS-T. For the second reaction, 100 μL of 10 μg/mL biotin labeled antibody in reaction buffer was dispensed. The plate was incubated for 1 hour at room temperature, and subsequently washed 5 times with PBS-T. 100 μL of horse radish peroxidase labeled streptavidin (Pierce) was dispensed. After 30 minutes incubation at room temperature, the plates were washed 5 times with PBS-T. Finally, for the color development, 100 μL of TMB solution (KPL) was dispensed and left for 15 minutes in dark. After stopping color development by adding 100 μL of 1N HCl, the absorption at 450 nm was read using a plate reader. All washing steps were automatically done by auto-plate washer (AMW-8, BioTec, Japan), and all EIA measurements were carried out in duplicate.

FIG. 8 depicts the EIA assay using MOV18 as the capture antibody and biotinylated MORAb-003 as the detector antibody.

2. Optimization of EIA Procedures

The above EIA procedures were arrived at in part based on the following experiments designed to optimize the procedure.

First, avidin-HRP, biotin labeled antibody and HRP labeled antibody were compared. Compared with HRP labeled antibody, biotin labeled antibody and avidin-HRP provided a higher signal; therefore, biotin labeled antibody and avidin-HRP were employed.

Second, one and two-step incubation procedures were compared. As depicted in FIG. 9, a two-step incubation procedure yielded a higher signal and was thus employed.

Third, to optimize the second incubation time, incubation times of one to four hours were compared. The results indicated that one hour incubation times provided the highest signal to noise ratio and therefore an incubation time of one hour was subsequently employed.

Fourth, in order to optimize the working concentration of biotin labeled antibody, HRP labeled antibody and sample volume, various concentrations were employed as set forth in the above description of the EIA assay. The optimal values concentrations are described above.

Example 10
Comparison of FRα in Human Plasma Using Electrochemiluminescence Immunoassay (ECLIA) and Enzyme Immunoassay (EIA)

The levels of FRα were measured in human plasma samples taken from ovarian cancer patients and healthy female controls using the electrochemiluminescence assay (ECLIA) described in Example 1 and FIG. 1 (using MORAb-003 as the capture antibody and ruthenium (Ru)-labeled MOV-18 as the labeled detector antibody) and the enzyme immunoassay (EIA) described in Example 9 and FIG. 8. In both assays, 40 μL of plasma was assayed.

Table 16 shows the plasma levels of FRα in ovarian cancer and normal control subjects, as determined using the EIA and ECLIA.

TABLE 16

Plasma concentrations of FRα determined

using EIA and ECLIA methods

Sample
FRα concentration (pg/mL)

Group
#
EIA
ECLIA

Ovarian cancer
1
10
73

2
<10
200

3
56
286

4
44
286

5
353
1606

6
83
494

Healthy control
7
110
127

8
162
112

9
88
252

10
180
254

11
262
471

12
206
396

With only one exception, the results for all of the subjects indicated that the concentrations of FRα detected in serum using EIA are lower than the levels detected using ECLIA, demonstrating that the EIA assay, as formatted, is not as sensitive as the ECLIA assay when this particular combination of capture (MOV-18) and detector antibodies (MORAb-003) is used. Therefore, further experiments with other types of antibodies were conducted to develop a more sensitive EIA procedure.

Example 11
Feasibility of Different Types of Antibodies for EIA Measurement of FRα in Human Plasma
1. Preliminary Experimentation of Antibody Combinations

Various combinations of capture/detector antibodies were considered. Preliminary experimentation rendered the results set forth in Table 17.

TABLE 17

Capture antibody

MORAB-003
MOV18
548908(R&D)
6D398

Biotin-labeled
003
Blank
Low
Blank
Low
Blank
Low
Blank
Low

detection antibody

Std.
−
Std.
+++
Std.
++
Std.
++

1-S
−
1-S
++
1-S
++
1-S
+

MOV18
Blank
Low
Blank
High
Blank
High
Blank
High

Std.
+
Std.
−
Std.
−
Std.
−

1-S
++
1-S
+++
1-S
++
1-S
+++

548908

Blank
Low

Std.
−

1-S
++

2. Comparison of EIA Assays Using Various Antibody Combinations and Comparison to the ECLIA Assay

The levels of FRα in plasma from ovarian cancer patients and normal healthy female controls were measured using an enzyme-linked immunosorbent assay (EIA) with different combinations of capture and biotin-labeled antibodies and compared with the levels of FRα measured using the ECLIA assay.

Materials and Methods

The ECLIA method was as described in Example 1 and depicted in FIG. 1 (using the MORAb-003 antibody as the capture antibody and the Mov-18 antibody as the labeled detector antibody). The EIA method was as described in Example 9, except that three different combinations of capture/detector antibodies were employed, as depicted in FIG. 10: MOV18/MORAb-003, 548908/MORAb-003 and 6D398/MORAb-003. The antibodies 548908 and 6D398 are commercially available. The 548908 antibody was obtained from R&D Systems (North Las Vegas, Nev.) and the 6D398 antibody was obtained from US Biological (Swampscott, Mass. 01907).

Results

The concentrations of FRα (pg/mL) determined using the EIA and ECLIA methods are shown in Table 18. In addition, the concentrations of FRα (pg/ml) determined by EIA using various combinations of capture/detector antibodies are depicted graphically in FIG. 11.

TABLE 18

Plasma concentrations of FRα (pg/mL) determined using the

EIA and ECLIA methods with various combinations of

capture and detector antibodies.

EIA
EIA
EIA
ECLIA

548908-
6D398-
MOV18-
MOV18-

Sample
MORAb-
MORAb-
MORAb-
MORAb-

Group
#
003
003
003
003

Ovarian
1
176
2
10
217

cancer
2
85
<0
—
165

3
257
35
—
296

4
117
42
44
322

5
2048
370
353
1335

6
447
63
83
390

Normal
7
247
66
110
137

control
8
213
110
162
185

9
367
78
88
219

10
364
152
180
228

11
804
224
262
388

12
473
194
206
318

The data in Table 18 indicate that the measurements of FRα levels with EIA using the 54908-MORAb-003 combination yields results that are most similar to the results obtained using the ECLIA assay. Quantitive analyses were performed, confirming this observation. Further, these data demonstrate that the detection of FRα is highly dependent on the antibodies and antibody combination employed. Accordingly, different antibody combinations can be employed for the determination of FRα in biological fluids. In addition, since the data obtained from the EIA and the ECLIA assay formats are similar, various assay formats can be used for the determination of FRα.

For each of the three combinations of capture and detector antibodies used for the EIA method, a regression analysis was performed, and the concentrations of FRα (pg/mL) determined with EIA were correlated with the concentrations determined with the ECLIA assay. The results of this analysis are shown in Table 19 and in FIG. 12.

TABLE 19

Correlations of plasma concentrations of FRα measured by ECLIA

with concentrations measured by EIA using three combinations

of capture and detector antibodies

Capture antibody-
548098-
6D398-
MOV18-

detector antibody
MORAb-003
MORAb-003
MORAB-003

r
0.960
0.781
0.715

Slope
1.595
0.285
0.223

Intercept
−87.06
−0.64
58.62

The results for EIA using the 548098-MORAb-003 capture-detector combination correlated highly (r=0.96) with the results for ECLIA.

Example 12
Plasma Levels of FRα Determined by EIA and ECLIA in Samples from Ovarian Cancer Patients

Measurements of serum FRα levels were determined in a group of ovarian cancer patients (n=17) and normal controls (n=35) using ECLIA and EIA. For the EIA measurements, the 548908 capture/MORAb-003 detector antibody combination was employed. The EIA procedure was otherwise as described in Example 9. The ECLIA procedure was as described in Example 1. The results are shown in Table 20.

TABLE 20

Plasma FRα concentrations in ovarian

cancer patients and normal controls,

as determined using EIA and ECLIA

Sample
EIA
ECLIA

Group
#
pg/mL
pg/mL

Ovarian cancer
1
245
217

2
247
223

3
194
229

4
2613
1335

5
154
153

6
319
215

7
516
390

8
370
271

9
933
449

10
4768
4502

11
385
266

12
251
322

13
404
349

14
338
371

15
4147
2344

16
179
165

17
380
296

Control
18
232
181

19
372
173

20
332
189

21
380
203

22
376
290

23
406
217

24
281
182

25
348
191

26
490
247

27
253
137

28
368
185

29
338
195

30
289
219

31
338
206

32
406
226

33
365
228

34
501
280

35
806
388

36
613
286

37
380
250

38
420
281

39
393
280

40
552
284

41
664
318

42
429
261

43
499
286

44
310
218

45
281
217

46
215
202

47
293
217

48
380
256

49
270
195

50
393
234

51
425
308

52
226
199

FIG. 13 shows the distribution of plasma FRα concentrations in subjects with ovarian cancer and normal female control subjects as determined using EIA.

Table 21 shows summary descriptive statistics for the plasma FRα concentrations in ovarian cancer and normal female control subjects as determined using EIA.

TABLE 21

Summary of FRα plasma concentrations

in ovarian cancer and normal female

control subjects as determined using EIA.

FRα (pg/mL)

Ovarian cancer
Normal control

n
17
35

Mean
967
389

SD
1438
126

Max.
4768
806

Min.
154
215

FIG. 14 further depicts the correlation between FRα plasma concentrations determined using EIA and ECLIA. The correlation is high (r=0.95).

Example 13
Determination of FRα Levels in Matched Urine and Serum Samples from Lung Cancer Patients and Ovarian Cancer Patients as Measured by Electrochemiluminescence Immunoassay (ECLIA)

FRα levels were determined in matched urine and serum samples from lung cancer and ovarian cancer patients using ECLIA where the samples were taken from the same patient. The correlation between serum and urine FRα levels was also determined.

Materials and Methods

The ECLIA methodology utilized is as described in Example 1. Guanidine was used to solubilize urine sediments as described in Example 6.

Results

The results of the ECLIA assays of serum and urine from lung cancer and ovarian cancer patients are presented in Table 22.

TABLE 22

FRα concentrations in matched urine and serum

samples of lung cancer patients and ovarian

cancer patients, as determined by ECLIA

Serum
Urine

Group
set ID
pg/mL
pg/mL

Lung cancer
1
146
2009

2
153
4496

3
206
—

4
70
3562

5
195
12381

6
352
21873

7
198
11296

8
120
18570

9
275
4455

10
163
8662

11
145
5294

12
178
—

13
165
1106

14
187
7446

15
168
11167

16
217
24448

17
142
6724

18
177
14514

19
236
822

20
101
4826

21
145
7723

22
213
9887

23
143
7422

24
253
3376

25
421
8045

ovarian cancer
26
282
9414

27
1605
7651

28
240
13059

29
695
10549

Summary data for serum and urine FRα levels of lung cancer patients is presented in Table 23.

TABLE 23

Summary statistics for FRα concentrations

in matched serum and urine samples of lung

cancer patients, as determined by ECLIA

FRα (pg/mL)

Lung cancer
Serum
Urine

n
25
23

Mean
191
8700

SD
75
6291

Max.
421
24448

Min.
70
822

Summary data for serum and urine FRα levels of ovarian cancer patients is presented in Table 24.

TABLE 24

Summary statistics for FRα concentrations

in matched serum and urine samples of ovarian

cancer patients, as determined by ECLIA

FRα (pg/mL)

Ovarian cancer
Serum
Urine

n
4
4

Mean
705
10168

SD
634
2266

Max.
1605
13059

Min.
240
7651

FIG. 15 shows correlations between ECLIA measures of FRα levels in matched serum and urine samples taken from the same patient. The correlation for lung cancer patients was r=0.24 (upper panel) and the correlation for ovarian cancer patients was r=−0.76 (lower panel).

These data demonstrate the relative lack of correlation between FRα concentrations measured in urine versus serum, especially as shown for lung cancer patients. Further, these data demonstrate that FRα is basically non-detectable above background levels in the serum of lung cancer patients versus normal controls whereas FRα is detectable in the urine of these patients.

Example 14
Assessment of Levels of FRα in Serum Samples from Patients with Ovarian Cancer, Patients with Lung Cancer, and Normal Controls

FRα levels in the serum of patients with ovarian cancer, patients with lung cancer, and normal controls were assessed. Serum FRα levels were assessed using ECLIA with two different pairs of capture-detector antibodies: Pair 1, in which 9F3 was the capture antibody and 24F12 was the detector antibody, and Pair 2, in which 26B3 was the capture antibody and 19D4 was the detector antibody.

The FRα pairs were tested with full calibrator curves and 196 individual serums diluted 1:4. In one experiment, 26B3 was used as the capture antibody after CR processing on a plate lot (75 μg/mL, +B, +T) and 19D4 was used as the detector antibody at 1.0 μg/mL. In another experiment, 9F3 was used as the capture antibody and 24F12 was used as the detector antibody at 1.0 μg/mL. Each were CR processed (lot 10070) with an label to protein ratio (L/P) of 13.3. Diluent 100 (Meso Scale Discovery, Gaithersburg, Md.)+human anti-mouse antibody (HAMA)+mIgG was used for samples and calibrator. Diluent 3 (Meso Scale Discovery, Gaithersburg, Md.) was used for detections.

The following protocol was employed for the ECLIA. Samples were added at 50 μL/well. The samples were shaken for 2 hours and subsequently washed with Phosphate Buffered Saline (PBS) solution with the detergent Tween 20 (PBST). The detector antibody was added at 25 μL/well. The samples were shaken for 2 hours and then were washed with PBST. Finally, the electrochemiluminescence (ECL) emission of the samples was read with 2×MSD® Buffer T.

The results are shown in Table 25 below.

TABLE 25

FRα levels in serum of patients with ovarian cancer, patients with lung cancer, and normal controls

LLOQ¹= 1 pg/mL

LLOQ¹= 5 pg/mL

FRα- Pair 2
FRα Pair 1

MSD Sample

Adjusted

Adjusted

Testing
Sample
backfit conc²

backfit conc²

Number
Type
(pg/mL)
% CV
(pg/mL)
% CV
stage
grade
gender
comments

1
Ovarian
3760
4%
3585
4%
III
2
F
Adenocarcinoma—

Serum

Ovary

2
Ovarian
223
3%
273
2%
III
3
F
Adenocarcinoma—

Serum

Ovary

3
Ovarian
950
1%
3346
8%
IIIC

F
Papillary Serous

Serum

Carcinoma

4
Ovarian
3827
4%
968
0%
III
2
F
Adenocarcinoma—

Serum

Ovary

5
Ovarian
251
6%
468
2%
IV
2
F
Adenocarcinoma—

Serum

Ovary

6
Ovarian
199
6%
328
1%
IIIC
2
F
Cystadenocarcinoma

Serum

7
Ovarian
166
1%
257
5%
IC
2
F
Cystadenocarcinoma

Serum

8
Ovarian
182
4%
248
2%
IIIC
2
F
Cystadenocarcinoma

Serum

9
Ovarian
155
6%
265
2%
IIIC
2
F
Cystadenocarcinoma

Serum

10
Ovarian
145
9%
253
5%
IIIC
2
F
Cystadenocarcinoma

Serum

11
Ovarian
142
5%
186
1%
IIB
1
F
Serous

Serum

adenocarcinoma

12
Ovarian
299
5%
456
2%
IB
3
F
Serous

Serum

adenocarcinoma

13
Ovarian
315
0%
768
8%
IIIB
high grade
F
Serous

Serum

cystadenocarcinoma

of the ovary

14
Ovarian
168
6%
351
1%
I
high grade
F
Serous

Serum

cystadenocarcinoma

of the ovary

15
Ovarian
187
8%
263
1%
I
Well to
F
Papillary serous

Serum

moderately

cystadenocarcinoma

differentiated

of the ovary

16
Ovarian
423
3%
229
5%
IA
poorly
F
Mucinous

Serum

differentiated

cystadenocarcinoma

of the ovary

17
Ovarian
86
7%
289
1%
I
moderately
F
Papillary

Serum

differentiated

cystadenocarcinoma

of the ovary

18
Ovarian
57
3%
255
1%
I
well
F
Mucinous

Serum

differentiated

cystadenocarcinoma

of the ovary

19
Ovarian
108
1%
393
1%
III
moderately
F
Papillary mucinous

Serum

differentiated

cystadenocarcinoma

of the ovary

20
Ovarian
207
3%
328
1%
missing
poorly
F
Papillary

Serum

differentiated

cystadenocarcinoma

of the ovary

21
Ovarian
66
0%
254
1%
missing
high grade
F
Adenocarcinoma of

Serum

the ovary

22
Ovarian
108
2%
197
2%

low grade
F
Papillary

Serum

cystadenocarcinoma

of the ovary

23
Ovarian
201
2%
457
1%
II
high grade
F
Papillary serous

Serum

cystadenocarcinoma

of the ovary

24
Ovarian
477
1%
808
11%
III
high grade
F
Serous

Serum

cystadenocarcinoma

of the ovary

25
Ovarian
423
3%
613
3%
n/a
n/a
F
transitional cell

Serum

carcinoma

26
Ovarian
249
8%
432
1%
n/a
2
F
ovarian carcinoma—

Serum

endometrioid type

27
Ovarian
152
7%
235
2%
IV
2
F
ovarian carcinoma—

Serum

serous papillary type

28
Ovarian
1409
5%
1287
3%
III C
3
F
ovarian carcinoma—

Serum

serous type

29
Ovarian
443
2%
547
2%
III C
2
F
ovarian carcinoma—

Serum

serous papillary type

30
Ovarian
208
1%
298
13%
IA
1
F
ovarian carcinoma—

Serum

serous type

31
Ovarian
114
9%
344
1%
III B
2
F
ovarian carcinoma—

Serum

serous papillary type

32
Ovarian
223
4%
157
133%
III C
1
F
ovarian carcinoma—

Serum

serous papillary type

33
Ovarian
5034
1%
4405
1%
III C
3
F
transitional cell

Serum

carcinoma

34
Ovarian
32966
6%
23228
4%
IV
n/a
F
ovarian carcinoma—

Serum

serous papillary type

35
Ovarian
94
6%
188
3%
n/a
3
F
clear cell

Serum

adenocarcinoma

36
Ovarian
866
6%
1317
1%
III C
3
F
poorly differentiated

Serum

adenocarcinoma

37
Ovarian
2916
8%
3121
0%
IV
3
F
ovarian carcinoma—

Serum

serous papillary type

38
Ovarian
679
4%
1037
17%
IV
3
F
ovarian carcinoma—

Serum

serous type

39
Ovarian
294
8%
478
3%
III C
3
F
ovarian carcinoma—

Serum

serous papillary type

40
Ovarian
2037
4%
12
74%
III C
3
F
ovarian carcinoma—

Serum

serous type

41
Ovarian
16289
6%
10431
3%
III C
2
F
ovarian carcinoma—

Serum

serous papillary type

42
Ovarian
386
6%
736
6%
n/a
3
F
ovarian carcinoma—

Serum

serous papillary type

43
Ovarian
1474
6%
2382
3%
IIIC

F
Papillary serous

Serum

cystadenocarcinoma

of the pelvic

44
Ovarian
169
2%
438
1%
I
3
F
Adenocarcinoma of

Serum

the ovary

45
Ovarian
257
4%
635
10%
I
high grade
F
Adenocarcinoma of

Serum

the ovary

46
Ovarian
184
6%
393
0%
IIIC
poorly
F
Adenocarcinoma of

Serum

differentiated

the ovary

47
Ovarian
251
6%
659
1%
IIA
2
F
Adenocarcinoma of

Serum

the ovary

48
Ovarian
165
2%
394
7%
I
2
F
Adenocarcinoma of

Serum

the ovary

49
Ovarian
64
7%
245
6%
IIIB
undifferentiated
F
Serous

Serum

cystadenocarcinoma

of the ovary

50
Ovarian
90
3%
203
3%
IIIC

F
Serous

Serum

adenocarcinoma nos

51
Ovarian
167
3%
376
11%
IIIC
high grade
F
Serous papillary

Serum

adenocarcinoma nos

52
Ovarian
112
4%
260
5%
IIIC
high grade
F
Serous

Serum

adenocarcinoma nos

53
Ovarian
198
2%
340
6%
IV
high grade
F
Serous

Serum

cystadenocarcinoma,

nos

54
Ovarian
134
3%
363
6%
I
moderately
F
Papillary mucinous

Serum

differentiated

cystadenocarcinoma

of the ovary

55
Ovarian
118
5%
304
10%
IB
high grade
F
Papillary serous

Serum

cystadenocarcinoma

of the ovary

56
Ovarian
107
1%
326
4%
IIIB
high grade
F
Papillary serous

Serum

cystadenocarcinoma

of the ovary

57
Ovarian
728
1%
1670
2%
IIIB

F
Papillary serous

Serum

cystadenocarcinoma

of the ovary

58
Ovarian
2138
1%
3257
2%
IIIC

F
Papillary

Serum

adenocarcinoma of

the ovary

59
Ovarian
167
4%
410
1%
III

F
Papillary serous

Serum

cystadenocarcinoma

of the ovary

60
Ovarian
3054
4%
3285
14%
IIIC
high grade
F
Serous carcinoma of

Serum

the ovary

61
Ovarian
97
3%
215
0%
IIIB
high grade
F
Papillary serous

Serum

cystadenocarcinoma

of the ovary

63
Lung
61
3%
366
10%
IA
moderate to
M
Adenocarcinoma of

Serum

poorly

the lung

differentiated

64
Lung
106
1%
319
4%
IB

M
Adenocarcinoma of

Serum

the lung

65
Lung
49
2%
257
1%
IB
moderately
M
Adenocarcinoma of

Serum

differentiated

the lung

66
Lung
75
2%
301
2%
II
3
M
Adenocarcinoma

Serum

67
Lung
79
3%
283
8%
II
2
M
Adenocarcinoma

Serum

68
Lung
145
2%
492
0%
II
2
F
Adenocarcinoma

Serum

69
Lung
142
2%
367
6%
IV
n/a
F
adenocarcinoma

Serum

70
Lung
103
2%
231
7%
IV
n/a
F
adenocarcinoma

Serum

71
Lung
153
1%
311
3%
III B
n/a
F
adenocarcinoma

Serum

72
Lung
54
3%
124
6%
III A
missing
M
large and solid cell

Serum

carcinoma

73
Lung
183
3%
391
10%
III B
missing
F
adenocarcinoma

Serum

74
Lung
91
2%
199
7%
missing
3
M
poorly differentiated

Serum

non-keratinizing

squamous cell

carcinoma

75
Lung
89
7%
221
2%
III B
3
F
poorly differentiated

Serum

adenocarcinoma

76
Lung
139
1%
330
1%
I A
2
F
moderately

Serum

differentiated

adenocarcinoma

77
Lung
197
3%
452
7%
III A
2
F
moderately

Serum

differentiated

adenocarcinoma

78
Lung
52
3%
183
5%
III A
n/a
F
pleomorphic carcinoma

Serum

79
Lung
80
3%
249
8%
III A
n/a
M
pleomorphic carcinoma

Serum

80
Lung
72
1%
158
7%
IIIA
2
F
moderately

Serum

differentiated

adenocarcinoma

81
Lung
130
12%
221
1%
IA
3
M
large and solid cell

Serum

carcinoma

82
Lung
81
6%
155
1%
IB
missing
M
large and solid cell

Serum

carcinoma

83
Lung
127
4%
278
3%
IIIB
missing
F
large and solid cell

Serum

carcinoma

84
Lung
129
3%
240
2%
missing
missing
F
large and solid cell

Serum

carcinoma

85
Lung
135
2%
231
7%
III B
2
M
moderately

Serum

differentiated

adenocarcinoma

86
Lung
235
1%
330
0%
IV
2
M
adenocarcinoma

Serum

87
Lung
243
5%
396
2%
IV
3
F
poorly differentiated

Serum

adenocarcinoma

88
Lung
204
3%
572
6%
IA
moderately
F
Squamous cell

Serum

differentiated

carcinoma of the

lung

89
Lung
54
9%
214
4%
IB
moderately
M
Adenocarcinoma of

Serum

differentiated

the lung

90
Lung
116
7%
270
0%
IB
moderately
F
Mucinous

Serum

differentiated

adenocarcinoma of

the lung

91
Lung
117
3%
292
5%
IIA
moderately
M
Adenocarcinoma of

Serum

differentiated

the lung

92
Lung
248
1%
578
2%
missing
moderately
M
Adenocarcinoma of

Serum

differentiated

the lung

93
Lung
86
2%
300
9%
IB
poorly
M
Adenocarcinoma of

Serum

differentiated

the lung

94
Lung
33
6%
117
5%
IIIA
moderate to
M
Adenocarcinoma of

Serum

poorly

the lung

differentiated

95
Lung
36
3%
196
3%
IIIA
poorly
M
Adenocarcinoma of

Serum

differentiated

the lung

96
Lung
237
3%
722
4%
IB
well
M
Adenocarcinoma of

Serum

differentiated

the lung

97
Lung
82
9%
286
2%
IB
poorly
M
Adenocarcinoma of

Serum

differentiated

the lung

98
Lung
112
1%
431
0%
IB
Well to
F
Adenocarcinoma of

Serum

moderately

the lung

differentiated

99
Lung
137
5%
379
0%
IA
moderately
F
Alveolar

Serum

differentiated

adenocarcinoma of

the lung

100
Lung
65
2%
181
9%
IA
moderate to
M
Adenocarcinoma of

Serum

poorly

the lung

differentiated

101
Lung
119
6%
280
4%
IB

M
Adenocarcinoma of

Serum

the lung

102
Normal
187
6%
391
2%

F

Serum

103
Normal
337
4%
560
6%

F

Serum

104
Normal
203
4%
405
3%

F

Serum

105
Normal
97
3%
311
2%

F

Serum

106
Normal
210
11%
393
6%

F

Serum

107
Normal
135
9%
271
6%

M

Serum

108
Normal
145
2%
225
3%

F

Serum

109
Normal
182
4%
257
5%

M

Serum

110
Normal
186
5%
297
2%

M

Serum

111
Normal
129
8%
197
4%

M

Serum

112
Normal
133
4%
254
4%

M

Serum

113
Normal
136
1%
298
9%

M

Serum

114
Normal
189
3%
321
1%

M

Serum

115
Normal
167
1%
257
6%

M

Serum

116
Normal
159
1%
315
1%

M

Serum

117
Normal
166
3%
270
1%

M

Serum

118
Normal
197
2%
339
0%

M

Serum

119
Normal
148
1%
389
4%

M

Serum

120
Normal
198
4%
833
9%

M

Serum

121
Normal
101
3%
137
0%

M

Serum

122
Normal
111
8%
266
1%

M

Serum

123
Normal
96
0%
172
2%

M

Serum

124
Normal
224
1%
249
7%

M

Serum

125
Normal
203
8%
312
1%

M

Serum

126
Normal
277
10%
388
5%

M

Serum

127
Normal
191
4%
272
4%

F

Serum

128
Normal
206
4%
297
3%

F

Serum

129
Normal
204
15%
194
3%

F

Serum

130
Normal
156
1%
106
2%

F

Serum

131
Normal
177
3%
195
3%

F

Serum

132
Normal
109
0%
148
5%

M

Serum

134
Normal
116
1%
281
1%

F

Serum

135
Normal
182
7%
250
6%

M

Serum

136
Normal
324
2%
475
7%

F

Serum

137
Normal
122
18%
191
1%

F

Serum

138
Normal
135
7%
185
1%

F

Serum

139
Normal
264
4%
372
2%

F

Serum

140
Normal
105
4%
188
5%

M

Serum

141
Normal
374
0%
649
0%

M

Serum

142
Normal
93
7%
162
7%

M

Serum

143
Normal
143
7%
326
4%

F

Serum

144
Normal
108
3%
202
2%

F

Serum

145
Normal
153
8%
341
3%

F

Serum

146
Normal
448
8%
400
5%

F

Serum

147
Normal
109
4%
196
3%

F

Serum

148
Normal
142
6%
218
1%

F

Serum

149
Normal
174
4%
309
9%

F

Serum

150
Normal
185
5%
270
2%

F

Serum

151
Normal
180
3%
241
0%

M

Serum

152
Normal
125
5%
314
4%

F

Serum

153
Normal
270
0%
449
2%

F

Serum

154
Normal
127
9%
232
1%

M

Serum

155
Normal
251
3%
415
6%

F

Serum

156
Normal
121
1%
349
0%

M

Serum

157
Normal
137
8%
223
0%

M

Serum

158
Normal
77
3%
173
6%

M

Serum

159
Normal
143
4%
223
7%

F

Serum

160
Normal
121
5%
411
8%

M

Serum

161
Normal
99
8%
199
3%

F

Serum

162
Normal
158
2%
236
0%

F

Serum

163
Normal
138
7%
235
3%

F

Serum

164
Normal
175
18%
290
2%

F

Serum

165
Normal
339
4%
589
8%

M

Serum

166
Normal
155
4%
372
1%

F

Serum

167
Normal
166
0%
278
1%

M

Serum

168
Normal
231
7%
377
3%

M

Serum

169
Normal
148
10%
255
3%

F

Serum

170
Normal
172
2%
312
4%

M

Serum

171
Normal
146
6%
344
1%

M

Serum

172
Normal
158
3%
306
4%

M

Serum

173
Normal
145
2%
274
6%

F

Serum

174
Normal
163
12%
279
1%

M

Serum

175
Normal
83
5%
196
0%

M

Serum

176
Normal
102
7%
282
5%

M

Serum

177
Normal
140
3%
330
6%

M

Serum

178
Normal
174
9%
277
15%

F

Serum

179
Normal
295
3%
281
8%

M

Serum

180
Normal
67
4%
308
13%

F

Serum

181
Normal
115
3%
324
0%

F

Serum

182
Normal
128
5%
287
0%

F

Serum

183
Normal
128
1%
112
79%

M

Serum

184
Normal
76
3%
147
53%

F

Serum

185
Normal
264
7%
377
4%

F

Serum

186
Normal
146
13%
258
3%

M

Serum

187
Normal
132
0%
264
1%

F

Serum

188
Normal
92
4%
249
1%

M

Serum

189
Normal
89
11%
251
4%

F

Serum

190
Normal
135
5%
268
4%

M

Serum

191
Normal
177
4%
394
3%

F

Serum

192
Normal
184
8%
367
2%

F

Serum

193
Normal
156
3%
387
5%

F

Serum

194
Normal
118
8%
275
4%

M

Serum

195
Normal
74
7%
217
6%

M

Serum

196
Normal
185
8%
373
5%

F

Serum

197
Normal
159
3%
378
2%

F

Serum

198
Normal
94
2%
245
1%

F

Serum

¹LLOQ is the lower limit of quantitation

²The adjusted backfit concentration is adjusted to take into account the sample dilution.

Based on the foregoing data, it was apparent that the 9F3, 2412, 26B3 and 19D4 antibodies were useful in detecting levels of FRα in biological samples, for example serum, derived from a subject. Moreover, the particular combinations of (i) 9F3 as a capture antibody and 24F12 as a detector antibody and (ii) 26B3 as a capture antibody and 19D4 as a detector antibody were capable and particularly effective of assessing levels of FRα in biological samples.

Example 15
Assessment of Levels of FRα in Urine Using Three Different Detector and Capture Antibody Pairs

The ability of three anti-FRα antibody pairs in detecting the levels of FRα in urine samples was assessed. The antibody pairs utilized were as follows: (1) 26B3 as detector antibody and 9F3 as capture antibody, and (2) 24F12 as detector antibody and 9F3 as capture antibody.

Method

Two antibody pairs were tested with full calibrator curves and urine pretreated with a 1:1 dilution for 2 minutes in either 6M guanidine, 3M guanidine or PBS control. The following urine samples were tested: three human urine pools diluted 1:80, and five human individual urines diluted 1:80 (one male, four female).

Plates were Biodotted at 150 μg/mL, +B, +T, on 4spot STD ((Meso Scale Discovery, Gaithersburg, Md.)), one capture per well. Detects were run at 1 μg/mL. Diluent 100+HAMA+mIgG was used for samples and calibrator. Diluent 3 was used for detections. Diluents were commercially available diluents obtained from Meso Scale Discovery.

The following protocol was employed for the ECLIA. Samples were added at 50 μL/well. The samples were shaken for 2 hours. The samples were washed with Phosphate Buffered Saline (PBS) solution with the detergent Tween 20 (PBST). The detector antibody was added at 25 μL/well. The samples were shaken for 2 hours and subsequently washed with PBST. The electrochemiluminescence (ECL) emission of the samples was read with 2×MSD Buffer T.

The results of these experiments are shown in Tables 26-27.

TABLE 26

Detection of FRα levels in urine using 26B3 as detector antibody and 9F3 as capture antibody

Detect 26B3

Capture 9F3

6M Guanidine
3M Guanidine
PBS Control

Adjusted

Adjusted

Adjusted

Backfit conc

% of
Backfit conc

% of
Backfit conc

Sample ID
pg/mL
% CV
control
pg/mL
% CV
control
pg/mL
% CV

Urine pool 1
13,252
2%
114%
14,505
10%
124%
11,655
17%

Urine pool 2
14,827
5%
133%
17,039
4%
152%
11,187
5%

Urine pool 3
11,280
5%
119%
9,065
10%
96%
9,479
9%

Urine Ind 1
1,747
3%
99%
1,754
6%
100%
1,760
12%

Urine Ind 2
40,505
7%
145%
46,622
5%
167%
27,920
13%

Urine Ind 3
1,623
1%
117%
1,496
5%
108%
1,381
4%

Urine Ind 4
12,091
2%
86%
14,941
5%
107%
13,996
13%

Urine Ind 5
22,829
2%
128%
24,607
8%
137%
17,899
5%

Average
3%
118%
Average
7%
124%
Average
10%

difference
6%

from 6M

condition

TABLE 27

Detection of FRα levels in urine using 24F12 as detector antibody and 9F3 as capture antibody

Detect 24F12

Capture 9F3

6M Guanidine
3M Guanidine
PBS Control

Adjusted

Adjusted

Adjusted

Backfit conc

% of
Backfit conc

% of
Backfit conc

Sample ID
pg/mL
% CV
control
pg/mL
% CV
control
pg/mL
% CV

Urine pool 1
10,883
2%
53%
14,689
9%
72%
20,504
10%

Urine pool 2
11,763
8%
60%
16,487
7%
85%
19,468
1%

Urine pool 3
7,456
9%
40%
9,362
17%
50%
18,677
7%

Urine Ind 1
1,376
1%
39%
1,894
7%
54%
3,501
3%

Urine Ind 2
29,567
0%
61%
37,843
13%
78%
48,607
5%

Urine Ind 3
1,621
4%
61%
2,153
2%
81%
2,667
1%

Urine Ind 4
10,470
6%
58%
14,116
5%
78%
18,175
6%

Urine Ind 5
19,390
6%
68%
22,076
23%
78%
28,421
4%

Average
5%
55%
Average
10%
72%
Average
5%

difference
17%

from 6M

condition

Based on the foregoing data, it was apparent that the 9F3, 24F12, 26B3 and 19D4 antibodies were useful in detecting levels of FRα in biological samples derived from a subject. Moreover, the combinations of (1) 26B3 as detector antibody and 9F3 as capture antibody and (2) 24F12 as detector antibody and 9F3 as capture antibody were capable and particularly effective of assessing levels of FRα in biological samples.

A second set of experiments, following the protocol described above and using the same two pairs of antibodies, were conducted utilizing four female human individual urines diluted 1:80. The urine was pretreated with a 1:1 dilution for 2 minutes in either 3M guanidine or PBS control. The results are shown in Tables 28-29.

TABLE 28

Detection of FRα levels in urine using 26B3 as detector

antibody and 9F3 as capture antibody

Detect
26B3

Capture
9F3

3M Guanidine
PBS Control

Adjusted

Adjusted

Backfit conc
%
% of
Backfit conc
%

Sample ID
pg/mL
CV
control
pg/mL
CV

Urine Ind 2
33,824
4%
98%
34,569
2%

Urine Ind 3
2,086
4%
99%
2,107
3%

Urine Ind 4
15,283
5%
97%
15,696
2%

Urine Ind 5
24,955
4%
92%
26,991
3%

Average
4%
97%
Average
3%

TABLE 29

Detection of FRα levels in urine using 24F12

as detector antibody and 9F3

as capture antibody

Detect
24F12

Capture
9F3

3M Guanidine
PBS Control

Adjusted

Adjusted

Backfit conc
%
% of
Backfit conc
%

Sample ID
pg/mL
CV
control
pg/mL
CV

Urine Ind 2
38,455
4%
106%
36,414
6%

Urine Ind 3
2,447
2%
109%
2,250
2%

Urine Ind 4
15,303
3%
81%
18,964
8%

Urine Ind 5
27,216
0%
95%
28,651
5%

Average
2%
98%
Average
5%

The results of this second set of experiments further confirm the results of the first set of experiments and demonstrate that the level of FRα which is not bound to a cell can be reliably assessed, for example, in urine, using assays such as the ECLIA assay and using the 26B3, 9F3, 24F12 antibodies. Further, the results demonstrate that such assays can effectively detect FRα using pairs of detector and capture antibodies that bind FRα (such as, e.g., 26B3 as detector antibody and 9F3 as capture antibody, and 24F12 as detector antibody and 9F3 as capture antibody).

Example 16
Assessment of Levels of FRα in Serum and Plasma

The levels of FRα were assessed in samples of serum and plasma on two separate days. The subjects from whom the samples were derived were either normal subjects or patients with ovarian or lung cancer.

The protocol for assessing FRα levels was the same as set forth in Example 14 above. The pairs of antibodies used for assessing FRα levels were also the same as in Example 14, i.e., Pair 1, in which 9F3 was the capture antibody and 24F12 was the detector antibody, and Pair 2, in which 26B3 was the capture antibody and 19D4 was the detector antibody.

The results are provided in Table 30.

TABLE 30

Levels of FRα as assessed in serum and plasma samples on different days

Day 1
Day 2
Day 1
Day 2
Day 1
Day 2
Day 1
Day 2

Biosample

FRα/pair1
FRα/pair1
FRα/pair1
FRα/pair1
FRα/pair2
FRα/pair2
FRα/pair2
FRα/pair2

Confirmed

Serum
Serum
Plasma
Plasma
Serum
Serum
Plasma
Plasma

Donor ID
Disease
Diagnosis
Stage
(pg/ml)
(pg/ml)
(pg/ml)
(pg/ml)
(pg/ml)
(pg/ml)
(pg/mL)
(pg/mL)

17168
ovary
Serum FRA - Pair 1
I
1236
1282
1466
1183
1298
1384
1410
1336

versus Pair 2

46464
ovary
Serous carcinoma
IIIC
1589
1848
2027
2147
1966
2018
2066
2210

47219
ovary
Adenocarcinoma
missing
447
432
1208
748
435
446
695
577

47721
ovary
Papillary serous
IIIB
1307
1400
2291
2100
1642
1479
1940
1807

cystadenocarcinoma

48185
ovary
Adenocarcinoma
missing
1058
1038
883
652
918
872
811
781

48254
ovary
Adenocarcinoma
IIIC
511
495
3030
2569
506
445
1332
1370

48258
ovary
Adenocarcinoma
missing
471
552
1978
1070
629
547
978
798

48282
ovary
Adenocarcinoma
missing
375
388
688
536
446
407
540
428

48698
ovary
Carcinoma,
IIIB
279
231
308
225
340
255
328
228

undifferentiated

49028
ovary
Serous carcinoma
IIIC
727
590
158
169
468
526
192
192

49030
ovary
Serous carcinoma
IIIC
215
205
695
485
362
291
734
590

49033
ovary
Serous
IIIC
579
457
805
717
511
451
629
668

cystadenocarcinoma

49071
ovary
Serous
IV
335
338
1884
1462
559
457
1224
1028

cystadenocarcinoma

49092
ovary
Papillary
missing
272
228
1235
615
399
334
678
535

cystadenocarcinoma

49258
ovary
Papillary serous
IIIB
201
190
343
142
328
253
368
244

cystadenocarcinoma

49335
ovary
Serous
IIIB
1904
1698
1560
1485
1879
1503
1868
1627

cystadenocarcinoma

49369
ovary
Serous carcinoma
IIIC
2451
2805
2589
2641
3402
2659
2898
2605

49551
ovary
Serous carcinoma
III
408
385
364
342
505
432
436
418

50009
ovary
Serous carcinoma
IIIC
2887
4127
2641
3811
4466
3914
3533
3519

50370
ovary
Serous
IIIB
619
570
788
611
813
762
708
758

cystadenocarcinoma

50378
ovary
Papillary serous
I
410
387
330
256
388
464
381
387

cystadenocarcinoma

50460
ovary
Papillary serous
IIIB
254
274
688
414
284
272
489
420

cystadenocarcinoma

50467
ovary
Clear cell
I
427
314
414
300
272
313
292
309

adenocarcinoma

50635
ovary
Serous
IA
247
227
462
367
355
345
392
392

cystadenocarcinoma

51503
ovary
Papillary
I
291
250
925
651
315
326
818
498

cystadenocarcinoma

51504
ovary
Mucinous
I
224
184
2438
1395
225
240
916
856

cystadenoma,

borderline

malignancy

51506
ovary
Papillary mucinous
III
270
258
713
324
335
384
457
424

cystadenocarcinoma

52949
ovary
Adenocarcinoma
missing
446
436
288
257
435
483
395
390

52952
ovary
Papillary serous
missing
480
415
451
376
310
351
299
321

cystadenocarcinoma

52957
ovary
Papillary serous
III
373
334
274
221
318
374
303
330

cystadenocarcinoma

52978
ovary
Papillary mucinous
II
348
318
533
429
525
559
596
624

cystadenocarcinoma

52980
ovary
Serous
III
627
630
1447
1019
834
905
964
996

cystadenocarcinoma

DLSN-057
normal

309
402
413
394
515
527
509
531

DLSN-056
normal

273
254
483
498
480
458
522
524

DLSN-052
normal

282
289
293
298
446
483
438
401

DLSN-049
normal

282
256
351
320
363
394
430
359

DLSN-048
normal

362
399
454
434
746
722
824
639

DLSN-047
normal

188
176
208
167
275
263
251
212

DLSN-046
normal

295
321
276
240
354
310
315
257

DLSN-045
normal

259
259
259
189
292
279
273
235

DLSN-044
normal

244
236
246
254
284
273
284
271

DLSN-042
normal

245
199
210
185
328
301
285
258

DLSN-040
normal

392
376
408
406
481
499
502
413

DLSN-039
normal

463
470
469
446
617
599
567
528

DLSN-037
normal

256
231
256
223
367
338
351
289

DLSN-029
normal

285
270
348
337
453
417
418
351

DLSN-023
normal

265
254
286
298
458
402
370
386

DLSN-020
normal

237
238
311
287
530
496
504
446

DLSN-011
normal

344
328
210
207
688
603
297
267

DLSN-039
normal

196
178
204
183
259
219
242
248

DLSN-047
normal

336

385

489

429

DLSN-052
normal

226

208

346

315

DLSL-012
lung

340

220

529

375

DLSL-015
lung

199

180

236

292

DLSL-023
lung

581

347

568

523

DLSL-031
lung

400

251

415

343

DLSL-034
lung

133

138

299

331

1
lung

238

339

462

460

3
lung

120

185

203

334

6
lung

295

1646

431

868

18
lung

328

288

466

418

18639
lung

124

333

128

216

18640
lung

246

275

221

221

50666
lung

372

357

405

338

2
lung

214

327

274

269

4
lung

347

625

526

575

7
lung

224

308

421

452

12
lung

409

424

778

725

13
lung

509

590

1251

1360

14
lung

250

250

409

357

15
lung

502

466

606

594

16
lung

153

274

246

275

19
lung

357

905

428

576

DLS4-0002
lung

234

245

410

347

DLS4-0004
lung

472

520

507

538

DLSO-007
ovary

389

593

574

544

DLSO-008
ovary

175

295

386

364

DLSO-009
ovary

232

331

299

349

DLSO-014
ovary

265

300

430

467

DLSO-020
ovary

536

261

453

389

DLSO-026
ovary

DLSO-027
ovary

290

140

269

218

DLSO-028
ovary

357

207

397

18

DLSO-029
ovary

412

236

369

361

DLSO-030
ovary

387

498

595

616

DLSO-031
ovary

348

496

353

413

DLSO-034
ovary

197

222

308

346

DLSO-035
ovary

144

540

298

587

DLSO-023
ovary

404

216

423

337

DLSO-025
ovary

306

156

301

272

DLSO-026
ovary

231

293

406

378

DLSO-032
ovary

151

190

240

255

DLSO-018
ovary

155

340

303

343

DLSO-019
ovary

350

330

DLSO-021
ovary

359

365

346

434

DLSO-024
ovary

260

140

338

318

10001627
ovary

1481

1396

1583

1655

11025393
ovary

5241

4069

4998

5486

11025394
ovary

473

371

488

518

110025395
ovary

3215

2920

3466

4043

110025397
ovary

109

145

245

232

110025398
ovary

476

497

613

543

110025399
ovary

166

145

234

229

110025402
ovary

219

221

389

357

110025403
ovary

7529

6990

13033

11888

110025405
ovary

510

508

836

835

5
ovary

164

328

252

375

8
ovary

251

709

473

573

9
ovary

249

743

482

561

10
ovary

288

569

412

446

11
ovary

180

417

310

397

17
ovary

296

760

342

628

110025392
ovary

1094

2210

907

1294

Based on the foregoing data, it was apparent that the 9F3, 2412, 26B3 and 19D4 antibodies were useful in detecting levels of FRα in biological samples, for example, serum or plasma, derived from a subject. Moreover, the particular combinations of (i) 9F3 as a capture antibody and 24F12 as a detector antibody and (ii) 26B3 as a capture antibody and 19D4 as a detector antibody were capable and particularly effective in assessing levels of FRα in biological samples.

For assays conducted using both Pair 1 and Pair 2, there was a high correlation between serum and plasma FRα levels. FIG. 16 shows the correlation in serum versus plasma FRα levels for assays conducted using Pair 1 (see Example 16). The R²value was 0.8604. FIG. 17 shows the correlation in serum versus plasma FRα levels for assays conducted using Pair 2 (see Example 16). The R²value was 0.9766.

For both serum and plasma samples, there was a high correlation between FRα levels measured using Pair 1 and Pair 2. FIG. 18 shows the correlation in serum FRα levels for assays conducted using Pair 1 versus Pair 2 (see Example 16). The R²value was 0.9028. FIG. 19 shows the correlation in plasma FRα levels for assays conducted using pair 1 versus pair 2 (see Example 16). The R²value was 0.8773.

The results also showed that there was a high correlation between FRα levels measured on different days. FIG. 20 shows the interday correlation in serum FRα levels for assays conducted using pair 2. The R²value was 0.9839.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims. Any combination of the embodiments disclosed in the dependent claims are contemplated to be within the scope of the invention.

TABLE 33

SEQUENCES

SEQ

ID

NO:
DESCRIPTION
SEQUENCE

1
MORAB-003
GFTFSGYGLS

CDRH1

2
MORAB-003
MISSGGSYTYYADSVKG

CDRH2

3
MORAB-003
HGDDPAWFAY

CDRH3

4
MORAB-003
SVSSSISSNNLH

CDRL1

5
MORAB-003
GTSNLAS

CDRL2

6
MORAB-003
QQWSSYPYMYT

CDRL3

7
MORAb-003
1
EVQLVESGGG VVQPGRSLRL SCSASGFTFS GYGLSWVRQA PGKGLEWVAM

Heavy Chain
51

ISSGGSYTYY ADSVKGRFAI SRDNAKNTLF LQMDSLRPED TGVYFCARHG

Mature
101

DDPAWFAYWG QGTPVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD

Polypeptide
151
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY

Amino Acid
201
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK

Sequence
251
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS

301
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV

351
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL

401
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK

8
MORAb-003
1
DIQLTQSPSS LSASVGDRVT ITCSVSSSIS SNNLHWYQQK PGKAPKPWIY

Light Chain
51

GTSNLASGVP SRFSGSGSGT DYTFTISSLQ PEDIATYYCQ QWSSYPYMYT

Mature
101
FGQGTKVEIK RTVAAPSVFI FPPSDEQLKS GTASVVCLLN NFYPREAKVQ

Polypeptide
151
WKVDNALQSG NSQESVTEQD SKDSTYSLSS TLTLSKADYE KHKVYACEVT

Amino Acid
201
HQGLSSPVTK SFNRGEC

Sequence

9
MORAb-003
1

MGWSCIILFL VATATGVHSE VQLVESGGGV VQPGRSLRLS CSASGFTFSG

Heavy Chain
51
YGLSWVRQAP GKGLEWVAMI SSGGSYTYYA DSVKGRFAIS RDNAKNTLFL

full length
101
QMDSLRPEDT GVYFCARHGD DPAWFAYWGQ GTPVTVSSAS TKGPSVFPLA

pre-protein
151
PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL

amino acid
201
YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC

sequence
251
PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV

301
DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP

351
APIEKTISKA KGQPREPQVY TLPPSRDELT KNQVSLTCLV KGFYPSDIAV

401
EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH

451
EALHNHYTQK SLSLSPGK

10
MORAb-003
1

MGWSCIILFL VATATGVHSD IQLTQSPSSL SASVGDRVTI TCSVSSSISS

Light Chain
51
NNLHWYQQKP GKAPKPWIYG TSNLASGVPS RFSGSGSGTD YTFTISSLQP

full length
101
EDIATYYCQQ WSSYPYMYTF GQGTKVEIKR TVAAPSVFIF PPSDEQLKSG

pre-protein
151
TASVVCLLNN FYPREAKVQW KVDNALQSGN SQESVTEQDS KDSTYSLSST

amino acid
201
LTLSKADYEK HKVYACEVTH QGLSSPVTKS FNRGEC

sequence

11
MORAb-003
1
ATGGGATGGA GCTGTATCAT CCTCTTCTTG GTAGCAACAG CTACAGGTGT

Heavy Chain
51
CCACTCCGAG GTCCAACTGG TGGAGAGCGG TGGAGGTGTT GTGCAACCTG

Nucleotide
101
GCCGGTCCCT GCGCCTGTCC TGCTCCGCAT CTGGCTTCAC CTTCAGCGGC

151
TATGGGTTGT CTTGGGTGAG ACAGGCACCT GGAAAAGGTC TTGAGTGGGT

201
TGCAATGATT AGTAGTGGTG GTAGTTATAC CTACTATGCA GACAGTGTGA

251
AGGGTAGATT TGCAATATCG CGAGACAACG CCAAGAACAC ATTGTTCCTG

301
CAAATGGACA GCCTGAGACC CGAAGACACC GGGGTCTATT TTTGTGCAAG

351
ACATGGGGAC GATCCCGCCT GGTTCGCTTA TTGGGGCCAA GGGACCCCGG

401
TCACCGTCTC CTCAGCCTCC ACCAAGGGCC CATCGGTCTT CCCCCTGGCA

451
CCCTCCTCCA AGAGCACCTC TGGGGGCACA GCGGCCCTGG GCTGCCTGGT

501
CAAGGACTAC TTCCCCGAAC CGGTGACGGT GTCGTGGAAC TCAGGCGCCC

551
TGACCAGCGG CGTGCACACC TTCCCGGCTG TCCTACAGTC CTCAGGACTC

601
TACTCCCTCA GCAGCGTGGT GACCGTGCCC TCCAGCAGCT TGGGCACCCA

651
GACCTACATC TGCAACGTGA ATCACAAGCC CAGCAACACC AAGGTGGACA

701
AGAAAGTTGA GCCCAAATCT TGTGACAAAA CTCACACATG CCCACCGTGC

751
CCAGCACCTG AACTCCTGGG GGGACCGTCA GTCTTCCTCT TCCCCCCAAA

801
ACCCAAGGAC ACCCTCATGA TCTCCCGGAC CCCTGAGGTC ACATGCGTGG

851
TGGTGGACGT GAGCCACGAA GACCCTGAGG TCAAGTTCAA CTGGTACGTG

901
GACGGCGTGG AGGTGCATAA TGCCAAGACA AAGCCGCGGG AGGAGCAGTA

951
CAACAGCACG TACCGTGTGG TCAGCGTCCT CACCGTCCTG CACCAGGACT

1001
GGCTGAATGG CAAGGAGTAC AAGTGCAAGG TCTCCAACAA AGCCCTCCCA

1051
GCCCCCATCG AGAAAACCAT CTCCAAAGCC AAAGGGCAGC CCCGAGAACC

1101
ACAGGTGTAC ACCCTGCCCC CATCCCGGGA TGAGCTGACC AAGAACCAGG

1151
TCAGCCTGAC CTGCCTGGTC AAAGGCTTCT ATCCCAGCGA CATCGCCGTG

1201
GAGTGGGAGA GCAATGGGCA GCCGGAGAAC AACTACAAGA CCACGCCTCC

1251
CGTGCTGGAC TCCGACGGCT CCTTCTTCTT ATATTCAAAG CTCACCGTGG

1301
ACAAGAGCAG GTGGCAGCAG GGGAACGTCT TCTCATGCTC CGTGATGCAT

1351
GAGGCTCTGC ACAACCACTA CACGCAGAAG AGCCTCTCCC TGTCTCCCGG

1401
GAAATGA

12
MORAb-003
1
ATGGGATGGA GCTGTATCAT CCTCTTCTTG GTAGCAACAG CTACAGGTGT

Light Chain
51
CCACTCCGAC ATCCAGCTGA CCCAGAGCCC AAGCAGCCTG AGCGCCAGCG

Nucleotide
101
TGGGTGACAG AGTGACCATC ACCTGTAGTG TCAGCTCAAG TATAAGTTCC

151
AACAACTTGC ACTGGTACCA GCAGAAGCCA GGTAAGGCTC CAAAGCCATG

201
GATCTACGGC ACATCCAACC TGGCTTCTGG TGTGCCAAGC AGATTCAGCG

251
GTAGCGGTAG CGGTACCGAC TACACCTTCA CCATCAGCAG CCTCCAGCCA

301
GAGGACATCG CCACCTACTA CTGCCAACAG TGGAGTAGTT ACCCGTACAT

351
GTACACGTTC GGCCAAGGGA CCAAGGTGGA AATCAAACGA ACTGTGGCTG

401
CACCATCTGT CTTCATCTTC CCGCCATCTG ATGAGCAGTT GAAATCTGGA

451
ACTGCCTCTG TTGTGTGCCT GCTGAATAAC TTCTATCCCA GAGAGGCCAA

501
AGTACAGTGG AAGGTGGATA ACGCCCTCCA ATCGGGTAAC TCCCAGGAGA

551
GTGTCACAGA GCAGGACAGC AAGGACAGCA CCTACAGCCT CAGCAGCACC

601
CTGACGCTGA GCAAAGCAGA CTACGAGAAA CACAAAGTCT ACGCCTGCGA

651
AGTCACCCAT CAGGGCCTGA GCTCGCCCGT CACAAAGAGC TTCAACAGGG

701
GAGAGTGTTA A

13
LK26HuVK
DIQLTQSPSSLSASVGDRVT

ITCSVSSSISSNNLHWYQQK

PGKAPKLLIYGTSNLASGVP

SRFSGSGSGTDFTFTISSLQ

PEDIATYYCQQWSSYPYMYT

FGQGTKVEIK*

14
LK26HuVKY
DIQLTQSPSSLSASVGDRVT

ITCSVSSSISSNNLHWYQQK

PGKAPKLLIYGTSNLASGVP

SRFSGSGSGTDYTFTISSLQ

PEDIATYYCQQWSSYPYMYT

FGQGTKVEIK*

15
LK26HuVKPW
DIQLTQSPSSLSASVGDRVT

ITCSVSSSISSNNLHWYQQK

PGKAPKPWIYGTSNLASGVP

SRFSGSGSGTDFTFTISSLQ

PEDIATYYCQQWSSYPYMYT

FGQGTKVEIK

16
LK26HuVKPW, Y
DIQLTQSPSSLSASVGDRVT

ITCSVSSSISSNNLHWYQQK

PGKAPKPWIYGTSNLASGVP

SRFSGSGSGTDYTFTISSLQ

PEDIATYYCQQWSSYPYMYT

FGQGTKVEIK

17
LK26HuVH
QVQLQESGPGLVRPSQTLSL

TCTASGFTFSGYGLSWVRQP

PGRGLEWVAMISSGGSYTYY

ADSVKGRVTMLRDTSKNQFS

LRLSSVTAADTAVYYCARHG

DDPAWFAYWGQGSLVTVSS

18
LK26HuVHFAIS,
QVQLQESGPGLVRPSQTLSL

N
TCTASGFTFSGYGLSWVRQP

PGRGLEWVAMISSGGSYTYY

ADSVKGRFAISRDNSKNQFS

LRLSSVTAADTAVYYCARHG

DDPAWFAYWGQGSLVTVSS*

19
LK26HuVHSLF
QVQLQESGPGLVRPSQTLSL

TCTASGFTFSGYGLSWVRQP

PGRGLEWVAMISSGGSYTYY

ADSVKGRVTMLRDTSKNSLF

LRLSSVTAADTAVYYCARHG

DDPAWFAYWGQGTTVTVSS*

20
LK26HuVHI, I
QVQLQESGPGLVRPSQTLSL

TCTASGFTFSGYGLSWVRQP

PGRGLEWVAMISSGGSYTYY

ADSVKGRVTMLRDTSKNQFS

LRLSSVTAADTAIYICARHG

DDPAWFAYWGQGSLVTVSS*

21
LK26KOLHuVH
EVQLVESGGGVVQPGRSLRL

SCSASGFTFSGYGLSWVRQA

PGKGLEWVAMISSGGSYTYY

ADSVKGRFAISRDNAKNTLF

LQMDSLRPEDTGVYFCARHG

DDPAWFAYWGQGTPVTVSS*

22
Murine LK26
QVXLQXSGGDLVKPGGSLKL

Ab Heavy
SCAASGFTFSGYGLSWVRQT

Chain
PDKRLEWVAMISSGGSYTYY

Sequence
ADSVKGRFAISRDNAKNSLF

LQMSSLKSDDTAIYICARHG

DDPAWFAYWGQGTLVTVSA*

23
Murine LK26
DIELTQSPALMAASPGEKVT

Ab Light
ITCSVSSSISSNNLHWYQQK

Chain
SETSPKPWIYGTSNLASGVP

Sequence
LRFRGFGSGTSYSLTISSME

AEDAATYYCQQWSSYPYMYT

FGGGTKLEIK*

24
Consensus
tcaaggttaa acgacaagga cagacatggc tcagcggatg acaacacagc tgctgctcct

Human FRα
tctagtgtgg gtggctgtag taggggaggc tcagacaagg attgcatggg ccaggactga

Nucleotide
gcttctcaat gtctgcatga acgccaagca ccacaaggaa aagccaggcc ccgaggacaa

Sequence
gttgcatgag cagtgtcgac cctggaggaa gaatgcctgc tgttctacca acaccagcca

ggaagcccat aaggatgttt cctacctata tagattcaac tggaaccact gtggagagat

ggcacctgcc tgcaaacggc atttcatcca ggacacctgc ctctacgagt gctcccccaa

cttggggccc tggatccagc aggtggatca gagctggcgc aaagagcggg tactgaacgt

gcccctgtgc aaagaggact gtgagcaatg gtgggaagat tgtcgcacct cctacacctg

caagagcaac tggcacaagg gctggaactg gacttcaggg tttaacaagt gcgcagtggg

agctgcctgc caacctttcc atttctactt ccccacaccc actgttctgt gcaatgaaat

ctggactcac tcctacaagg tcagcaacta cagccgaggg agtggccgct gcatccagat

gtggttcgac ccagcccagg gcaaccccaa tgaggaggtg gcgaggttct atgctgcagc

catgagtggg gctgggccct gggcagcctg gcctttcctg cttagcctgg ccctaatgct

gctgtggctg ctcagctgac ctccttttac cttctgatac ctggaaatcc ctgccctgtt

cagccccaca gctcccaact atttggttcc tgctccatgg tcgggcctct gacagccact

ttgaataaac cagacaccgc acatgtgtct tgagaattat ttggaaaaaa aaaaaaaaaa

aa

25
Consensus
maqrmttqll lllvwvavvg eaqtriawar tellnvcmna khhkekpgpe dklheqcrpw

Human FRα
rknaccstnt sqeahkdvsy lyrfnwnhcg emapackrhf iqdtclyecs pnlgpwiqqv

Amino Acid
dqswrkervl nvplckedce qwwedcrtsy tcksnwhkgw nwtsgfnkca vgaacqpfhf

Sequence
yfptptvlcn eiwthsykvs nysrgsgrci qmwfdpaqgn pneevarfya aamsgagpwa

awpfllslal mllwlls

26
Mov-18
TELLNVXMNAK*XKEKPXPX

epitope
*KLXXQX

sequence

27
9F3 Light
RASSTVSYSYLH

Chain CDR1

28
9F3 Light
GTSNLAS

Chain CDR2

29
9F3 Light
QQYSGYPLT

Chain CDR3

30
9F3 Light
PAIMSASPGEKVTMTCRASSTVSYSYLHWYQQKSGASPQLWIYGTSNLAS

Chain
GVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFGAGTKLELK

Variable
RADAAP

Domain

31
9F3 Heavy
SGYYWN

Chain CDR1

32
9F3 Heavy
YIKSDGSNNYNPSLKN

Chain CDR2

33
9F3 Heavy
EWKAMDY

Chain CDR3

34
9F3 Heavy
ESGPGLVRPSQSLSLTCSVTGYSITSGYYWNWIRQFPGSRLEWMGYIKSDG

Chain
SNNYNPSLKNRISITRDTSKNQFFLKLNSVTTEDTATYFCTREWKAMDYW

Variable
GQGTSVTVSSAKTTPPSVYPLAPGCGDT

Domain

35
19D4 Light
RASESVDTYGNNFIH

Chain CDR1

36
19D4 Light
LASNLES

Chain CDR2

37
19D4 Light
QQNNGDPWT

Chain CDR3

38
19D4 Light
PASLAVSLGQRATISCRASESVDTYGNNFIHWYQQKPGQPPKLLIYLASNL

Chain
ESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNGDPWTFGGGTKL

Variable
EIKRADAAP

Domain

39
19D4 Heavy
HPYMH

Chain CDR1

40
19D4 Heavy
RIDPANGNTKYDPKFQG

Chain CDR2

41
19D4 Heavy
EEVADYTMDY

Chain CDR3

42
19D4 Heavy
GAELVKPGASVKLSCTASGFNIKHPYMHWVKQRPDQGLEWIGRIDPANG

Chain
NTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCGREEVADYTM

Variable
DYWGQGTSVTVSSAKTTAPSVYPLAPV

Domain

43
24F12 Light
SASQGINNFLN

Chain CDR1

44
24F12 Light
YTSSLHS

Chain CDR2

45
24F12 Light
QHFSKLPWT

Chain CDR3

46
24F12 Light
TSSLSASLGDRVTISCSASQGINNFLNWYQQKPDGTVKLLIYYTSSLHSGVP

Chain
SRFSGSGSGTDYSLTISNLEPEDIAIYYCQHFSKLPWTFGGGTKLEIKRADA

Variable
AP

Domain

47
24F12 Heavy
SYAMS

Chain CDR1

48
24F12 Heavy
EIGSGGSYTYYPDTVTG

Chain CDR2

49
24F12 Heavy
ETTAGYFDY

Chain CDR3

50
24F12 Heavy
SGGGLVRPGGSLKLSCAASGFTFSSYAMSWVRQSPEKRLEWVAEIGSGGS

Chain
YTYYPDTVTGRFTISRDNAKSTLYLEMSSLRSEDTAIYYCARETTAGYFDY

Variable
WGQGTTLTVSS

Domain

51
26B3 Light
RTSENIFSYLA

Chain CDR1

52
26B3 Light
NAKTLAE

Chain CDR2

53
26B3 Light
QHHYAFPWT

Chain CDR3

54
26B3 Light
PASLSASVGETVTITCRTSENIFSYLAWYQQKQGISPQLLVYNAKTLAEGV

Chain
PSRFSGSGSGTQFSLKINSLQPEDFGSYYCQHHYAFPWTFGGGSKLEIKRA

Variable
DAAP

Domain

55
26B3 Heavy
GYFMN

Chain CDR1

56
26B3 Heavy
RIFPYNGDTFYNQKFKG

Chain CDR2

57
26B3 Heavy
GTHYFDY

Chain CDR3

58
26B3 Heavy
GPELVKPGASVKISCKASDYSFTGYFMNWVMQSHGKSLEWIGRIFPYNGD

Chain
TFYNQKFKGRATLTVDKSSSTAHMELRSLASEDSAVYFCARGTHYFDYW

Variable
GQGTTLTVSSAKTTPPSVYPLAPGSAAQT

Domain

59
9F3 Light
AGGGCCAGCTCAACTGTAAGTTACAGTTACTTGCAC

Chain CDR1

60
9F3 Light
GGCACATCCAACTTGGCTTCT

Chain CDR2

61
9F3 Light
CAGCAGTACAGTGGTTACCCACTCACG

Chain CDR3

62
9F3 Light
CCAGCAATCATGTCTGCATCTCCAGGGGAAAAGGTCACCATGACCTGC

Chain
AGGGCCAGCTCAACTGTAAGTTACAGTTACTTGCACTGGTACCAGCAG

Variable
AAGTCAGGTGCCTCCCCCCAACTCTGGATTTATGGCACATCCAACTTGG

Domain
CTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGGTCTGGGACCTCTTA

CTCTCTCACAATCAGCAGTGTGGAGGCTGAAGATGCTGCCACTTATTAC

TGCCAGCAGTACAGTGGTTACCCACTCACGTTCGGTGCTGGGACCAAG

CTGGAGCTGAAACGGGCTGATGCTGCACCAAC

63
9F3 Heavy
AGTGGTTATTACTGGAAC

Chain CDR1

64
9F3 Heavy
TACATAAAGTCCGACGGTAGCAATAATTACAACCCATCTCTCAAAAAT

Chain CDR2

65
9F3 Heavy
GAGTGGAAGGCTATGGACTAC

Chain CDR3

66
9F3 Heavy
GAGTCAGGACCTGGCCTCGTGAGACCTTCTCAGTCTCTGTCTCTCACCT

Chain
GCTCTGTCACTGGCTACTCCATCACCAGTGGTTATTACTGGAACTGGAT

Variable
CCGGCAGTTTCCAGGAAGCAGACTGGAATGGATGGGCTACATAAAGTC

Domain
CGACGGTAGCAATAATTACAACCCATCTCTCAAAAATCGAATCTCCAT

CACTCGTGACACATCTAAGAACCAGTTTTTCCTGAAGTTGAATTCTGTG

ACTACTGAGGACACAGCTACATATTTCTGTACAAGGGAGTGGAAGGCT

ATGGACTACTGGGGTCAGGGAACCTCAGTCACCGTCTCCTCAGCCAAA

ACAACACCCCCATCAGTCTATCCACTGGCCCCTGGGTGTGGAGATACA

AC

67
19D4 Light
AGAGCCAGTGAAAGTGTTGATACTTATGGCAATAATTTTATACAC

Chain CDR1

68
19D4 Light
CTTGCATCCAACCTAGAATCT

Chain CDR2

69
19D4 Light
CAGCAAAATAATGGGGATCCGTGGACG

Chain CDR3

70
19D4 Light
CCAGCTTCTTTGGCTGTGTCTCTAGGGCAGAGGGCCACCATATCCTGCA

Chain
GAGCCAGTGAAAGTGTTGATACTTATGGCAATAATTTTATACACTGGT

Variable
ACCAGCAGAAACCAGGACAGCCACCCAAACTCCTCATTTATCTTGCAT

Domain
CCAACCTAGAATCTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTA

GGACAGACTTCACCCTCACCATTGATCCTGTGGAGGCTGATGATGCTG

CAACCTATTACTGTCAGCAAAATAATGGGGATCCGTGGACGTTCGGTG

GAGGCACCAAGCTGGAGATCAAACGGGCTGATGCTGCACCAA

71
19D4 Heavy
CACCCCTATATGCAC

Chain CDR1

72
19D4 Heavy
AGGATTGATCCTGCGAATGGTAATACTAAATATGACCCGAAGTTCCAG

Chain CDR2
GGC

73
19D4 Heavy
GAGGAGGTGGCGGACTATACTATGGACTAC

Chain CDR3

74
19D4 Heavy
GGGGCAGAGCTTGTGAAGCCAGGGGCCTCAGTCAAGTTGTCCTGCACA

Chain
GCTTCTGGCTTCAACATTAAACACCCCTATATGCACTGGGTGAAGCAG

Variable
AGGCCTGACCAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCGAAT

Domain
GGTAATACTAAATATGACCCGAAGTTCCAGGGCAAGGCCACTATAACA

GCAGACACATCCTCCAACACAGCCTACCTACAGCTCAGCAGCCTGACA

TCTGAGGACACTGCCGTCTATTACTGTGGTAGAGAGGAGGTGGCGGAC

TATACTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCA

GCCAAAACAACAGCCCCATCGGTCTATCCACTGGCCCCTGTGTG

75
24F12 Light
AGTGCAAGTCAGGGCATTAACAATTTTTTAAAC

Chain CDR1

76
24F12 Light
TACACATCAAGTTTACACTCA

Chain CDR2

77
24F12 Light
CAGCACTTTAGTAAGCTTCCGTGGACG

Chain CDR3

78
24F12 Light
ACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAGTCACCATCAGTTGCA

Chain
GTGCAAGTCAGGGCATTAACAATTTTTTAAACTGGTATCAGCAGAAAC

Variable
CAGATGGCACTGTTAAACTCCTGATCTATTACACATCAAGTTTACACTC

Domain
AGGAGTCCCATCAAGGTTCAGTGGCAGTGGGTCTGGGACAGATTATTC

TCTCACCATCAGCAACCTGGAACCTGAAGATATTGCCATATACTATTGT

CAGCACTTTAGTAAGCTTCCGTGGACGTTCGGTGGAGGCACCAAGCTG

GAAATCAAACGGGCTGATGCTGCACCAAC

79
24F12 Heavy
AGCTATGCCATGTCT

Chain CDR1

80
24F12 Heavy
GAAATTGGTAGTGGTGGTAGTTACACCTACTATCCAGACACTGTGACG

Chain CDR2
GGC

81
24F12 Heavy
GAAACTACGGCGGGCTACTTTGACTAC

Chain CDR3

82
24F12 Heavy
TCTGGGGGAGGCTTAGTGAGGCCTGGAGGGTCCCTGAAACTCTCCTGT

Chain
GCAGCCTCTGGATTCACTTTCAGTAGCTATGCCATGTCTTGGGTTCGCC

Variable
AGTCTCCAGAGAAGAGGCTGGAGTGGGTCGCAGAAATTGGTAGTGGTG

Domain
GTAGTTACACCTACTATCCAGACACTGTGACGGGCCGATTCACCATCTC

CAGAGACAATGCCAAGAGCACCCTGTACCTGGAAATGAGCAGTCTGAG

GTCTGAGGACACGGCCATCTATTACTGTGCAAGGGAAACTACGGCGGG

CTACTTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCA

83
26B3 Light
CGAACAAGTGAGAATATTTTCAGTTATTTAGCA

Chain CDR1

84
26B3 Light
AATGCAAAAACCTTAGCAGAG

Chain CDR2

85
26B3 Light
CAACATCATTATGCTTTTCCGTGGACG

Chain CDR3

86
26B3 Light
CCAGCCTCCCTATCTGCATCTGTGGGAGAAACTGTCACCATCACATGTC

Chain
GAACAAGTGAGAATATTTTCAGTTATTTAGCATGGTATCAGCAGAAAC

Variable
AGGGAATATCTCCTCAGCTCCTGGTCTATAATGCAAAAACCTTAGCAG

Domain
AGGGTGTGCCATCAAGGTTCAGTGGCAGTGGATCAGGCACACAGTTTT

CTCTGAAGATCAACAGCCTGCAGCCTGAAGATTTTGGGAGTTATTACT

GTCAACATCATTATGCTTTTCCGTGGACGTTCGGTGGAGGCTCCAAGCT

GGAAATCAAACGGGCTGATGCTGCACCAAC

87
26B3 Heavy
GGCTACTTTATGAAC

Chain CDR1

88
26B3 Heavy
CGTATTTTTCCTTACAATGGTGATACTTTCTACAACCAGAAGTTCAAGG

Chain CDR2
GC

89
26B3 Heavy
GGGACTCATTACTTTGACTAC

Chain CDR3

90
26B3 Heavy
GGACCTGAGCTGGTGAAGCCTGGGGCTTCAGTGAAGATATCCTGCAAG

Chain
GCTTCTGATTACTCTTTTACTGGCTACTTTATGAACTGGGTGATGCAGA

Variable
GCCATGGAAAGAGCCTTGAGTGGATTGGACGTATTTTTCCTTACAATG

Domain
GTGATACTTTCTACAACCAGAAGTTCAAGGGCAGGGCCACATTGACTG

TAGACAAATCCTCTAGCACAGCCCACATGGAGCTCCGGAGCCTGGCAT

CTGAGGACTCTGCAGTCTATTTTTGTGCAAGAGGGACTCATTACTTTGA

CTACTGGGGCCAAGGCACCACTCTCACTGTCTCCTCAGCCAAAACGAC

ACCCCCATCTGTCTATCCACTGGCCCCTGGATCTGCTGCCCAAACTAA

	Number	Date	Country
	61410497	Nov 2010	US
	61508444	Jul 2011	US

FOLATE RECEPTOR ALPHA AS A DIAGNOSTIC AND PROGNOSTIC MARKER FOR FOLATE RECEPTOR ALPHA-EXPRESSING CANCERS

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

US Classifications

International Classifications

Abstract

Description

Claims

RELATED APPLICATIONS

Provisional Applications (2)